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Current treatments for hemophilia B, a hereditary bleeding disorder characterized 
by the deficiency of coagulation factor IX (FIX), rely on injection-based administration 
that  cause pain and discomfort, leading to noncompliance and risk of subsequent bleeding 
episodes. A non-invasive protein replacement therapy using an oral delivery system can 
both overcome such issues and improve access to treatment in developing countries. Oral 
delivery is a desirable route for protein therapeutics; however, two main challenges—
increasing bioavailability and maintaining protein functionality—need to be addressed 
when designing a delivery platform. The overarching goal of this work presented here is to 
develop an oral delivery system for human factor IX (hFIX) as a convenient prophylactic 
treatment. Complexation hydrogels have been engineered to protect biologics from the 
harsh environment of the GI tract and deliver them to the small intestine for absorption. 
We have successfully developed pH-responsive hydrogel networks based on 
poly(methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)] as delivery vehicles 
for hFIX.  
We have focused on optimizing the drug loading and release, as well as evaluating 
in vitro drug absorption and in vivo biocompatibility and biodistribution of the 
microcarrier. Tailoring the networks of P(MAA-g-EG) hydrogels improved the loading of 
hFIX within the microcarriers, which is critical for minimizing protein degradation. 
 vii 
Optimizing the loading conditions by increasing the incubation time and using a reduced 
ionic strength buffer further improved the delivery potential of the microcarriers. The 
presence of the microcarriers significantly improved the in vitro absorption of hFIX. As an 
alternative strategy designed to further increase the delivery potential, we incorporated an 
enzymatically degradable component into the P(MAA-g-EG) microcarrier system. 
Evaluation of this degradable system demonstrated the increased levels of hFIX in 
intestinal conditions, which has the potential to promote the oral bioavailability of hFIX. 
We performed stability testing of lyophilized hFIX-loaded microparticles to determine the 
effects of storage conditions on hFIX release and activity. Lastly, in vivo biocompatibility 
and biodistribution studies were performed to establish the safety of multiple oral doses of 
P(MAA-g-EG) microparticles and to determine the residence time and clearance of these 
microcarriers. In vivo preclinical studies were critical for clinical applications of these drug 
delivery systems. This works shows that P(MAA-g-EG) microcarriers are promising 
candidates for the oral delivery of hFIX for treating hemophilia B. 
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Chapter 1: Introduction 
Hemophilia B is a hereditary bleeding disorder characterized by the deficiency of 
clotting factor IX (FIX). Protein replacement therapy has successfully improved the 
patient’s life expectancy and quality of life. However, current treatment methods rely on 
injections and infusions of factor IX concentrates which causes pain and discomfort, 
leading to noncompliance and risk of subsequent bleeding episodes. Additionally, such 
treatment regimens are limited to developed countries mainly due to costs of the drug, 
medical care (e.g. hospital visits, surgery), and possible serious complications from therapy 
(e.g. severe allergic reactions).  A non-invasive treatment for hemophilia B, such as an oral 
delivery system, is desired both to overcome these issues associated with current methods 
and to increase global access to protein therapy.  
Oral delivery is a desirable route of administration for a diversity of therapeutics 
for the treatment of systemic and local diseases. The benefits of oral delivery include ease 
of administration, increased compliance, and lower costs. However, there are two main 
challenges—maintaining protein functionality and increasing bioavailability—that need to 
be addressed when designing an oral delivery system. In the oral route, the protein 
therapeutic must survive the transit along the gastrointestinal (GI) tract. The protein must 
pass through harsh environment of the stomach before reaching the small intestine where 
it can be absorbed into the bloodstream. The second challenge to oral delivery is increasing 
the bioavailability of the protein. In order to reach circulation, the protein must be absorbed 
in the upper small intestine and pass through the epithelium into the bloodstream.  
Increasing the permeability of the protein is critical for achieving therapeutically relevant 
levels in the bloodstream.  
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Anionic complexation hydrogels have been engineered to protect proteins from the 
harsh environment of the GI tract and deliver them to the small intestine due to pH-
responsive swelling. Our lab has successfully developed environmentally responsive 
polymeric systems, notably poly(methacrylic acid) grafted with poly(ethylene glycol), 
denoted as P(MAA-g-EG), as vehicles for the delivery of insulin (5.8 kDa), calcitonin (3.4 
kDa), and interferon alpha (23 kDa). However, a polymeric carrier system had not yet been 
optimized for high molecular weight proteins, such as blood clotting factor IX (57 kDa).  
Work presented here considers the development of environmentally responsive 
hydrogel systems for the oral delivery of clotting factor IX. We cover strategies for 
tailoring the crosslinked networks of P(MAA-g-EG) hydrogels for loading and release of 
factor IX, as well as systematically developing methods to improve factor IX loading and 
release. As an alternative strategy, we explored the use of an enzymatically degradable 
crosslinking agent in the P(MAA-g-EG) system to improve the site-specific release of 
factor IX.  In addition to the amount of factor IX release, we evaluated the biological 
activity of factor IX and selected hydrogel systems that maintained protein function, which 
is essential to therapeutic use.  
In addition to preserving biological activity, the overall bioavailability of orally 
administered factor IX also depends on transport across the intestinal epithelium. We 
explored the effects of these microparticle drug delivery systems in enhancing the 
permeability of factor IX across an in vitro intestinal epithelium.  
For further development of oral delivery systems, we included stability testing and 
preclinical studies. Stability testing is used for predicting shelf life and recommending 
storage conditions that maintain the desired release profile while preserving the biological 
activity of factor IX. Furthermore, evaluating in vivo biocompatibility of drug delivery 
systems is essential to establishing safe use in clinical applications. Knowledge of the in 
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vivo biodistribution of the microcarriers provides information about the residence time in 
the small intestine and clearance time, which is important for understanding the 
pharmacokinetics and safety.  
Successful outcomes of this work can have positive implications for protein 
replacement therapy for hemophilia B patients. As a non-invasive method, oral 
administration of factor IX could change the treatment regimens of hemophilic patients 
worldwide. 
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Chapter 2: Background 
2.1 COAGULATION AND HEMOSTASIS 
2.1.1 Overview 
Knowledge of coagulation and hemostasis is necessary for understanding bleeding 
disorders, such as hemophilia B, and their treatments. Generally, the coagulation cascade 
leads to the localized generation of thrombin, then the conversion of fibrinogen to insoluble 
fibrin polymers that, together with platelet aggregation, functions in maintaining 
hemostasis (Figure 2-1). Coagulation can be divided into (1) fibrin formation, (2) 
fibrinolysis, (3) platelet function, and (4) natural anticoagulants.1  
The coagulation cascade is a series of enzymatic reactions involving activated 
coagulations proteins and activated platelets designed to amplify the signal from initial 
trauma into the formation of a fibrin plug. The classic coagulation pathway describes two 
separate pathways—extrinsic and intrinsic pathways—which were developed based on in 
vitro laboratory tests, but do not match clinical observations. The “new pathway” of 
coagulation describes the in vivo mechanism.1, 2  
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Figure 2-1. Simple diagram of the coagulation cascade. As a result of trauma, tissue 
factor (TF) initiates the cascade by activating factor VII and binding to 
factor VIIa. The TF-VIIa complex activates factor X both directly and 
indirectly via IXa/VIIIa. The initial factor Xa generates a small amount of 
thrombin, which then begins the propagation and amplification of the 
cascade. Then, thrombin activates factors VIII and V, which assemble with 
factors IXa and Xa, respectively, on the platelet surface. The direct 
activation of factor X is rapidly shut down by tissue factor pathway inhibitor 
(TFPI). The indirect generation of factor Xa via factor IXa from factor Xia 
is necessary for effective coagulation to proceed. During the propagation 
phase, thrombin is amplified and fibrinogen forms the principle structural 
protein of the clot. Thrombin cleaves fibrinogen into fibrin monomers that 
form fibrin polymers, which assemble by non-covalent interactions. Factor 
XIIa covalently crosslinks the fibrin, making a stable clot. (Note: For 
simplicity, Roman numerals denote coagulation factors and an ‘a’ indicates 
the activated form. Figure adapted from Francischetti2.)  
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2.1.2 Coagulation Proteins 
The coagulation cascade involves various coagulation proteins, which are typically 
either enzymes (serine proteases) or cofactors (Table 2-1). For coagulation proteins 
classified as enzymes, the protein frameworks consist of a serine protease and various 
domains with specific functions in clotting. Enzymatic coagulation proteins are 
synthesized as biologically inactive proenzymes, and most become activated by post-
translation modification. For example, factors II, VII, IX, and X, protein C, and protein S 
have vitamin K-dependent glutamic acid (Gla) domains on the amino terminus. In order to 
become activated, the 9-11 glutamic acids in the Gla domain are modified by carboxylation 
of glutamic acid, forming gamma-carboxyglutamic acid. The carboxylation requires 
vitamin K. The gamma-carboxyglutamic acid residues allow for the binding of calcium. 
The binding of calcium to the Gla domains serves two functions: (1) inducing a 
conformational change in the protein necessary for its enzymatic activity, and (2) enabling 
the protein to bind to the phospholipid surfaces.3  
The binding of coagulation proteins to phospholipid surfaces of platelets and 
endothelial cells localizes the coagulation reactions, improving their efficiency. Most 
coagulation reactions involve a “quaternary complex” containing (1) an active enzyme 
binding to (2) a cofactor that is bonded by (3) calcium to (4) a phospholipid surface. The 
cofactors increase the rate of reaction by orders of magnitude.1 
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Table 2-1. Classifications of coagulation proteins.1 
Enzymes Cofactors Miscellaneous 
Factor IIa Tissue factor Fibrinogen 
Factor VIIa Factor V Factor XIII 
Factor IXa Factor VIII Alpha2 antiplasmin 
Factor Xa Protein S PAI-1 
Factor XIa  Antithrombin 
Protein C   
tPA   
Plasmin   
 
2.1.3 Initiation of Coagulation 
The coagulation cascade begins with exposure to tissue factor (TF). TF is a 
membrane-bound glycoprotein that located mainly in the adventitia of a vessel wall. TF is 
on mostly all cell surfaces except for that of endothelial cells and circulating blood cells.4 
Trauma causing vessel injury exposes TF to factor VII (FVII) and active FVII (FVIIa) 
present in the circulating blood, forming an active TF-FVIIa complex.5 The formation of 
the TF-FVIIa complex initiates the coagulation cascade, by activating FIX and FX. 
Additionally, FIXa with its cofactor FVIIIa activates FX. Notably, the two most common 
forms of hemophilia, A and B, are caused by the deficiency in FVIII and FIX, respectively. 
Then FXa binds with cofactor FVa to generate a small amount of thrombin from 
prothrombin (FII), marking the final step of the initiation phase. The production of 
thrombin is the most crucial step in hemostasis.1  
2.1.4 Propagation and Amplification of Coagulation 
The generation of thrombin marks the commencement of the propagation and 
amplification phase of the coagulation cascade. Thrombin is a multifunctional enzyme 
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involved in various coagulation reactions. Unlike other coagulation proteins, thrombin 
does not require a cofactor for enzymatic function, and activated thrombin separates from 
its Gla domain allowing it to float around to promote clotting. Thrombin provides both 
positive feedback by activating FV, FVIII, FXI, FXIII, and thrombin-activatable 
fibrinolysis inhibitor (TAFI) and negative feedback by activating protein C and promoting 
fibrinolysis. Overall, the propagation phase amplifies the amount of thrombin generated 
and fibrinogen forms the principle structural protein of the clot.1, 2   
2.1.5 Fibrin Clot Formation 
During clot formation, the fibrinogen is converted into an insoluble, stable fibrin 
thrombus. Thrombin converts fibrinogen into fibrin monomer by clipping off two peptides 
(fibrinopeptides A and B) from either end of the fibrinogen molecule. Removal of these 
peptides exposes the polymerization sites of the fibrin monomer, which can bind to other 
fibrin monomers producing fibrin polymers. The fibrin polymers assemble by non-covalent 
interactions, forming a loose clot. FXIIIa then covalently crosslinks the fibrin polymers by 
forming ε-(γ glutamyl) lysine bonds between the side chains, resulting in a stable 
thrombus.6 Additionally, thrombin activates TAFI, inhibiting fibrinolysis and promoting 
coagulation. TAFI catalyzing the removal of C-terminal lysines of partially degraded 
fibrin, which are binding sites for plasminogen (see below).7  
2.1.6 Fibrinolysis 
Fibrinolysis is the breakdown of blood clots, which prevents clots from growing 
too large and becoming problematic, aids in wound healing, and prevents thrombosis in 
undesired locations. Plasminogen, an inactive precursor to plasmin, is in circulation and 
becomes incorporated into the clot. Plasminogen is activated by tissue plasminogen 
activator (tPA), urokinase plasminogen activator (uPA), FXIa, and FXIIa.  
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The most important plasminogen activator is tPA, which is slowly released from 
the endothelium of the injured blood vessel. As tPA filters through the clot, it can bind to 
fibrin to convert plasminogen into plasmin. Plasmin is a serine protease that cleaves bonds 
in fibrin and fibrinogen, released during clot lysis. The rate at which tPA cleaves 
plasminogen is significantly higher when both molecules are bound to the fibrin clot. 
Plasminogen binds to the C-terminal lysine residues of fibrin.1, 8 
Fibrinolysis is also regulated by several mechanisms. First, uPA and tPA are 
inhibited by plasminogen activator inhibitors (PAI-1 and PAI-2). Any excess uPA and tPA 
in the plasma is rapidly bound and inactivated by PAI-1 and PAI-2, which helps confine 
active fibrinolysis to the thrombus. Additionally, any plasmin free in the plasma is rapidly 
deactivated by α2-antiplasmin and α2-macroglobulin. However, plasmin bound to fibrin is 
protected from inactivation.  Lastly, the fibrin clot is protected by TAFI, an enzyme 
activated by thrombin, that removes C-terminal lysine residues from the fibrin strand that 
are required for the binding of plasminogen to the clot.8  
 
 
 
Figure 2-2. Simplified pathway of fibrinolysis.8 
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2.1.7 Function of Platelets 
Briefly, platelets are produced in the bone marrow by budding off the edges of 
megakaryocytes. Platelets are found freely circulating or sequestered in the spleen (one-
third of platelets are in the spleen). The four main functions of platelets are to (1) adhere 
to damaged endothelium, (2) store adenosine diphosphate (ADP) and proteins, (3) 
aggregate with other platelets, and (4) provide a surface for coagulation reactions 
(“quaternary complex”).  
Platelets in circulation survey the integrity of the vascular system, responding to 
lesions adhering to damaged endothelial cells and to extracellular matrix components 
exposed to flowing blood. Platelet adhesion to wound sites is mediated by von Willebrand 
factor (VWF), an adhesive glycoprotein present in plasma. VWF binds to exposed 
collagen, inducing a structural change in VWF for platelet attachment. The two distinct 
platelet receptors for VWF are glycoprotein (GP) Ibα in the GP Ib-IX-V complex and the 
integrin αIIbβ3 in the GP IIb-IIa complex. Binding of VWF to platelet receptors initiates 
platelet activation and creates a platelet monolayer over the injured surface.9 
Platelets contain granules for storage functions. Alpha granules store proteins, such 
as vWF and FV, and dense granules store chemicals, such as serotonin and ADP. Release 
of ADP activates nearby platelets, and further platelet activation also leads to the 
production of another platelet activator/agonist, thromboxane A2. Such platelet agonists 
play an important role in platelet aggregation.1  
After platelets have formed a monolayer on an injured surface by adhering to the 
vasculature, they release platelet agonists such as ADP, which activates the platelet 
receptors GP IIb/IIIa of nearby platelets. Activation of GP IIb/IIIa can occur due to various 
processes including: (1) binding of vWF to GP Ib, (2) binding of platelet agonist such as 
ADP and thromboxane A2 to platelet receptors, and (3) binding of thrombin to platelet 
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thrombin receptor. Thrombin is known as the most potent physiologic activator of platelets. 
Furthermore, thrombin links the humoral phase of coagulation (e.g. tissue factor, etc.) to 
platelet activation. Activation of GP IIb/IIIa leads to platelet aggregation. Active GP 
IIb/IIIa receptors exposed on the platelet surface bind to fibrinogen (abundant in the 
plasma), which acts as glue for platelet aggregation. As the platelets aggregate into a large 
mass, they form a platelet plug to stop bleeding.1  
Furthermore, as part of the “quaternary complexes”, activated platelets serve as a 
surface on which coagulation reactions occur. Activation of platelets exposes a negatively 
charged phospholipid called phosphatidylserine which augments the binding of 
coagulation proteins to the injured site. Additionally, blebs called platelet microparticles 
bubble off the surface of activated platelets to increase the surface area for coagulation 
reactions.1  
2.1.8 Natural Anticoagulants 
 Natural anticoagulants regulate the coagulation cascade, ensuring that excess 
thrombosis does not occur. These protein inhibitors are tissue factor pathway inhibitor 
(TFPI), protein C, protein S, and antithrombin. TFPI rapidly shuts down the activation of 
FX by binding to FXa. This TFPI-FXa complex then forms a quaternary complex with TF-
FVIIa, which also stops the activation of FIX. However, the coagulation cascade can still 
proceed through thrombin activation of FXI, which then actives FIX and leads to more 
thrombin generation.   Protein C is serine protease that cleaves FVa and FVIIIa specifically. 
Protein S is a cofactor that is critical for the function of protein C. Protein S circulates in 
two forms, a free form and a form bound to C4B-binding protein, and free form (normally 
around 40% of protein S) serves as a cofactor to protein C. Lastly, antithrombin is a serine 
protease inhibitor that binds and inactivates all serine proteases in the coagulation cascade 
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(see Table 2-1). Heparan (a glycosaminoglycan in extracellular matrix produced by all cell 
types) and heparin (a glycosaminoglycan produced only by mast cells) are anticoagulants 
that dramatically increase the function of antithrombin.1 
 
2.2 HEMOPHILIA B 
2.2.1 Overview 
Hemophilia, the oldest known hereditary bleeding disorder, is characterized by 
spontaneous and prolonged bleeding in the joints, muscle and internal organs 10. It is 
potentially life-threatening and is often associated with disabling arthropathy resulting 
from recurring joint bleeding episodes. Hemophilia A and hemophilia B are congenital X-
chromosome linked coagulation disorders, which arise from the deficiency in coagulation 
factor VIII (FVIII, MW=264 kDa) or factor IX (FIX, MW=57 kDa), respectively, normally 
expressed in the liver. Hemophilia A is the most common with approximately 80% of 
hemophilia cases.11, 12 However, hemophilia B affects 80,000 males worldwide.10 We have 
selected hemophilia B as the target disease for developing an oral delivery system of FIX, 
taking into consideration protein size.  
2.2.2 Causes 
Hemophilia B is a genetic disorder caused by a mutation in the F9 gene encoding 
FIX located on the X chromosome. (See Section 2.3.2 Mutations in F9 Gene for more 
details about the genetic causes.) Hemophilia B is usually inherited; however, in 30% of 
the cases, hemophilia B is caused by a sporadic mutation.11-13 In the inherited cases, 
hemophilia B is inherited in an X-linked recessive manner, meaning that males (XY) with 
one mutated X chromosome and females (XX) with two mutated X chromosomes 
(although rare) have hemophilia B. A female with a single mutated X chromosome is a 
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genetic carrier. In the case of a father without hemophilia and a mother who is a carrier, 
50% of their sons will have hemophilia and 50% of their daughters will be carriers (Figure 
2-3). In the case of a father with hemophilia and mother without hemophilia, none of their 
sons will have hemophilia, but all their daughters will be carriers. Female carriers may 
exhibit symptoms of hemophilia B due to the lyonization (X-inactivation). Lyonization is 
a normal phenomenon in which one of the two haploid sets of X-linked genes in a cell are 
inactivated at random and have no phenotypic expression. On average, carriers have about 
50% of the normal amount of clotting factor due to suppression of about half of the normal 
F9 gene. However, some carriers have far lower levels of FIX.12  
 
 
Figure 2-3. Inheritance of hemophilia in the case of a father without hemophilia and a 
mother who is a carrier.11 
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2.2.3 Symptoms 
The clinical severity of hemophilia is related to level of factor IX deficiency in the 
blood, which affects the symptoms. The classifications of hemophilia B and associated 
symptoms are outlined in Table 2-2.2, 10, 13-16 Generally, patients with severe disease often 
have unprovoked bleeding, while patients with moderate disease tend to bleed with trauma. 
Patients with severe disease often only bleed as a result of severe trauma, surgery, or dental 
procedures.  
 
Table 2-2. Classification of hemophilia B. Classifications are based on in vitro clotting 
activity (1 % = 1 IU/dL).13  
Clinical 
severity 
Factor IX 
clotting 
activity 
Cases 
by 
severity 
Symptoms 
Typical 
age of 
diagnosis 
Severe < 1% 60% 
Frequent spontaneous bleeding (2-5/mo.); 
spontaneous joint bleeding; bruises and 
hematomas not due to trauma 
≤ 2 years 
Moderate 1% - 5% 15% 
Rare spontaneous bleeding (1/mo.–1/yr.); 
joint bleeding; bruises and hematomas not 
due to trauma 
< 5 – 6 
years 
Mild >5%- 30% 25% 
No spontaneous bleeding (< 1/yr.); often 
no outward signs 
Often later 
in life 
 
Hemarthrosis, bleeding into joint spaces, is a common symptom of hemophilia. The 
knee and elbow are the most common sites of joint bleeding, but the ankle and shoulder 
can also be affected. Typically, the bleeding starts with hemorrhage into the synovial space, 
where the presence of intrasynovial blood causes an inflammatory reaction. Inflammation 
leads to pain, warmth, and swelling. Subsequently, synovium hypertrophies 
(inflammation) and increased vascularity lead to the recurrence of joint bleeding. Patients 
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can develop “target joints” where recurrent bleeding episodes can occur, leading to 
permanent damage and chronic pain. Untreated hemarthroses commonly results in 
crippling arthritis and ultimately joint failure, typically requiring joint replacement. 
Furthermore, hemophilia patients have a 15-40 times greater incidence rate of developing 
septic arthritis than the general population.17   
Another common symptom of hemophilia is intramuscular hematomas caused by 
muscle bleeding. Muscle bleeding in any limb can be further complicated by compartment 
syndrome (excessive pressure build up caused by internal bleeding and swelling), which 
may require surgical decompression if they progress despite factor replacement. Iliopsoas 
(inner hip muscles) muscle hematomas are particularly devastating to the patient, and may 
also be life-threatening. If compartment syndrome is developed in the psoas muscle as 
result of iliopsoas muscle hematomas, compression of the femoral nerve can result in 
paralysis of the quadriceps muscle group.1 
Internal bleeding in the brain is a very serious complication of hemophilia may be 
a result of minor trauma or may occur spontaneously, particularly in patients with severe 
disease. Associated symptoms include long-lasting headaches, repeated vomiting, 
sleepiness, behavioral changes, double vision, convulsions, and seizures.11 Cerebral 
hemorrhages are the leading case of hemorrhagic death.1 
About one third of carriers are classified as a symptomatic carrier, meaning she has 
40-60% of FIX activity levels and experiences abnormal bleeding. In most cases, the 
symptoms of symptomatic carriers are similar to that of men with mild hemophilia. 
However, symptomatic carriers often have heavier, more prolonged menstrual bleeding 
(termed menorrhagia) and are more likely to require an iron supplement. Females are also 
more likely to experience pain during menstrual bleeding (termed dysmenorrhea), as well 
as experience some internal bleeding during ovulation causing mid-cycle pain. Mid-cycle 
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bleeding can become severe or even life-threatening, especially in carriers with very low 
FIX levels. Carriers also have a higher risk of developing hemorrhagic ovarian cysts due 
to increased internal bleeding during ovulation. These cysts are typically painful and may 
require urgent medical care. Additionally, carriers are also at higher risk to develop 
endometriosis.12  
Additionally, labor and delivery can affect carriers (and females with hemophilia 
B), as well as male babies with hemophilia B. Male babies with hemophilia are at an 
increased risk of head bleeding during labor and delivery, particularly if the process is 
prolonged. Carriers of hemophilia, especially symptomatic carriers and women with 
hemophilia, have an increased risk of postpartum hemorrhage. In developing countries, 
postpartum hemorrhage is a major cause of maternal death and disability.12  
2.2.4 Diagnosis  
The typical age at diagnosis depends on the clinical severity of hemophilia B (Table 
2-2). In the United States, most people with hemophilia are diagnosed at a young age. Over 
the past decade, increased awareness and improved recognition has resulted in over 50% 
of cases being diagnosed in the newborn period.18  In the United States, the median age at 
diagnosis is 36 months for mild hemophilia, 8 months for moderate hemophilia, and 1 
month for severe hemophilia, which is particularly affected by known family history.19   
Diagnosis includes screening tests to determine if the blood is clotting properly and 
clotting factor tests (factor assays) to diagnose the specific bleeding disorder. Various 
screening tests are complete blood count (CBC), activated partial thromboplastin time 
(APTT) test, prothrombin time (PT) test, and fibrinogen test.  CBC is a common test used 
to measure the amount of hemoglobin, the size and number of red blood cells, and the 
amounts of different types of white blood cells and platelets. Typically, the CBC results 
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are normal in hemophilia patients; however, the hemoglobin and red blood cell count might 
be low due to unusually heavy or prolonged bleeding.11 APTT tests measure clotting time, 
primarily based on the clotting abilities of FVIII, FIX, FXI, and FXII. Normal times are 
25-35 seconds, while deficiency of FIX prolongs clotting by up to 2.5 times. PT tests 
measure clotting time, primarily based on the clotting abilities of fibrinogen, prothrombin, 
FV, FVII, and FX. Results for hemophilia B patients are not affected. Fibrinogen tests, 
which measure clotting time based on fibrinogen activity, are used when APPT and PT 
results are abnormal. Specific clotting factor tests are used to determine the activity of 
individual clotting factors, which determine the type of hemophilia and severity.11  
Given a known family history of bleeding disorders, many families elect to have 
their male babies tested after delivery. If a mother is a known carrier of hemophilia, testing 
can be performed during pregnancy. Options for prenatal diagnosis include chorionic villus 
sampling at 9 to 11 weeks or amniocentesis (amniotic fluid sampling) at 15 to 20 weeks.12 
Immediately after birth, a blood sample is drawn from the umbilical cord and tested for 
clotting factor levels. While low levels of FVIII are strongly indicative of hemophilia A, 
results for FIX are not as conclusive. FIX takes longer to develop, taking about 6 months 
of age to reach normal levels. Mildly low FIX level at birth are not necessary due to 
hemophilia B, but significantly decreased levels are indicative of hemophilia B. Repeating 
the test is recommended when the baby is older.11  Without knowledge of family history 
or in the case of sporadic hemophilia, the time of diagnosis is based on outward signs and 
symptoms.  
Genetic testing is also available; however, accessibility may be limited by cost and 
regulatory bodies, and are associated with ethical and cultural concerns. Genetic testing 
may be useful for carrier testing, treatment of hemophilia patients, and, in the future, 
determination of eligibility for gene therapy. Genetic testing for factor IX mutations require 
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scanning the entire gene, since there are no common mutations causing hemophilia B. In 
the case of a potential carrier, the National Hemophilia Foundation’s Medical and 
Scientific Advisory Council recommends carrier testing before becoming pregnant. Carrier 
testing will first use clotting factor tests. However, if these test results are inclusive, genetic 
testing is recommended.13  
In the case of known family history, especially if the female is a known carrier, 
families should consider genetic counseling when family planning. Female carriers have 
options available for conception, prenatal diagnosis, and fetal sex determination. To 
minimize or eliminate the risk of having a child with hemophilia, there are currently three 
conception options:  
 In vitro fertilization (IVF) with pre-implantation diagnosis: embryos are 
genetically tested and ones without the mutated gene are implanted 
 IVF with egg donation: donor eggs from a woman that is not a carrier 
 Sperm sorting: only sperm carrying an X chromosome are used, ensuring 
the birth of a female child 
All these procedures are expensive and not available in many parts of the world, as well as 
have ethical, cultural, and religious implications. Additionally, they have other associated 
risks. The success rate of IVF is approximately 30%. For the pre-implantation diagnosis, 
prenatal testing is still recommended. In the case of sperm sorting, this method is only 
available in specialized centers as a research tool and is still under evaluation. Furthermore, 
sperm sorting will only ensure a female child, but this child may still inherit the altered 
gene and be a carrier. For a female carrier, male babies will inherit the mutated gene for 
hemophilia. Determining the sex can provide options regarding the pregnancy, as well as 
allow for planning of labor and delivery to minimize bleeding of the male fetus. Fetal sex 
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determination can be tested by fetal sex typing from maternal plasma at 8 weeks or by 
ultrasound scan at 15 weeks.12  
 Genetic testing for F9 mutations requires sequencing of the entire F9 gene. A well-
standardized method is DNA amplification by PCR followed by direct sequencing. 
However, PCR is generally not able to detect large deletions or other gross abnormalities 
in carriers due to the presence of the other allele (normal F9 gene). Although such 
mutations are uncommon, they are nearly always associated with severe disease, making 
the carrier status important.20 Recently new techniques, such as multiplex ligation-
dependent probe amplification (MLPA) and multiplex amplification and probe 
hybridization (MAPH), have been successfully applied to sequencing the F9 gene.21, 22   
 
2.3 FACTOR IX 
2.3.1 Structure and Function 
Factor IX (also known as Christmas factor) is a vitamin K-dependent coagulation 
glycoprotein (17 wt. % carbohydrate). The average plasma concentration of FIX is 2.5-5 
μg/mL, and its half-life in circulation is 24 hours. hFIX is a single chain consisting of 415 
amino acid (aa) residues with a molecular weight of 57 kDa (note that recombinant hFIX 
is 55 kDa). F9 gene (for FIX) was fully sequenced in 1985.23 F9 is located at Xq27.1, 
spanning 33 kbp (kilo-base pair). The gene contains eight exons which are transcribed into 
a 2802-bp mRNA. This mRNA is then translated into a 461-amino acid (aa) sequence from 
which a 28-aa signal peptide and a 18-aa propeptide are removed, leaving a 415-aa mature 
protein. The primary translocation product has an approximate molecular weight of 52-
kDa.20 
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The structure of FIX can be broken down into six domains: (1) γ-carboxylation acid 
(Gla), (2) short hydrophobic stack, (3) epidermal growth factor 1 (EGF1), (4) EGF2, (5) 
activation peptide, and (6) serine protease (Figure 2-4). 24, 25  The activation of FIX, either 
by TF-FVIIa or FXIa, occurs after the double cleavage of peptide bonds after the Arg192 
and Arg 266, releasing the activation peptide (MW=11 kDa). Activated FIX (FIXa) has a 
light chain, (Gla, EGF1, and EGF2 domains) and a heavy chain (serine protease) held 
together by a single disulfide bond (Cys178-Cys335). FIXa has catalytic activity due to the 
exposed catalytic triad of the serine protease domain. 24   
 
 
Figure 2-4. Structure of factor IX. Individual domains are color coded. Note that the red 
spheres are calcium ions. (Adapted from College.25) 
 
The Gla domain contains 11 glutamic acid residues that are post-translationally 
modified to 4-carboxyglutamate. As previously mentioned, these modified residues are 
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necessary for the binding of calcium ions. The binding of calcium ions give the Gla domain 
a positive charge which interacts with the negatively charged phospholipid membrane.20  
The catalytic triad, which is characteristic of serine proteases, is made up of His267, 
Asp315, and Ser411.20 FIXa on its own is relatively inefficient in activating its preferred 
substrate, FX. However, when FIXa is non-covalently bound to its cofactor, FVIIIa, and 
forms a macromolecular intrinsic tenase complex, its specific activity is increased by 
50,000-fold.26 Additionally, docking on a phospholipid membrane (forming a “quaternary 
complex”) further enhances its catalytic activity. While the structure of the FIXa-FVIIIa 
complex has not been determined, it can be inferred from published crystal structures of 
porcine FIXa,27 individual domains of hFIXa,28-30 and hFVIII.31, 32 Based on the porcine 
FIXa structure shown in Figure 2-5, the light chain (Gla, EGF1, and EGF2 domains) of 
FIXa forms a stalk with the Gla domain at bottom end, allowing the Gla domain to attach 
to the phospholipid membrane. The top of the stalk is the serine protease (catalytic 
domain), which has a globular structure.20 Interactions with FVIIIa include critical residues 
in the EGF1, EGF2, and catalytic domains of FIXa.32, 33  
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Figure 2-5. Structure of porcine activated factor IX. Individual domains are shown in 
shades of grey. (PDB ID: 1PFX)20 
 
2.3.2 Mutations in F9 Gene 
Approximately 900 distinct mutations in the F9 gene are reported across three 
public databases (Haemophilia B Mutation Database; Coagulation Serine Protease 
Mutation Database; The Human Gene Mutation Database). The different types of genetic 
defects reported in hemophilia B are categorized in Figure 2-6.  
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Figure 2-6. Categories of genetic defects reported in hemophilia B. (Note that indel 
means insertion or deletion of bases in DNA.)20    
 
Point mutations are the most common type of abnormality found in hemophilia B 
(64% of all mutations). Analysis of the number of mutations reported at each position 
showed that certain nucleotides are more frequently mutated (“mutation hotspots”). One 
example of “mutation hotspots” is the overexpression of arginine residues, which can be 
explained by the effect of CpG islands (increased mutation rate in the regions with a high 
frequency of cytosine and guanine nucleotides typically found near transcription start sites 
of genes).34 Furthermore, point mutations causing hemophilia B that occur during meiosis 
are more frequent in the male gamete.35  The location of the point mutation affects the 
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severity of the disease. Point mutations can result in missense mutations, premature stop 
codons, or splicing.  
Missense mutations can provide information about the function of specific regions 
of the protein. Missense mutations are classified into two broad types: 
 Type I: quantitative mutations resulting in reduced levels of an otherwise 
normal protein 
 Type II: qualitative mutants of the protein having reduced function that may be 
presence at either normal or reduced amount.  
Many missense mutations can belong to both categories. 
Type I mutations can be a result of a mutation in the signal peptide (residues 1-28), 
which directs intracellular trafficking of the protein and has no effect on the function of the 
circulating form. Defects in the signal peptide can lead to reduced levels of secretion, 
producing a full spectrum of disease severity. Most Type I defects are caused by 
impairment of transcription or protein secretion.20 
However, approximately 60% of the mutations that cause hemophilia B are 
predominantly type II, which is unusual in coagulation factor deficiency. Type II mutations 
that occur in triad of residues forming the active site render the protein in incapable of 
catalytic activity, resulting in severe hemophilia B. Another example of type II defects is 
mutations in the propeptide (residues 29-46), which mediates the interaction with the 
vitamin K-dependent γ-carboxylase. Mutations in this region produce proteins with 
reduced function due to impaired phospholipid binding.36  
A nonsense mutation is a single point mutation that results in a premature stop 
codon. Generally, nonsense mutations result in a severe type I defect with no protein 
production. However, nonsense mutations can occur near the C-terminal end which results 
in the production of a truncated, non-functional protein (type II defect).  
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Splicing defects accounts for 9% of all mutations and can results in a range of 
disease severity. One cause of splicing mutations is a single point mutation that destroys a 
splice donor site, generally resulting in a nonsense mRNA. Secondly, a point mutation in 
the sequence of an intron can create an alternative splice acceptor site which may result in 
a nonsense mRNA.20  
Other occurrences of “mutation hotspots” can be explained by the founder effect 
where specific mutations occur more frequently in a particular, geographically restricted 
hemophilia B population. Such mutations indicate the inheritance of a discrete rare 
haplotype, which has become more prevalent in population with a relatively restricted gene 
pool. Examples of mutations due to the founder effect have been reported in North 
America,37 the United Kingdom,38 and Ireland.39  
Unlike the previously described mutations in the coding sequence, mutations in the 
gene’s regulatory elements in the non-coding sequence (2% of all mutations) can result in 
type I defects. There are several known mutations that affect transcription factor binding 
sites in the F9 promoter. Some of these mutations cause a type I defect with FIX levels at 
a stable low level throughout life. However, mutations in the F9 promoter region can also 
cause hemophilia B Leyden. The hemophilia B Leyden phenotype is characterized by a 
severe deficiency in FIX at birth, then FIX levels starts to increase during the second decade 
of life, and FIX levels near normality are achieved in the third decade. After that, normal 
or near-normal levels are maintained through life. The mutations that cause hemophilia B 
Leyden occur in promoter regions not associated with the androgen response element 
(ARE), which regulates transcription levels following the hormonal changes associated 
with puberty. Transcription of the F9 gene is upregulated as testosterone levels increase, 
which therefore produces more FIX after puberty.40, 41  
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The insertion or deletion of a few nucleotides can result in hemophilia B (indels are 
18% of all mutations). These mutations, which often occur in sequences of dinucleotide 
repeats, are commonly in the intron sequence and, therefore, have no effect. However, 
indels can occasionally occur in regulatory elements or result in frame-shifts. Frame-shift 
errors likely result in a severe FIX deficiency.20 
Gross genetic abnormalities, which include gene rearrangements or large deletions, 
account for 7% of hemophilia B cases. In hemophilia B, deletions are more common than 
inversions in F9. A complete deletion of F9, or null allele, results in severe hemophilia B. 
Since the probability of inhibitor formation is related to severity and type of genetic defect, 
a null allele results in the greatest risk of inhibitor formation.42  
 
2.4 HEMOPHILIA B TREATMENTS 
2.4.1 Treatment 
In the late 1950s and early 1960s, hemophilia B was treated using fresh frozen 
plasma (FFP) or prothrombin complex concentrates (PCC). PCCs were prepared by 
absorbing plasma from the vitamin K-dependent proteins and the final product not only 
contained FIX, but prothrombin, FVII, and FX. Due to the lack of purity, these products 
were associated with numerous complications including excessive activation of the 
coagulation pathway and large volumes (especially for FFP) to achieve desired FIX 
levels.1, 13 By the 1970s, lyophilized powder concentrates of FIX became available, 
allowing for home storage and self-infusion.13  However, these blood factors were 
originally plasma derived. Until relatively recently, procuring a safe blood supply was 
difficult, with risks of transmitting hepatitis and HIV viruses to patients receiving blood-
derived products. Specifically, over 60% of hemophiliac patients were accidently 
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infected.43 Due to the advancements in blood screening for infectious agents and methods 
for viral inactivation, the production process for deriving factors from human plasma is 
now significantly safer.43 In the 1990s, plasma-derived FIX products with improved purity 
and safety entered the market.13 In 1997, the first recombinant FIX (granted to Genetics 
Institute; now a Pfizer product under the tradename BeneFIX®) was approved by the 
FDA.43 Additionally, use of prophylaxis in children became more common during the mid-
1990s, which has improved patients’ quality of life and life expectancy. Now, fusion 
proteins are engineered to improve pharmacokinetics in order prolong circulation time. In 
March 2014, the FDA approved the first long-lasting recombinant FIX Fc fusion protein 
(ALPROLIX®  by Biogen Idec®).44  
 
 
Figure 2-7. Average life expectancy of hemophilia patients. Better treatments have 
increased the life expectancy of hemophilia patients.13 
 
Current treatment for hemophilia B consists of protein replacement therapy of 
plasma-derived or, more recently, recombinant factor IX concentrates. On-demand 
treatment, required after a bleeding event, is given as an intravenous (IV) injection or by 
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continuous infusion. Advancements in hemophilia treatments have significantly increased 
the life expectancy of hemophilia patients (Figure 2-7). Although this treatment markedly 
improves both the life expectancy and the quality of life of the hemophilia patients, it 
suffers from low patient compliance due to fear, pain, and embarrassment associated with 
needle-based treatments.45  
Prophylactic therapy is the administration of replacement therapy in the absence of 
bleeding as a protective measure. Regimens are tailored on a per patient basis with intervals 
typically ranging from every other day to two or three infusions per week 45. ALPROLIX® 
(Biogen Idec®), a recombinant FIX Fc fusion protein with a longer half-life in the 
circulation, only requires infusions once per week (at maximum) for hemophilia B 
prophylactic therapy. 44 The benefits of a prophylaxis regimen include: 
 Greatly reduced or ceased spontaneous bleeding episodes by a one to five 
percent increase in circulating factor IX 45  
 Prevention of future joint disease by early initiation (1-2 years of age) of 
prophylaxis 46  
 More effective than on-demand treatment, even at a later start (> 2 years of age). 
47, 48 
In 2007, the National Hemophilia Foundation Medical and Scientific Advisory Council 
recommend prophylactic treatments as optimal therapy for children with severe hemophilia 
B.13 In 2013, about 33% of patients with severe hemophilia B used prophylaxis, while 
patients with moderate and mild hemophilia B mainly relied on on-demand treatments. The 
average prophylaxis rates were 15% globally and 27% in the United States in 2013.49 
However, the major challenge, especially with children, is the need for venous 
access. Central venous access devices must be surgically implanted and have associated 
risks of infection and thrombosis. An alternative is using an arteriovenous fistula to treat 
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children, but long-term effects are not well established.48 Issues with venous access, as well 
as variability in severe hemophilic phenotype, can result in unnecessary invasive 
procedures for children. 
Overall, therapies, both on-demand and prophylactic, are not getting to those who 
need them due to economic, societal, and practical hindrances. Global accessibility is 
limited due to costs associated with the drug, medical care, and possible complications with 
therapy.45 Without modern treatments, the median life expectancy is 11 years, which is still 
the case in many developing countries.14 In order to improve the worldwide use of 
prophylactic therapy and prevent invasive procedures in children, alternative delivery 
methods and less expensive treatment approaches are necessary.  
2.4.2 Commercially Available Products and Market 
Current products for the treatment of hemophilia B include plasma-derived FIX, 
recombinant FIX, and long-lasting recombinant FIX, as outlined in Table 2-3.  
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Table 2-3. Current commercially available products for hemophilia B treatment.49 
Company Product Type Use 
FDA 
Approval 
CSL Behring Mononine/Berinin-P Plasma-derived On-demand  1992 
Baxter/Baxalta Immunine Plasma-derived 
On-demand and 
prophylaxis  
Not for 
use in US 
Grifols AlphaNine SD Plasma-derived On-demand 1996 
Octapharma Octanine Plasma-derived On-demand 
Not for 
use in US 
Pfizer BeneFIX Recombinant On-demand 1997 
Baxter/Baxalta RIXUBUS Recombinant 
On-demand and 
prophylaxis 
June 
2013 
Biogen Idec ALPROLIX 
Long-lasting 
recombinant,  
Fc fusion 
On-demand and 
prophylaxis 
March 
2014 
Cangene/Emergent 
BioSolutions 
IXINITY Recombinant  On-demand  
May 
2015 
CSL Behring IDELVION 
Long-lasting 
recombinant, 
albumin fusion 
On-demand and 
prophylaxis 
March 
2016 
 
 
The global market for hemophilia B in 2013 was $1.2B for the 80,000 patients 
worldwide. Currently, it is estimated that 30% of individuals with hemophilia B have been 
diagnosed and are receiving treatment. Additionally, more patients are seeking out 
prophylactic treatments, especially as new products are entering the market. As a result, 
the global market is projected to grow at an average rate of 9% to reach over $1.8B by 
2016.49 
Pfizer is the market share leader in hemophilia B treatment. BeneFIX® is one of 
Pfizer’s major products with an annual revenue of $213M worldwide and $97M in the 
United States in 2013. Baxter/Baxalta released RIXUBISTM, the first recombinant FIX 
product for prophylaxis (FDA approved in June 2013), which resulted in a short term 
market advantage.49 However, the emergence of long-lasting products with reduced 
 31 
injection frequency and therefore increased patient compliance are expected to capture a 
significant share of the market. For example, Biogen Idec’s ALPROLIX® is a long-lasting 
therapy that offers the convenience of less frequent injections. As the first long-lasting 
factor IX to reach the market, ALPROLIX® is expected to capture a significant share of 
the market. Since receiving FDA approval in March 2014, Aprolix has brought in $10M in 
revenue for Q2. Barclays Capital analysis forecasted $75M in annual sales for 
ALPROLIX® in 2014, reaching $581M in 2020.50 The market for hemophilia B treatments 
is beginning to shift to therapies that offer improved patient compliance and convenience 
(Figure 2-8). 
 
 
Figure 2-8. The market share for recombinant factor IX products. Based on 2016 
estimates, the market is expected to shift to emerging long-lasting 
products.49 
 
2.4.3 Product Pipeline and Recently Approved Products 
The trend in emerging products for hemophilia is engineering FIX for improved 
pharmacokinetics with prolonged circulation times. Increasing the half-life (t1/2) of a 
recombinant FIX product can reduce the frequency of injections and improve patient 
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compliance. Table 2-4 summarizes the FIX products that have been recently FDA 
approved, as well as products that are currently in the development pipeline.  
 One strategy for prolonging circulation time is based on the widespread approach 
of Fc fusion proteins. The complete fusion protein molecule can be expressed 
recombinantly, eliminating the need for a chemical modification step (i.e. PEGylation).43   
Notably, ALPROLIXTM is a recombinant factor IX-Fc fusion protein (rFIXFc) that was 
designed to contain a single FIX molecule recombinantly attached to the constant region 
(Fc) of immunoglobulin G (IgG). The purpose of the Fc domain is to protect the fusion 
protein from catabolism by using the natural pathway mediated by Fc receptor (FcRn) that 
protects IgG antibodies from degradation.51 
 PEGylation of proteins is another strategy to improve intestinal delivery by 
minimizing activity loss and extending circulation time.52-54 Novo Nordisk has post-
translationally modified FIX by using the GlycoPEGylationTM technology. Using this 
method, site-specific PEGylation was achieved by targeting native N-glycans as 
attachment sites for PEG (40 kDa). The PEG is covalently attached to the activation 
peptide, which is released when FIX is activated. PEGylation of FIX in this site-specific 
manner preserves its biologic activity while prolonging circulation time.52-54  
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Table 2-4. Recently marketed products and pipeline product for hemophilia B treatment. (Adapted from CHS55) 
Company Product Type Clinical Trials Description 
Baxter/Baxalta RIXUBUS Recombinant 
FDA approved in June 2013. In October 2014, received 
pediatric indication from FDA for children (< 12 
years). 
3rd generation rFIX manufactured 
without exposure to human and 
animal proteins, and with a normal 
half-life 
Biogen Idec 
ALPROLIX 
(rFIXFc) 
Recombinant,  
Fc fusion 
Phase III trial (B-Long) ended in June 2012; In July 
2012, Phase III trial was extended to children under 12. 
FDA approved in March 2014 for prophylaxis and to 
treat bleeding in patients (≥ 12 years). 
rFIX fused with Fc to extend half-life; 
Phase II/III trials showed a 2.5 times 
increase in half-life 
Emergent 
BioSolutions 
(previously 
Cangene) 
Ixinity 
Recombinant 
(trenonacog 
alfa) 
Phase III trials showed similar pharmacokinetics to 
BeneFIX with 24-h half-life, 84% of bleeds were 
controlled with 1-2 infusions, and no inhibitors or 
thrombotic events were observed.  
FDA approved in May 2015. 
3rd generation rFIX manufactured in a 
Chinese Hamster Ovary cell line 
without exposure to human and 
animal proteins, and with a normal 
half-life 
Baxter/Baxalta RIXUBUS Recombinant 
FDA approved in June 2013. In October 2014, received 
pediatric indication from FDA for children (< 12 
years). 
3rd generation rFIX manufactured 
without exposure to human and 
animal proteins, and with a normal 
half-life. 
CSL Behring IDELVION 
Recombinant, 
albumin 
fusion 
Granted orphan drug status by FDA in June 2012.  
Phase III trials in previously treated patients were 
completed. No serious adverse reactions were reported. 
FDA approved in March 2016. 
 
rFIX fused with recombinant human 
albumin. Phase III trials showed a 5 
times increase in half-life.  
Novo Nordisk 
NN79 (N9-
GP) 
Recombinant, 
PEGylated 
Phase III trial (paradigm 2) was completed in May 
2013. No inhibitors formed. 
In January 2016, filed a license application with the 
European Medicines Agency. 
Site-specific PEGylation for 
prolonged half-life. Reported a 5 
times increase in half-life. 
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2.4.4 Cost of Treatment 
The cost of treatment depends on the clinical severity, and therefore the use of 
prophylaxis. Generally, the total cost of treatment (including medications, inpatient, and 
outpatient care) increases with increasing severity. In a recent study with hemophilia A 
patients, patients with severe disease receiving prophylaxis had a total annual cost of about 
$300,000 on average, while the total annual cost for patients with mild disease was about 
$60,000. However, 94% of total costs for the patients with severe disease receiving 
prophylaxis was for clotting factors, while only 54% of total costs for patients with mild 
disease was for clotting factors.56 This cost breakdown showed that patients on 
prophylactic therapy have fewer bleeding episodes and less ER visits, especially compared 
to patient with severe disease only using on-demand treatment. Similar trends in costs 
based on severity and treatment type can be expected for hemophilia B patients.  
A recent study also showed that treatment costs vary with age. For hemophilia B 
patients with moderate and severe disease (not including patients with inhibitor formation) 
in the United States, the total cost of treatment increases during the first three decades of 
life, peaking at an annual cost of $453,179 at age 29, and then decreasing during the fourth 
and fifth decades of life (Figure 2-9).57 However, the annual out-of-pocket costs per patient 
remain relatively steady at an average of $1,838 per year. In 2012, the breakdown of the 
payer cost (insurance cost) was on average $206,027 for medications, $109,401 for 
inpatient care, and $34,702 for outpatient care.57  
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Figure 2-9. Payer costs for hemophilia A and hemophilia B patients by patient age. (Data 
from Eldar-Lissai et al.57, figure from OptumRx 58).  
 
2.4.5 Inhibitors 
Another serious complication associated with protein replacement therapy is the 
development of humoral immune (Th2) responses to functional clotting factors in some 
hemophilia patients.59 As a result of a helper-T-cell-dependent (Th2) response, inhibitory 
antibodies (inhibitors) form against the replaced clotting factor, which, in turn, increases 
the risk of bleeding-related morbidity, specifically nephrosis, and mortality. Furthermore, 
high-titer inhibitors (>5 Bethesda units, BU/mL) prevent treatment with coagulation factor 
products. Immune tolerance induction (ITI) protocols, requiring frequent high dose IV 
infusions for months to several years, can eliminate inhibitor development. ITI costs can 
reach up to several million US dollars annually, 59 which is significantly greater than 
treating patients without inhibitor development. Although the overall incidence of 
inhibitors for hemophilia B is relatively low (1.5-3% of all cases), 9-23% of patients with 
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severe hemophilia form high-titer inhibitors. In addition, ITI protocols are less effective in 
treating FIX inhibitors than FVIII inhibitors.42, 60 Up to 50% of patients with FIX inhibitors 
may experience potentially life-threatening anaphylactic reactions.42 
2.4.6 Exploratory Treatments 
Gene therapy is one of the approaches currently under investigation for treatment 
of the disease. For hemophilia, this alternative can potentially provide constant, sustained 
FIX synthesis within the patient, thereby obviating the risk of spontaneous bleeding and 
the need for repeated injections or infusions. Gene therapy for hemophilia thus could 
completely cure the disease,61 but it is plagued by challenges related to safety, ethical 
issues, accessibility, and cost. Some of the issues with gene therapy, particularly with 
adeno-associated virus (AAV)-mediated options, include:   
 Human uncertainty with gene therapy, especially due to limited long-term 
studies and possible development of side effects 62, 63 
 High prevalence of neutralizing antibodies to AAV62-64 
 As a result, restricted access to the three ongoing clinical trials of AAV-
mediated gene therapy for severe hemophilia B patients 62, 65-67 
 Issue with manufacturing, such as product-related impurities and limited 
production size. 63, 68 
Additional overarching challenges deal with accessibility and affordability of gene 
therapy in both advanced and developing countries. According to one report, the cost of 
gene therapy is currently unknown. In the US, policy and insurance coverage also 
contribute to the uncertainties associated with gene therapy as a potential treatment for 
hemophilia B.69 Despite recent advantages in gene therapy for hemophilia, the clinical 
realization of this treatment is limited by challenges related to safety, ethical issues, 
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accessibility, and cost. Gene therapy has not met the need for a new method of treating 
hemophilia B, and an innovative treatment approach is still desired.  
Another exploratory treatment is an oral delivery method developed by Dr. Daniell, 
Dr. Herzog, and collaborators for FIX fused with cholera toxin B (CTB) (CTB-FIX) in the 
chloroplasts of transgenic tobacco plants for ITI therapy. Treatment by this method 
demonstrated suppression of an immune response and prevention of anaphylactic reactions 
to systemically delivered proteins in humanized hemophilia B mice.70 The CTB-FIX 
proteins orally administered in transgenic plant cells were non-functional, indicating that 
they serve only as antigens that prevent inhibitor responses and cannot function as protein 
replacement therapy. 70, 71 Additionally, possible genetic instability of transgenic plants 
could lead to unexpected side effects. 72 This approach only offers an alternative to ITI 
therapy, but does not treat nor prevent bleeding episodes and other symptoms associated 
with hemophilia.  
Further testing of this oral tolerance induction method showed effective inhibitor 
suppression in hemophilia B mice. Delivery of bioencapsulated CTB-FIX fusion protein 
to the Peyer’s patches of the intestinal epithelium induced an immune response that results 
in cytokine-mediated suppression,73 as well as regulation involving tolerogenic dendritic 
cells and T cell subsets.74 To further improve the safety of this bioencapsulated system, the 
investigators generated transplastomic lettuce cells for CTB-hFIX expression and 
demonstrated the suppression of inhibitor formation with orally delivered CTB-hFIX in 
lettuce cells. Furthermore, they have successfully generated transplastomic lettuces plants 
at an industrial scale that is highly efficient, cost-effective, and environmentally friendly. 
This study demonstrates the first clinical advancement of a protein drug made in edible 
plant cells for oral delivery. Additionally, these results are promising for developing a 
clinical ITI protocol in hemophilia patients.75  
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2.4 ORAL DELIVERY OF PROTEINS 
2.4.1 Oral Route of Administration 
The oral delivery of protein therapeutics is an ideal route of administration which 
offers a means to overcoming the issues with injections.  The benefits of oral delivery 
include ease of administration, increased compliance, and lower costs. However, there are 
two main challenges—maintaining protein functionality and increasing bioavailability—
that need to be addressed when designing an oral delivery system. In the oral delivery route, 
the protein therapeutic must first pass through the harsh environment of the gastrointestinal 
(GI) tract.  The protein structure must be maintained in the stomach which contains a large 
quantity of gastric juice and proteolytic enzymes to denature proteins. The second 
challenge to oral delivery is increasing the bioavailability of the protein. In order to reach 
circulation, the protein must be absorbed in the upper small intestine and pass through the 
epithelium into the bloodstream.  There is a narrow absorption window (4-6 hours) within 
the upper small intestine (pH ~5-7).  Due to its large surface area, the small intestine is the 
site of 95% of nutrient absorption. However, the epithelial layer can act as physical barrier 
and not readily uptake large molecules, such as proteins (~5-5000 kDa). Furthermore, the 
tight junctions between the epithelial cells are specifically designed to prevent the transfer 
of foreign material from the intestinal epithelium into the blood stream.76 Addressing the 
issues of the narrow absorption window and the barrier of the epithelium is necessary for 
increasing the bioavailability of orally delivered protein therapeutics. 
2.4.2 Complexation Hydrogels 
Hydrogels are three dimensional polymer networks that are insoluble due to the 
presence of physical and/or chemical crosslinks.77 In addition, hydrogels are often used in 
biomedical applications due to their biocompatibility and ability to imbibe large amounts 
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of water.  Complexation hydrogels are a specific class of hydrogels that form physical 
crosslinks through non-covalent interactions, such as hydrogen bonding.78 Our lab has 
successfully developed a class of environmentally sensitive complexation hydrogels 
capable of swelling and deswelling in response to the pH gradient found in the GI tract.  
Previous work by Peppas and collaborators has focused on the use of pH-
responsive anionic complexation hydrogels, specifically ones consisting of a 
poly(methacrylic acid) (PMAA) backbone with poly(ethylene glycol) (PEG) tethers 
(designated as P(MAA-g-EG)) crosslinked with PEG dimethacrylate (PEGDMA), as 
vehicles for oral protein delivery.79-83 Anionic complexation hydrogels have been 
engineered to overcome the challenges of an oral administration route by protecting 
proteins from the harsh environment of the stomach and delivering them to the small 
intestine (Figure 2-10). Their pH-responsive swelling, imparted by ionization of acid 
pendant groups, exploits the physiological changes along the gastrointestinal (GI) tract. At 
a low pH, hydrogen bonding between the carboxyl group of MAA and the etheric oxygen 
of the PEG chains results a collapsed polymer network with a small mesh size, ξ. As the 
environmental pH increases above the pKa of MAA (~4.8), deprotonation disrupts these 
interpolymer complexes and causes ionization and electrostatic repulsion of the acid groups 
of MAA, resulting in hydrogel swelling and increased mesh size.77, 84 Such hydrogels have 
been evaluated for the oral delivery of insulin (5.8 kDa),79, 81-83 calcitonin (3.4 kDa),85, 86 
interferon beta (23 kDa),85 and growth hormone (22 kDa).86 However, a polymeric carrier 
system has not been optimized for high molecular weight coagulation proteins, such as 
hFIX (57 kDa).  
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Figure 2-10. Complexation hydrogels are engineered to exploit the pH changes in the GI 
tract in order to (A) protect proteins from the harsh gastric conditions and 
(B) deliver them to the small intestine, where they can be absorbed into the 
bloodstream.  
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Chapter 3: Specific Aims 
Hemophilia B is a hereditary bleeding disorder caused by the deficiency of clotting 
protein factor IX (FIX), affecting 80,000 males worldwide. Protein replacement therapy 
can prevent spontaneous bleeding episodes and restore hemostasis, significantly improving 
the patient’s lifespan and quality of life. However, current treatment is limited to injection-
based methods which are associated with noncompliance, increased risk of needle injury, 
costly medical care (e.g. hospital visits, surgeries), and other complications (e.g. severe 
allergic reactions). As a result, such treatments are not readily available worldwide, and 
without treatment the median life expectancy drops to 11 years. Oral delivery of clotting 
factors can improve patients’ quality of life by ensuring safety, convenience, and ease of 
administration. A non-invasive oral delivery therapy is a highly desirable alternative and 
has the potential to make hemophilia treatment globally available. Development of a pH-
responsive polymeric microcarrier system for the oral delivery of human FIX (hFIX) has 
the potential to provide a novel method for treating hemophilia B patients and was 
accomplished by completing the following specific aims: 
 
 Specific Aim 1. Synthesize and characterize pH-responsive polymeric carriers 
composed of methacrylic acid and ethylene glycol as vehicles for the oral 
delivery of factor IX. P(MAA-g-EG) hydrogels were synthesized by bulk UV 
polymerization. Purified, dried polymer films were crushed and sieved into 
microparticles. Physical characterization included SEM for surface morphology 
and size distribution, potentiometric titration and FTIR for polymer composition, 
swelling studies for pH-responsive behavior, and in vitro cytotoxicity for 
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cytocompatibility. Formulations that exhibited the desired pH-responsive swelling 
and cytocompatibility were selected for further analysis. 
 Specific Aim 2. Evaluate the performance of P(MAA-g-EG) carriers in 
delivering active factor IX, and evaluate the formulation stability. 
Microparticles were loaded with hFIX by swelling in a protein solution at pH 7.4, 
and were then collapsed with acid to trap the protein in the polymer network. 
Loading efficiency was optimized by tailoring loading conditions, such as 
temperature, time, and buffer ionic strength. Release studies were performed using 
two-stage dissolution in biorelevant media mimicking the GI tract. hFIX was 
quantified by ELISA, and its activity was measured by a chromogenic activity 
assay. In vitro permeability of hFIX was assessed in transport studies using 
intestinal epithelial models. Stability testing of hFIX-loaded microparticles was 
conducted using three conditions specified by the FDA. An optimal formulation 
was selected for further in vivo analysis.  
 Specific Aim 3. Develop and characterize enzymatically degradable, pH-
responsive P(MAA-g-EG) carriers, and evaluate the performance in 
delivering active factor IX. An enzymatically degradable system was designed to 
improve hFIX release in the small intestine and therefore improve overall 
bioavailability. Uncrosslinked P(MAA-g-EG) polymer was synthesized by UV 
polymerization, and then purified uncrosslinked polymer was crosslinked with a 
peptide by EDC-NHS chemistry. The peptide-based crosslinking agent was 
designed to resist degradation by gastric enzymes, such as pepsin, and target 
degradation by intestinal enzymes, such as trypsin. The pH-responsive swelling and 
enzymatic degradation was confirmed by bright-field microscopy. In vitro 
cytotoxicity studies was performed to quantify the cytocompatibility of degradation 
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products. Loading efficiency of hFIX was determined for such carriers, and release 
studies were conducted using simulated gastric and intestinal conditions containing 
relevant enzymes. The effects of these microparticles and their degradation 
products on hFIX permeability was assessed using in vitro transport studies. 
 Specific Aim 4. Determine the in vivo biocompatibility and biodistribution of 
P(MAA-g-EG) carriers. For all in vivo studies, mice were administered 
microparticles by oral gavage. The acute and long-term toxicity of P(MAA-g-EG) 
carriers was evaluated by cytokine analysis, biochemical analysis for kidney and 
liver function, and tissue histology. For biodistribution and clearance, 
fluorescently-tagged microparticles were tracked over time using the IVIS® in vivo 
imaging system. For further analysis of biodistribution and bioadhesion, the 
gastrointestinal tract was removed and imaged.  
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Chapter 4: Design and Development of pH-Responsive Delivery 
Systems1 
4.1 INTRODUCTION 
This work focused the development of pH-responsive biomaterials to enable the 
oral route of human factor IX (hFIX). Previous work by Peppas and collaborators1-5 has 
focused on the use of pH-responsive anionic complexation hydrogels, specifically ones 
consisting of a poly(methacrylic acid) (PMAA) backbone with poly(ethylene glycol) 
(PEG) tethers (designated as P(MAA-g-EG)) crosslinked with PEG dimethacrylate 
(PEGDMA), as vehicles for oral protein delivery. 
Anionic complexation hydrogels have been engineered to overcome the challenges 
of an oral administration route by protecting proteins from the harsh environment of the 
stomach and delivering them to the small intestine. Their pH-responsive swelling, imparted 
by ionization of acid pendant groups, exploits the physiological changes along the 
gastrointestinal (GI) tract. At a low pH, hydrogen bonding between the carboxyl group of 
MAA and the etheric oxygen of the PEG chains results a collapsed polymer network with 
a small mesh size, ξ. As the environmental pH increases above the pKa of MAA (~4.8), 
deprotonation disrupts these interpolymer complexes and causes ionization and 
electrostatic repulsion of the acid groups of MAA, resulting in hydrogel swelling and 
increased mesh size.6, 7 Such hydrogels have been evaluated for the oral delivery of insulin 
(5.8 kDa),1, 3-5 calcitonin (3.4 kDa),8, 9 interferon beta (23 kDa),8 and growth hormone (22 
kDa).9 However, a polymeric carrier system has not been optimized for high molecular 
weight coagulation proteins, such as hFIX (57 kDa).  
                                                 
1 Portions of this chapter have been previously published in Horava, S. D.; Peppas, N. A., Design of pH-
Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX. Annals of Biomedical 
Engineering 2016, 1-13. 
 52 
Here, we outline the synthesis and characterization of P(MAA-g-EG) hydrogels. In 
order to tailor the delivery system for hFIX loading and release, P(MAA-g-EG) hydrogels 
were formulated with different mesh sizes, by varying the length of the PEGDMA 
crosslinking agent. All formulations were evaluated for surface morphology and size 
distribution of microparticles, polymer composition, and swelling behavior.  
 
4.2 METHODS 
4.2.1. Materials 
Methacrylic acid (MAA) and Irgacure 184® (1-hydroxy-cyclohexyl-phenylketone) 
were purchased from Sigma-Aldrich (St. Louis, MO). Poly(ethylene glycol) (MW=1000) 
mono methyl ether monomethacrylate (PEGMMA1000), poly(ethylene glycol) 
(MW=400) dimethacrylate (PEGDMA400), PEGDMA600 (MW=600), and 
PEGDMA1000 (MW=1000) were purchased from Polysciences (Warrington, PA). 
4.2.2 Polymer Synthesis 
P(MAA-g-EG) hydrogels were synthesized by bulk UV-polymerization. MAA and 
PEGMMA1000 were added at a 2:1 molar ratio of hydrogen bonding groups to a 1:1 (w/w) 
mixture of deionized water and ethanol to result in a 1:1 (w/w) ratio of total monomer to 
solvent.  A PEGDMA crosslinking agent, varying in molecular weight (MW of PEG= 400, 
600, or 1000), was added at 1.0 mol % of total monomers, and the Irgacure 184® 
photoinitiator was added at 1.0 wt. % of total monomers. After the addition of all 
components (shown in Figure 4-1), the pre-polymer mixture was sonicated for 20 minutes 
in a Bransonic® CPX3800 ultrasonic digital bath (Branson Ultrasonics Corporation, 
Danbury, CT).   
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In an oxygen-deficient environment of a MBRAUN LABmaster 130 glove box 
(Garching, Germany), the pre-polymer mixture was needle purged with nitrogen for 5 
minutes to remove residual oxygen (a free radical scavenger). The mixture was then 
dispensed between two quartz glass plates, which were separated with a 0.7 mm Teflon® 
spacer, and then polymerized for 30 minutes under 35 mW cm-2 UV light using a UV flood 
source. After synthesis, the resulting polymer was removed from the glass plates, and 10 
mm diameter disks were punched for swelling studies. The polymer was washed in 1 L of 
deionized water, changed daily 10 times, to remove any unreacted monomer. After 
washing, the polymer was air dried for 3 days, followed by drying at 37°C under vacuum 
for 3 days. Dried films were crushed using a mortar and pestle and sieved into 
microparticles, sized 30-45 µm. Figure 4-2 shows a schematic of the synthesis process.  
 
 
 
Figure 4-1. Components of the monomer solution. The two monomers are (a) methacrylic 
acid and (b) poly(ethylene glycol) monomethylether monomethacrylate. The 
crosslinking agent is (c) poly(ethylene glycol) dimethacrylate, and the 
photoinitiator is (d) Irgacure184 ®.  
(a) (b) 
(c) (d) 
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Figure 4-2 Schematic of the synthesis of P(MAA-g-EG) hydrogels.  
 
4.2.3 Scanning Electron Microscopic (SEM) Studies 
Scanning electron microscopy (SEM) was used to examine the surface morphology 
and size distribution of the microparticles. For SEM sample preparation, vacuum-dried 
microparticles were dusted onto carbon tape-covered aluminum stubs. Samples were 
coated with 10 nm of Pt/Pd using a Cressington 208 Benchtop sputter coater (Watford, 
England, UK). SEM images were obtained using a Zeiss Supra 40VP Scanning Electron 
Microscope (Oberkochen, Germany).  
4.2.4 Potentiometric Titration  
Potentiometric titration was used to quantify the MAA content of the 
microparticles. P(MAA-g-EG) microparticles were suspended in 10 mM NaCl at a 
concentration of 2 mg/mL, and then titrated to a pH of 10.5 using 0.2 N NaOH at 25°C 
with constant stirring. HCl was added (10-60 µL) to the polymer solution, and the pH was 
measured until reaching a steady value (three consecutive readings within ± 0.02) at each 
step using a Thermo Scientific Orion Star A211 pH benchtop meter (Waltham, MA). The 
molar amount of MAA was calculated based on equivalence point and a charge balance. 
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4.2.5 Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR is a surface analysis technique that was used to confirm the polymer 
composition. Vacuum dried microparticles were added at 1-2.5 wt. % to crushed and dried 
potassium bromide (KBr), and samples were pressed into disks. FTIR spectra were 
obtained using a Thermo Mattson Infinity Gold spectrometer. Background spectra of KBr 
only were subtracted from all sample spectra. FTIR was performed for all formulations. 
For each sample, 512 scans were performed with a resolution of 2 cm-1 and a gain of one. 
4.2.6 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was conducted using a TA Instruments TGA 
Q500 (New Castle, DE) to determine the thermal stability of the polymers (2-5 mg of 
vacuum dried microparticle samples).  Decomposition profiles were recorded from 25°C 
ramped at 10°C/min to 550°C in nitrogen and then isothermal at 550°C for 5 minutes.  
4.2.7 Dynamic and Equilibrium Swelling Studies 
Swelling studies were conducted to quantify the water uptake into the networks 
during the initial contact process and determined the associated structural changes which 
affect the overall loading and release behavior. Dried 10 mm disks were weighed prior to 
all swelling studies. Dynamic swelling studies were performed using a series of 0.1 M 3,3-
dimethylglutaric acid (DMGA) buffers between pH 1.2 and 7.6 at constant ionic strength 
at 37°C. The disks were stepped through the buffers in order of increasing pH, spending 
30 minutes in each buffer. Between each step, the disks were blotted and weighed.  
For equilibrium swelling, the relaxed weight of the polymer disks was measured in 
air and heptane immediately after the disks were punched from the freshly polymerized 
film. Dried weights in air and heptane were obtained prior to the start of the study. Dried 
disks were placed in a pH 2.0 buffer solution at 37°C for at least 72 hours, then blotted and 
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weighed in air and heptane. The same disks were then placed in a pH 6.5 buffer solution at 
37°C for at least 72 hours, then blotted and weighed in air and heptane. Equilibrium 
swelling studies were at constant ionic strength using 167 mM NaCl as the pH 2 buffer and 
the 1x PBS as the pH 6.5 buffer. The buffered solutions were selected to represent the 
gastric (pH 2.0) and the intestinal (pH 6.5) conditions. 
4.2.8 Turbidimetric Studies 
The timescale of microparticle swelling, which is critical to drug release, was 
measured by kinetic turbidity. Microparticles suspensions of 5 mg mL-1 were prepared with 
1x PBS with 2% (v/v) 1 N NaOH at 37°C. Immediately following suspension, 200 µL of 
solution, including all particle suspensions and buffer only, was added in quadruplicate to 
a 96-well plate. The absorbance was then measured at 520 nm in 1 minute intervals over 
60 minutes at 37°C, with 20 seconds of shaking prior to each measurement, using a BioTek 
Cytation 3 multi-mode reader (Winooski, VT). 
4.2.9 In Vitro Cytocompatibility Studies 
To examine the cytocompatibility of the newly developed systems with biological 
systems, we conducted basic studies of compatibility with well-known cell lines. Human 
epithelial colorectal adenocarcinoma (Caco-2) and mucus-secreting goblet-like human 
colorectal adenocarcinoma (HT29-MTX) cells were obtained from American Type Culture 
Collection (ATCC, Rockwell, MD). Both cell lines were cultured in modified Dulbecco’s 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells, either 
Caco-2 cells (at passages 65-75) or HT29-MTX cells (at passages 15-20), were plated on 
a 96-well plate at an initial seeding density of 105 cells per well and then cultured to 80% 
confluence. Separately, microparticles were sterilized under UV exposure for 10 minutes 
and then added to DMEM without phenol red with 2% FBS at concentrations of 1.25, 2.5, 
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and 5 mg mL-1 and allowed to swell overnight. After reaching 80% confluence, growth 
media was removed, and 100 µL of solution—microparticle suspensions (n=4 for each 
formulation and concentration), media (positive control, n=8), or water/lysis solution 
(negative control for MTS/LDH, n=8)—was applied to the cells. The cells were then 
incubated for 6 hours.  
For the CellTiter 96® Aqueous One Solution Cell Proliferation (MTS) assay 
(Promega Corporation, Madison, WI), MTS reagent (20 µL well-1) was added, and then 
incubated for an additional 90 minutes. The absorbance was read at 490 nm for MTS and 
690 nm for background using a BioTek Cytation 3 multi-mode reader (Winooski, VT). For 
the CytoTox ONE Homogeneous Membrane Integrity (LDH) assay (Promega 
Corporation), lysis solution (2 µL well-1) was added to the negative control wells after the 
6-hour incubation. After equilibrating to room temperature, cell solution (50 µL well-1) was 
removed and added to a black-wall 96-well plate with CytoTox ONE reagent (50 µL well-
1). After a 30-second shaking period and a 10-minute incubation, the fluorescence was 
measured at 560 nm excitation and 590 nm emission.  
4.2.10 Statistical Analysis 
Data are reported as mean ± standard error. All statistical analysis, either a 
Student’s two-tailed t-test for two groups or an ANOVA for multiple groups, were 
computed using GraphPad Prism 6. Significant differences were considered when *p < 
0.05 and **p < 0.01.  
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4.3 RESULTS AND DISCUSSION 
4.3.1 Polymer Synthesis 
P(MAA-g-EG) hydrogels were successfully synthesized as films and then purified 
and dried. Dried polymer films were crushed into microparticles using a mortar and pestle, 
and then sieved into the desired size ranges. The three formulations of P(MAA-g-EG) 
hydrogels were synthesized 1 mol% PEGDMA crosslinking agent, which varies in the 
length of the PEG chain as outlined in Table 4-1.  
 
Table 4-1. P(MAA-g-EG) formulations vary in the length of the PEGDMA crosslinking 
agent.  
Crosslinking agent # EG repeat units 
PEGDMA400 9 
PEGDMA600 14 
PEGDMA1000 23 
 
4.3.2 SEM Studies 
P(MAA-g-EG) hydrogels were successfully synthesized and crushed into 
microparticles. SEM micrographs of dried P(MAA-g-EG) microparticles (35-45 µm) 
shows the irregular morphology due to the crushing process (Figure 4-3). Additionally, the 
wide polydispersity of microparticle size can be attributed to sieving, which only defines 
two of the three dimensions. The difference in formulation shows no observable effect on 
the physical characteristics of the microparticles.  
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Figure 4-3. SEM images of crushed, dried P(MAA-g-EG) microparticles (30-45 µm) 
shown for each formulation—PEGDMA400, PEGDMA 600, and 
PEGDMA1000 (scale bar = 50 µm). 
 
4.3.3 Potentiometric Titration  
Microparticle suspensions were titrated with 0.2 N NaOH to quantify the amount 
of MAA. Calculated based on equivalence point and a charge balance, the molar amount 
of MAA in each formulation is reported in Table 4-2. The initial feed of MAA in the 
monomer solution prior to polymerization was 97.8 mol%, and the resulting polymers have 
a MAA content that closely matches that of the feed composition.  
 
Table 4-2. Molar methacrylic acid content of the P(MAA-g-EG) polymers based on 
titration.  
Crosslinking agent MAA (mol %) 
PEGDMA400 96.9 ± 0.1 
PEGDMA600 95.7 ± 0.1 
PEGDMA1000 95.8 ± 0.1 
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4.3.4 Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR spectra of crosslinked P(MAA-g-EG) shows characteristics of both MAA and 
PEG. As shown in Figure 4-4, the wide band in the 2800-3600 cm-1 is attributed to 
stretching of hydrogen bonded carboxylic acid dimers (2800-3100 cm-1) of MAA and 
stretching of hydroxyl groups (3200-3600 cm-1) of MAA. The characteristic peaks around 
1700 cm-1 are attributed to the stretching of carbonyl groups (1725-1700 cm-1) of MAA, 
which shifted toward 1730 cm-1 due to hydrogen bonding interactions. An additional 
contribution to this peak is due to the carbonyl stretching of the ester group (1750-1735 
cm-1) of PEG. The peaks in the 1500- 1300 cm-1 are characteristic of hydroxyl in-plane 
bending (1440-1395 cm-1) of the carboxylic acid and in-plane methylene bending (1450 
cm-1). The peak around 1350 cm-1 can be attributed to methylene wagging, mostly 
attributed to PEG.10  
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Figure 4-4. FTIR spectra of crosslinked P(MAA-g-EG) microparticles.  
 
4.3.5 Thermogravimetric Analysis (TGA) 
The thermal decomposition shows that the P(MAA-g-EG) polymer is stable at 
temperatures at which it can be exposed during processing and storage. The thermal 
degradation of the P(MAA-g-EG) formulations is shown by TGA curves (Figure 4-5). The 
first drop in the decomposition curves around 100°C is due to the removal of residual water. 
The first decomposition region at 240°C is a result of the conversion of PMAA into 
poly(methacrylic anhydride). The second decomposition region at 470°C is the degradation 
of poly(methacrylic anhydride) due to ring fragmentation and further decomposition into 
CO, CO2, and various carbonyls.11  
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Figure 4-5. Thermal decomposition of P(MAA-g-EG) polymers. 
 
4.3.6 pH-Responsive Swelling 
Swelling behavior is critical for proper protein loading and release. To prevent 
degradation, protein is loaded post synthesis and processing. Therefore, the microparticles 
are loaded by swelling, and then collapsed to entrap the protein. Then the targeted release 
of protein relies on the pH-responsive swelling characteristics to provide protection in the 
stomach and release in the small intestine. Dynamic swelling studies were conducted to 
determine effect of buffer pH on the hydrogel’s swelling response on a short timescale (30 
minutes per buffer). Weight swelling ratios, q, were calculated at each pH condition 
according to: 
𝑞 =
𝑊𝑆
𝑊𝐷
                 (Eq. 4-1) 
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where WS is the swollen weight (mg) and WD is the initial dry weight (mg) of the disk. All 
formulations remained collapsed at low pH (1.2-4.2), which is critical for protecting the 
payload in the stomach. As the pH increased to ~5.2, all formulations started to swell, with 
q increasing as pH increased (Figure 4-6). The effect of the PEGDMA crosslinking agent 
type (i.e. the length of the PEG unit) was not apparent on the short timescale (30 minute 
intervals) for the macroscopic level (10-mm diameter disks).  
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Figure 4-6. Dynamic swelling curves show the weight swelling ratio of hydrogel disks in 
response to change in buffer pH (n=3, mean ± SE).  
 
4.3.7 Equilibrium Swelling and Mesh Size 
Equilibrium swelling studies were conducted to determine the maximum water 
imbibition at both gastric and intestinal conditions, as well as determine the effect of the 
PEGMDA length on swelling and mesh size. As shown in Figure 4-7, all formulations 
remained collapsed at pH 2 (q≈1.4) due to hydrogen-bonding forming interpolymer 
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complexes between the protonated carboxylic acid groups of MAA and the etheric oxygen 
of the PEG. This collapsed state is desired to prevent premature release in the stomach. At 
pH 6.5, all formulations swell significantly due to the deprotonation of the carboxylic acid 
group, which causes disruption of interpolymer complexes and increased mesh size, as well 
as ionization and electrostatic repulsion resulting in water imbibition 6, 7. This swollen state 
is critical for the release of protein in the small intestine. Hydrogel disks were monitored 
over the initial 24 h exposure to the pH 6.5 buffer. The PEGDMA400 and PEGDMA600 
formulations began to burst at 6-8 h, which may be due to stresses caused by the shorter 
length of the crosslinking agents. However, the PEGDMA1000 formulation remained 
intact for the first 24 h, which may be attributed to the increased crosslinking length 
allowing increased water imbibition before breaking. The equilibrium swelling at pH 6.5 
(Figure 4-7) shows a significant increase in the weight swelling ratio at pH 6.5 (measured 
after 5 days). The PEGDMA600 formulation shows a significantly reduced weight 
swelling ratio at pH 6.5, which is likely an artifact of mass loss (i.e. difficulty collecting 
all the small pieces of the broken hydrogel). Instead, it is expected that the equilibrium 
weight swelling ratio of the PEGDMA600 formulation would fall in between that of the 
PEGDMA400 and PEGDMA1000.  
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Figure 4-7. Equilibrium swelling studies show the weight swelling ratio of P(MAA-g-
EG) hydrogel disks. ***Note that the weight swelling of the PEGDMA600 
at pH 6.5 is likely reduced due to mass loss (n=3, mean ± SE). 
 
Data from the equilibrium swelling studies can also be used to determine the mesh 
size of the hydrogel network. The mesh size, ξ, can be expressed as:  
 
𝜉 = 𝜈2,𝑠
−
1
2 (
2𝐶𝑛?̅?𝑐
𝑀𝑟
)
1/2
𝑙                 (Eq. 4-2) 
where 𝜈2,𝑠 is the volume fraction of the polymer in the swollen state, 𝐶𝑛 is the characteristic 
ratio of the polymer (14.6 for PMAA),12 ?̅?𝑐 is the average molecular weight between 
crosslinks, 𝑀𝑟 is the molecular weight of the repeat unit (calculated as a weighted average 
of the molecular weights of the monomers), and 𝑙 is the bond length (1.54 Å for carbon-
carbon bond).13 
Based on Archimedes’ principle, the volume fraction for x state (swollen or relaxed) 
can be expressed as: 
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𝜈2,𝑥 =
𝑤𝑎,𝑑−𝑤ℎ,𝑑
𝑤𝑎,𝑥−𝑤ℎ,𝑥
                 (Eq. 4-3) 
where 𝑤𝑎,𝑑 is the weight of the polymer in air in the dried state, similarly the subscript h  
is for heptane, and the subscript x can be substituted for either r or s for the relaxed or 
swollen state, respectively.  
The Peppas-Merrill theory is a modification of the Flory-Rehner model of the 
equilibrium swelling of polymer networks that takes into account the preparation of a 
polymer network in the presence of a solvent. The average molecular weight between 
crosslinks, ?̅?𝑐, can be calculated using the Peppas-Merrill equation: 
 
1
?̅?𝑐
=
2
?̅?𝑛
−
(?̅? 𝑉1⁄ )[ln(1−𝜈2,𝑠)+𝜈2,𝑠+𝜒1𝜈2,𝑠
2]
𝜈2,𝑟[(
𝜈2,𝑠
𝜈2,𝑟
)
1/3
−
𝜈2,𝑠
2𝜈2,𝑟
]
             (Eq. 4-4) 
where ?̅?𝑛 is the average molecular weight of the linear polymer, ?̅? is the specific volume 
of the polymer, 𝑉1 is the molar volume of water (18.0 mL/mol), and 𝜒1 is the Flory 
interaction parameter.13 Specific volume of polymer, ?̅?: 
 
?̅? =
1
𝜌ℎ
𝑤𝑎,𝑑−𝑤ℎ,𝑑
𝑤𝑎,𝑑
                (Eq. 4-5) 
where 𝜌ℎ is the density of heptane (0.668 g/mL).  
Flory interaction parameter, 𝜒1, is an indicator of how good a solvent is for a 
particular polymer (𝜒1 < 0.5 is a good solvent and 𝜒1 > 0.5 is a poor solvent). The Flory-
Rehner theory and the Peppas-Merrill theory require  𝜒1 < 0.5 . For PMAA, 𝜒1 can be 
expressed as a function of the polymer volume fraction in the swollen state as: 
𝜒1 = 0.44 + 0.6𝜈2,𝑠               (Eq. 4-6). 
However, the Peppas-Merrill model is applicable for neutral polymer networks. To 
take into account the ionic contribution of swelling, the Brannon-Peppas equation must be 
used.14 For polyelectrolyte networks with monoprotic ionizable moieties, the average 
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molecular weight between crosslinks, ?̅?𝑐, can be calculated using the Brannon-Peppas 
equation:  
 
𝑉1
4𝐼
(
10−𝑝𝐾𝑎
10−𝑝𝐻+10−𝑝𝐾𝑎
) (
𝜈2,𝑠𝑋
?̅?𝑀𝑟
) = [ln(1 − 𝜈2,𝑠) + 𝜈2,𝑠 + 𝜒1𝜈2,𝑠
2] +
                                                               (
𝑉1
?̅??̅?𝑐
) (1 −
2?̅?𝑐
?̅?𝑛
) 𝜈2,𝑟 [(
𝜈2,𝑠
𝜈2,𝑟
)
1/3
−
1
2
(
𝜈2,𝑠
𝜈2,𝑟
)]       (Eq. 4-7) 
where 𝐼 is the ionic strength of the buffer (in units of mol/mL), the pKa is 4.8 for MAA, 𝑋 
is the molar fraction of the ionizable groups in the polymer (determined by titration).14 
 The average molecular weight between crosslinks, ?̅?𝑐, for P(MAA-g-EG) 
polymers was calculated using the Brannon-Peppas equation, where the average molecular 
weight of the linear polymer,  ?̅?𝑛, was determined empirically. By varying ?̅?𝑛, nonlinear 
regression was used to solve for ?̅?𝑐. ?̅?𝑛 reaches a critical threshold where increasing its 
value has no significant effect on the value of  ?̅?𝑐. In this case ?̅?𝑛= 50,000 g/mol, the 
average values for  ?̅?𝑐 as calculated by the Brannon-Peppas equation shown in Figure 4-
8. Based on these  ?̅?𝑐 values, the mesh size, ξ, of the networks can be calculated by 
Equation 4-2 (Figure 4-9).  
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Figure 4-8. The average values for the average molecular weight between crosslinks, ?̅?𝑐, 
for P(MAA-g-EG) polymer networks were calculated using the Brannon-
Peppas equation, where ?̅?𝑛= 50,000 g/mol (n=3, mean ± SE). 
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Figure 4-9. The average values for mesh size, ξ, for P(MAA-g-EG) polymer networks 
were calculated using the Brannon-Peppas equation, where ?̅?𝑛= 50,000 
g/mol (n=3, mean ± SE). 
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Based on the mesh size calculations using the Brannon-Peppas equation to 
determine  ?̅?𝑐, the mesh sizes of the swollen hydrogel networks at pH 6.5 range from 78.9 
± 5.1 Å for the PEGDMA400 formulation to 103.3 ± 5.2 Å for the PEGDMA1000 
formulation. Previously reported mesh sizes for P(MAA-g-EG) polymers crosslinked with 
tetraethylene glycol dimethacrylate (TEGDMA, n=4) are approximately 200 Å under 
neutral conditions. However, these mesh size calculations used the Peppas-Merrill equation 
to determine  ?̅?𝑐. In order to compare mesh size values, the  ?̅?𝑐 must be calculated using 
the Peppas-Merrill equation ( ?̅?𝑐 = 1.95 x 10
4 Å for the PEGDMA1000 formulation). 
Based on the Peppas-Merrill equation, the mesh size for the PEGDMA1000 formulation is 
338.0 ± 13.8 Å at pH 6.5. However, use of the Peppas-Merrill equation is inappropriate for 
an ionizable polymer network, and the  ?̅?𝑐 values are an order of magnitude higher than 
that calculated from the Brannon-Peppas equation (1.83 x 103 Å for the PEGDMA1000 
formulation). This significant difference in  ?̅?𝑐 values accounts for the significant 
difference in the mesh size. Another limitation for both the Brannon-Peppas and Peppas-
Merrill equations is that these models assume that the crosslinks are just a single point; 
however, in this case, the crosslinks contain PEG chains of various lengths.  
Tailoring the mesh size of the swollen hydrogel is important for selecting a 
formulation that can properly load and release factor IX. The hydrodynamic radius of a 50-
kDa protein is approximately 3.2 nm (32 Å).15 By increasing the PEGDMA length, the 
mesh size of the polymer in the swollen state (intestinal pH conditions) increases, while 
the mesh size under acidic conditions (gastric pH conditions) remains relatively unaffected. 
Increasing the PEGDMA length can help improve factor IX release under intestinal 
conditions, while still preventing release under gastric conditions.  
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4.3.8 Timescale of Microparticle Swelling 
The timescale of microparticle swelling, which affects drug release, was quantified 
by kinetic turbidimetric measurements.16, 17 As microparticles swell, the dispersions 
become more optically transparent, and the refractive index of the swollen microparticle 
dispersion approaches that of the solvent. Therefore, the swelling of microparticle 
dispersions reduces the turbidity. Theoretically, turbidity is defined as:  
𝜏 =
𝑐𝑄𝑒𝑥𝑡
2𝑑𝜌
                 (Eq. 4-8) 
where c is the mass concentration of particles,  Qext is the Mie extinction coefficient, d is 
the particle diameter, and ρ is the particle density. The value of Qext is a function of the 
relative refractive index of the particles and solvent, np/n0.
17 As the microparticles swell, 
the relative refractive index decreases (i.e. approaches one), reducing the turbidity. The 
degree of microparticle swelling is related to the relative turbidity of the particle dispersion 
to the solvent, defined as:  
𝜏 = −ln (𝐼𝑡 𝐼0⁄ )                (Eq. 4-9) 
where It is the transmittance of the sample at time t and I0 is that of the pure solvent. With 
A being the absorbance, transmittance is defined as:  
𝐼 = 10(2−𝐴)               (Eq. 4-10) 
where, the turbidity can be expressed as: 
𝜏 = [𝐴𝑡 − 𝐴0]ln (10)             (Eq. 4-11). 
To monitor the change in turbidity over time for an individual sample, the relative turbidity 
is defined as:  
𝜏𝑟𝑒𝑙 =
𝜏𝑡
𝜏𝑡=0
               (Eq. 4-12). 
By converting the turbidity data to relative swelling, as defined as: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑠𝑤𝑒𝑙𝑙𝑖𝑛𝑔 =
𝜏𝑡−𝜏𝑡=0
𝜏∞−𝜏0
             (Eq. 4-13) 
where τ∞ is the average τ values at long times (e.g. t= 50-60 minutes).   
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P(MAA-g-EG) microparticle swelling occurred within the first 5-10 minutes, with 
relative turbidity values and relative swelling values remaining stable for the remainder of 
the 60 minutes (Figures 4-10 and 4-11). Differences in the relative turbidity values across 
the different formulations cannot be easily discerned due to the irregular particle 
morphology and wide polydispersity in size. 
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Figure 4-10. Relative turbidity curves of P(MAA-g-EG) microparticles show the kinetics 
of the decreasing turbidity as microparticles swell (n=4, mean ± SE). 
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Figure 4-11. Relative swelling curves show the timescale of microparticles swelling (n=4, 
mean ± SE). 
 
4.3.9 Cytocompatibility Studies 
Microparticle cytotoxicity was assessed in Caco-2 and HT29-MTX cells to screen 
for potentially harmful carriers. Both the effect on cellular metabolic activity (MTS assay) 
and membrane integrity (LDH assay) were evaluated to determine the concentration 
dependence of microparticle cytotoxicity after a 6-hour exposure, where the average transit 
time in the small intestine is 2-6 hours. For this evaluation, 80% cell viability is considered 
cytocompatible. At a low concentration (1.25 mg particles mL-1), there is no significant 
effect on the metabolic activity across all formulations for both cell types (Figures 4-12 
and 4-13).  
The metabolic activity is reduced due to increasing the microparticle concentration, 
with particularly inhibitory effects observed for 5 mg mL-1 for Caco-2 cells. However, one 
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limitation of these cytotoxicity studies is that the microparticles have settled into a stagnant 
layer on the cells, possibly creating a barrier to nutrient transport. As a secondary method, 
the cell membrane integrity was assessed. For all conditions, cell viability is approximately 
100% indicating that a 6-hour exposure to the microparticles is not membrane disruptive 
(Figure 4-14 and 4-15).  
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Figure 4-12. Cytocompatibility of P(MAA-g-EG) microparticles was evaluated in Caco-2 
cells using a cellular metabolic activity MTS assay (n=3, mean ± SE). 
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Figure 4-13. Cytocompatibility of P(MAA-g-EG) microparticles was evaluated in HT29-
MTX cells using a cellular metabolic activity MTS assay (n=3, mean ± SE). 
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Figure 4-14. Cytocompatibility of P(MAA-g-EG) microparticles was evaluated in Caco-2 
cells using a cell membrane integrity LDH assay (n=3, mean ± SE). 
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Figure 4-15. Cytocompatibility of P(MAA-g-EG) microparticles was evaluated in HT29-
MTX cells using a cell membrane integrity LDH assay (n=3, mean ± SE). 
 
4.4 CONCLUSIONS 
In order to achieve the overarching goal of developing an oral delivery system for 
factor IX, we first designed, synthesized, and characterized pH-responsive P(MAA-g-EG) 
hydrogels. As confirmed by physical characterization, we synthesized hydrogels with the 
desired composition. Methacrylic acid was incorporated to achieve the desired pH-
responsive behavior due to the ionization of pendant carboxylic acid groups (pKa=4.8). 
The PEG tethers serve as hydrogen-bonding acceptors to form interpolymer complexes in 
the collapsed state in gastric conditions. Additionally, the hydrophilicity of the PEG chains 
improves the water uptake in the swollen state. The pH-responsive behavior, as 
demonstrated by various swelling studies, is critical to providing protection of the hFIX in 
gastric conditions and allowing for targeted intestinal release. Furthermore, tailoring the 
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mesh size of the polymer networks by varying the PEGDMA length is critical for 
determining the effect of mesh size on the drug delivery performance of the microcarriers.  
Furthermore, selection of polymeric components, such as methacrylic acid 
(currently used in enteric coating formulations) and PEG (considered a “FDA-friendly” 
polymer),18 minimizes safety concerns of our P(MAA-g-EG) hydrogel systems. The 
combination of these polymeric components in the P(MAA-g-EG) systems were also found 
to be cytocompatible as evaluated in intestinal epithelial cells. Such hydrogels exhibited 
the desired characteristics—pH-responsive swelling and cytocompatibility—necessary for 
therapeutic applications.  
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Chapter 5: Evaluation of pH-Responsive P(MAA-g-EG) Delivery 
Systems for Factor IX2 
5.1 INTRODUCTION 
Hemophilia B, a hereditary bleeding disorder caused by the deficiency of clotting 
factor IX (FIX), affects 80,000 males worldwide.1 Protein replacement therapy by 
intravenous (IV) injection or continuous infusion can prevent spontaneous bleeding 
episodes and restore hemostasis, significantly improving the patient’s lifespan and quality 
of life.  Prophylactic treatments, requiring multiple injections per week, are recommended 
for 75% of hemophilia B patients, classified as severe (<1% FIX clotting activity) or 
moderate (1-5% FIX clotting activity).1-2  However, current treatments are limited by 
noncompliance, increased risk of needle injury, costly medical care, and potential 
complications (e.g. severe allergic reactions).  
A major challenge for prophylactic regimens, especially in children, is the need for 
a surgically implanted venous access port, which may lead to risks of infection and 
thrombosis.3 As a result, such treatments are not readily available worldwide. Without 
treatment, the median life expectancy of a hemophilia B patient drops to 11 years.4 
Therefore, a non-invasive alternative is highly desirable to overcome such limitations and 
promote the global availability of hemophilia treatment.  
Oral delivery of coagulation proteins can improve the patients’ quality of life by 
ensuring safety, convenience, and ease of administration. In this work, we focus on 
developing an oral delivery system for a therapeutically effective prophylactic treatment 
                                                 
2 Portions of this chapter have been previously published in Horava, S. D.; Peppas, N. A., Design of pH-
Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX. Annals of Biomedical 
Engineering 2016, 1-13. 
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for hemophilia. There is currently no commercially available oral delivery method of factor 
IX for protein replacement therapy.  
In this chapter, we focus on the evaluation of pH-responsive biomaterials as 
delivery vehicles to enable the oral route of hematological factor IX.5 The mesh size of the 
hydrogel networks was tailored to optimize the diffusional processes necessary for 
improving protein loading and release. Additionally, loading conditions were modified to 
further adjust the therapeutic delivery potential. An evaluation of delivery system’s 
performance, including loading, release, protein activity, and in vitro transport, is detailed 
herein. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Methacrylic acid (MAA) and Irgacure 184® (1-hydroxy-cyclohexyl-phenylketone) 
were purchased from Sigma-Aldrich (St. Louis, MO). Poly(ethylene glycol) (MW=1000) 
mono methyl ether monomethacrylate (PEGMMA1000), poly(ethylene glycol) 
(MW=400) dimethacrylate (PEGDMA400), PEGDMA600 (MW=600), and 
PEGDMA1000 (MW=1000) were purchased from Polysciences (Warrington, PA). 
Plasma-derived human factor IX (hFIX) was purchased from Haematologic Technologies 
Inc. (Essex Junction, VT). Human factor IX ELISA kits were purchased from AssayPro 
LLC. (St. Charles, MO), and the BIOPHEN factor IX activity assays were purchased from 
HYPHEN Biomed SAS (Neuville-sur-Oise, France). FaSSIF, FeSSIF & FaSSGF Powder 
was purchased from Biorelevant.com (London, England, UK). All reagents were used as 
received. All other solvents and buffers were purchased from Fisher Scientific (Waltham, 
MA).  
 80 
5.2.2 Factor IX Activity Assay 
The biological activity of hFIX was determined using hFIX chromogenic activity 
assays according to the manufacturer’s protocol (BIOPHEN factor IX activity assay, 
HYPHEN Biomed SAS). This chromogenic activity assay relies on a portion of the 
coagulation cascade (Figure 5-1), where the enzymatic activity is directly related to hFIX, 
the limiting factor. The generated factor Xa (FXa) can be quantified with high sensitivity 
(detection range 0.1-30 ng/mL) based on its specific activity on factor Xa chromogenic 
substrate (SXa-11). FXa can cleave the substrate to release a pNA chromophore.  The free 
pNA can be quantified by color development at 405 nm. The amount of active FIX in the 
sample is linearly related to the FXa activity, as measured by the amount of pNA released.  
 
 
Figure 5-1. Reaction scheme for the BIOPHEN factor IX chromogenic activity assay.  
 
5.2.3 Equilibrium Swelling Studies at Reduced Ionic Strength 
Ionic strength of the buffer affects the swelling of P(MAA-g-EG) hydrogels, which 
may also affect the protein loading. For equilibrium swelling, dried disks were placed in a 
pH 2.0 buffer solution at 37°C for at least 72 hours, then blotted and weighed. The same 
disks were then placed in a pH 7.4 buffer solution at 37°C for at least 72 hours, then blotted 
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and weighed. Equilibrium swelling studies were conducted using buffers of two different 
ionic strengths—5 mM and 167 mM. The lower ionic strength buffers were 5 mM 
NaH2PO4 and the pH was adjusted using 1 N NaOH and 1 N HCl as necessary. For the 
higher ionic strength buffers, the pH 2 buffer was 167 mM NaCl and the pH 7.4 buffer was 
1x PBS. The buffered solutions at pH of 2.0 and 7.4 were selected because these values 
represent the loading (pH 7.4) and collapse (pH 2.0) conditions. 
5.2.4 Protein Stability 
In order to optimize loading, the stability of the hFIX was evaluated in two different 
buffers (pH 7.4)—1x PBS and 5 mM NaH2PO4— at three different temperatures—4, 20, 
and 37°C—over a 7-day period. For the study duration, 0.5 mg mL-1 hFIX solutions in 
either buffer were stored at the designated controlled temperature under constant end-to-
end rotation. The activity of hFIX was quantified at days 1, 2, 5, and 7, as compared to a 
freshly prepared stock of hFIX in the same buffer, using hFIX chromogenic activity assays 
according to the manufacturer’s protocol (BIOPHEN factor IX activity assay, HYPHEN 
Biomed SAS).  
5.2.5 Protein Loading Studies 
Dried particles were added to a 0.5 mg mL-1 hFIX solution (1x PBS with 2% 1(v/v) 
N NaOH) to a final concentration of 5 mg mL-1 and pH of 7.4. hFIX loading was carried 
out by equilibrium partitioning for 24 hours with particle/protein suspensions under 
constant end-to-end rotation at 37°C. After 24 hours, particles were collected by Buchner 
filtration using Whatman 50 filter paper. Particles were then collapsed with 0.1 N HCl and 
then triple rinsed with 0.1 N HCl, DI water, and 0.1 N HCl. Samples were collected after 
each step—end of loading, collapse, and rinse—for protein quantification using hFIX 
ELISAs. Protein-loaded particles were then lyophilized overnight.  
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To optimize loading, the ionic strength of the loading, length of loading time, and 
temperature at which loading occurs were modified, while other parameters remained 
constant. Loading was increased to 5 days at 4°C using two different buffers (pH 7.4)—1x 
PBS and 5 mM NaH2PO4. 
5.2.6 Protein Distribution Studies 
To visually confirm the distribution of protein within the loaded microparticles, 
loading studies were completed using fluorescein isothiocyanate (FITC)-conjugated hFIX. 
hFIX was labeled with FITC (MW=389) using Thermo ScientificTM PierceTM FITC 
Antibody Labeling Kits according to the manufacturer’s protocol. The isothiocyanate of 
FITC reacts with primary amines of proteins. The molar ratio of FITC to protein was 
calculated from the absorbance measurements at 280 nm and 495 nm. 
Loading studies were conducted as previously described at 37°C for 24 hours. 
Following the collapse and rinse steps, microparticles were collected and then added to 
microscope slides with Molecular ProbesTM ProLongTM Gold Antifade Mountant, which 
was allowed to cure for 24 hours at room temperature. Confocal images, both fluorescent 
and bright field channels, were captured using an Olympus All-in-one Confocal Laser 
Scanning Microscope FV10i (Shinjuku, Tokyo, Japan).  
5.2.7 Protein Release Studies 
Protein release studies were conducted following a two-stage dissolution procedure 
using biorelevant media. Biorelevant media were prepared using a FaSSIF, FeSSIF & 
FaSSGF Powder which contains bile salts and phospholipids. Fasted-state simulated 
gastric fluid (FaSSGF) was prepared at a 1x concentration with a final pH of 1.6 according 
to the manufacturer’s protocol (Biorelevant).  Fasted-state simulated intestinal fluid 
(FaSSIF) was prepared at 2x concentration with a final pH of 6.9. For the two-stage 
 83 
dissolution procedure, a 1:1 (v/v) FaSSGF:FaSSIF mixture at a final pH of 6.5 is required 
for the intestinal condition.  
Dissolution testing was performed using an USP apparatus 2 (with paddles) setup 
for small volume (100 mL vessel) with low evaporation mini vessel covers using a Distek 
2100B dissolution apparatus (North Brunswick, NJ). A 5 mg sample of hFIX-loaded 
microparticles was added to a Sigmacoted (i.e., siliconized) vessel containing 30 mL of 
SGF (1x, pH 1.6) at 37°C. After 30 minutes, 30 mL of FaSSIF (2x) at 37°C was added, 
raising the pH to 6.5. The solution was continuously stirred at 75 rpm and maintained at 
37°C for both stages. The FaSSIF stage was carried out for up to 6 h. Over the course of 
the dissolution, 1 mL samples were taken using a 1/8 cannula sample probe (Distek, Inc.) 
with a 10 micron polyethylene filter tip (Agilent Technologies, Santa Clara, CA). Samples 
were replaced with an equal volume of appropriate prewarmed media. hFIX released was 
quantified by hFIX ELISAs and its activity was measured by hFIX chromogenic activity 
assays.  
5.2.8 Endotoxin Depletion 
For in vitro use, hFIX was endotoxin-depleted using Thermo ScientificTM PierceTM 
High-Capacity Endotoxin Removal Spin Columns according to the manufacturer’s 
protocol. After endotoxin removal, the amount of endotoxin in hFIX samples was 
measured using a Thermo ScientificTM PierceTM LAL Chromogenic Endotoxin 
Quantification Kit. To verify the lack of product inhibition, a spiked hFIX sample was 
included in the assay.   
5.2.9 In Vitro Transport Studies 
In vitro transport studies using an intestinal epithelial model were conducted to 
determine the effect of the presence of the microcarriers on protein transport. Caco-2 and 
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HT29-MTX cells were cultured with DMEM with 10% FBS in separate flasks. For the 
transport studies, cells (either Caco-2 cells only or 1:1 Caco-2:HT29-MTX cell mixture) 
were seeded on the apical side of 12-well Transwell® plates (12 mm diameter, 0.4 µm 
pores, Corning, Corning, NY) at 105 cells per well. Monolayers were cultured for 21-25 
days to allow the cells to fully differentiate and reach confluence. Every other day, media 
(DMEM supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin) 
was changed, and the transepithelial electrical resistance (TEER) was monitored with an 
EVOM2 epithelial voltohmmeter and a chopstick electrode (World Precision Instruments, 
Sarasota, FL). 
One hour prior to the transport experiment, the medium was removed and replaced 
with Hank’s balanced salt solution (HBSS) at 37°C with 0.5 mg mL-1 bovine serum 
albumin (BSA) to allow the cells to equilibrate. After removing the HBSS/BSA solution 
from the apical side, the cells were exposed to one of the following conditions: HBSS/BSA, 
neat protein (0.04 mg mL-1 hFIX), and microparticles (0.875 mg mL-1= 0.391 mg cm-2) 
with protein (0.04 mg mL-1 hFIX). Over the course of the 4-hour experiment, the TEER 
was measured, and then 200 µL samples were collected from the basolateral side and 
replaced with HBSS/BSA at 37°C for each time point. After 4 hours, final samples from 
both the apical and basolateral sides were collected, then cells were rinsed with media, and 
fresh media was added to both sides. At 24 hours post study completion, final TEER 
measurements were collected to determine the recovery of the monolayers. The amount of 
hFIX on the basolateral side was quantified using hFIX ELISAs.  
5.2.10 Statistical Analysis 
Data are reported as mean ± standard error. Comparisons between groups were 
performed using a Student’s two-tailed t-test, and comparisons among multiple groups 
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were performed using an ANOVA. Significant differences were considered when *p < 0.05 
and **p < 0.01. All statistical analysis was computed using GraphPad Prism 6.  
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Protein Loading and Release Studies 
High molecular weight proteins, like factor IX, have difficulty being transported in 
molecular structures, including polymer networks. For factor IX, we investigated the effect 
of the mesh size, by varying the length of the PEGDMA crosslinking agent, on loading and 
release. The final amount of protein loaded was calculated based on the concentration of 
the supernatant after incubation, collapse, and triple rinse. Protein lost during the collapse 
and rinse was likely surface loaded. The loading level (µg hFIX mg-1 particles) was 
calculated as:  
 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑐0𝑉0−𝑐𝑓𝑉𝑓
𝑐𝑝𝑉0
                 (Eq. 5-1) 
where c0 is the initial protein concentration (µg mL
-1), V0 is the initial volume (mL), cf is 
the final protein concentration (µg mL-1) after rinsing, Vf is the final volume (mL) after 
rinsing, and cp is the particle concentration (mg mL
-1).  
As shown in Figure 5-2, increasing the PEGDMA length increased the amount of 
hFIX loaded, with significantly higher loading achieved with both the PEGDMA600 and 
PEGDMA1000 formulations than the PEGDMA400 formulation. To further investigate 
the effect of PEGDMA length on loading, FITC-hFIX (0.37 mol FITC per mol hFIX) was 
loaded to visualize the protein distribution within the microparticles.  As confirmed by 
confocal microscopy (Figure 5-3), hFIX was surface loaded on microparticles for both the 
PEGDMA400 and PEGDMA600 formulations. However, hFIX was loaded uniformly 
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throughout the microparticles for the PEGDMA1000 formulation as shown in Figure 5-4. 
Protein loading within the microparticle can be achieved by increasing the mesh size (i.e. 
longer PEGDMA crosslinking agent), which can lead to improved protection of the protein.  
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Figure 5-2. Loading level of hFIX is dependent on the PEGDMA crosslinking agent 
length of P(MAA-g-EG) hydrogels (n=3, mean ± SE, **p<0.01). 
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Figure 5-3. The distribution of hFIX loaded is improved by increasing the PEGDMA 
crosslinking agent length. Confocal images of FITC-hFIX loaded 
microparticles (orthogonal view, fluorescence channel) show that hFIX 
surface loaded for the PEGDMA400 and PEGDMA6000 formulations, and 
hFIX loaded throughout the microparticles for the PEGDMA1000 
formulation (scale bar = 50 µm).  
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Figure 5-4. Confocal image of FITC-hFIX loaded P(MAA-g-EG) crosslinked with 1 
mol% PEGMDA1000 microparticle (channels: bright field, fluorescence, 
and overlay) (scale bar = 50 µm).  
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The release of hFIX from P(MAA-g-EG) microparticles was tested using a two-
stage dissolution procedure in biorelevant media. For all formulations, hFIX release was 
minimal in the simulated gastric conditions (FaSSGF), while release significantly 
increased in the simulated intestinal conditions (FaSSIF) (Figure 5-5).  The cumulative 
release in the FaSSIF conditions was higher for the PEGDMA400 and PEGDMA600 
formulations, as compared to PEGDMA1000, due to hFIX being surface loaded and 
therefore released faster. Release from the PEGDMA100 formulation is expected to be 
sustained over longer periods as the hFIX must diffuse out of the hydrogel network.  While 
the cumulative protein release showed the desired release profile, the activity of the 
released protein is critical for its therapeutic use. The activity of released hFIX is better 
maintained as the length of the PEGDMA crosslinking agent increases (Figure 5-6). Protein 
released from P(MAA-g-EG) microparticles crosslinked with 1 mol % PEGDMA1000 
maintained approximately 100% of its activity, which was significantly higher than the 
other two formulations. For the PEGDMA1000 formulation, hFIX loading within the 
microparticle improved protection as confirmed by the activity of released protein. To 
compare the overall performance among the three formulations, the amount of active hFIX 
released (Figure 5-7) was calculated as the product of the total release of hFIX and the 
activity percentage of released hFIX at a given time point. The PEGDMA1000 formulation 
is the most promising due to significantly higher release of active hFIX.  
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Figure 5-5. Release of hFIX from P(MAA-g-EG microparticles using two-stage 
dissolution in biorelevant conditions shows the desired release profile. (n=3, 
mean ± SE, *p<0.05, **p<0.01). 
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Figure 5-6.  Activity of release hFIX is better maintained as the length of the PEGDMA 
crosslinking agent increases. (n=3, mean ± SE, *p<0.5, **p<0.01). 
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Figure 5-7. The amount of active hFIX released (the product of the total release and its 
activity) shows that the PEGMDA1000 formulation is the most promising 
candidate. (n=3, mean ± SE, *p<0.5, **p<0.01).  
 91 
5.3.2 Optimization of Loading and Release 
To further optimize the loading efficiency, three parameters—ionic strength of the 
buffer, time, and temperature—were modified. As previously described,6 reducing the 
ionic strength of the buffer increases the swelling of anionic hydrogels. Increasing swelling 
can result in higher protein loading.7 Additionally, increasing both time and temperature 
can increase the rate of diffusion to increase the amount of protein loaded. However, 
increasing time and temperature can also reduce the protein stability. A balance between 
increasing loading and maintaining the protein stability/activity is necessary for 
determining improved loading conditions.  
In order to analyze these parameters, two buffers—1x PBS (162.7 mM) and 5 mM 
NaH2PO4—were evaluated for their effects on hydrogel swelling and protein stability. 
Equilibrium swelling studies using the PEGDMA1000 formulation showed minimal 
swelling at pH 2 and significantly increased swelling at pH 7 (Figure 5-8). At pH 7, the 
weight-swelling ratio was ~2.3-fold higher for the reduced ionic strength buffer. 
Additionally, the effect of temperature and time on the stability of hFIX in both buffers at 
pH 7 was assessed to determine the time and temperature that maintained at least 95% of 
its activity. After 5 days at 4°C, hFIX was stable in both buffer conditions; however, at 
higher temperatures, the stability of hFIX dropped over time down to 12% of its relative 
activity (in 5 mM  NaH2PO4 at 37°C) (Figure 5-9).  
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Figure 5-8. Hydrogel disks show increased equilibrium swelling in a reduced ionic 
strength buffer. (n=3, mean ± SE, *p<0.05, **p<0.01).  
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Figure 5-9. Time, temperature, and ionic strength affect hFIX stability. (n=3, mean ± SE, 
*p<0.05, **p<0.01).  
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Loading studies were conducted at 4°C for 5 days in both buffers to determine if 
hFIX loaded can be improved for the PEGDMA1000 formulation. Compared to loading at 
37°C for 1 day, the new loading conditions resulted in significantly higher hFIX loading 
levels (Figure 5-10). Reducing the buffer’s ionic strength also improved hFIX loading. 
Release of hFIX from P(MAA-g-EG) particles showed the desired profile with minimal 
release in gastric conditions and significantly higher release in intestinal conditions (Figure 
5-11).  
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Figure 5-10. Optimized loading conditions (5 days at 4°C) significantly improved hFIX 
loading into P(MAA-g-EG) microparticles, and a reduced ionic strength 
buffer further improved loading. (n=3, mean ± SE, *p<0.05, **p<0.01).  
 
The particles loaded in the reduced ionic strength buffer (5mM NaH2PO4) have 
higher delivery potential likely due to a higher loading level compared to those using a 
higher ionic strength buffer (1x PBS). Additionally, released hFIX maintained 
approximately 80% of its activity in intestinal conditions (Figure 5-12). Overall, improving 
the amount of hFIX loaded in P(MAA-g-EG) microparticles (PEGDMA1000 formulation) 
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increased the amount of active hFIX released in intestinal conditions (Figure 5-13), which 
can lead to improved bioavailability of orally delivered therapies.  
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Figure 5-11. Release of hFIX from the PEGDMA1000 formulation using two-stage 
dissolution in biorelevant conditions shows the desired release profile. 
Improved hFIX loading (in 5 mM NaH2PO4 compared to 1x PBS) resulted 
in higher release of hFIX in intestinal conditions. (n=3, mean ± SE).  
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Figure 5-12. Activity of released hFIX is maintained in intestinal conditions. (n=3, mean 
± SE).  
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Figure 5-13. Improved hFIX loading resulted in significantly higher release of active 
hFIX in intestinal conditions, which can improve the efficacy of an orally 
delivered therapy. (n=3, mean ± SE, *p<0.05).  
 
5.3.3 Dose Calculation 
The dose for FIX depends on the patient’s severity of hemophilia B, body weight, 
age, and type of treatment required (e.g. prophylactic and on-demand for minor, moderate, 
or major surgeries/trauma). The amount of factor IX international units (IU) required in 
units of IU can be calculated as:  
𝐹𝐼𝑋 𝐼𝑈 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 = 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 × 𝑑𝑒𝑠𝑖𝑟𝑒𝑑𝐹𝐼𝑋 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 × 𝑟𝑒𝑐𝑖𝑝𝑟𝑜𝑐𝑎𝑙 𝑜𝑓 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦         (Eq. 5-2) 
where the body weight is in kg, desired FIX increase in units of % or IU/dL and reciprocal 
of recovery is in IU/kg per IU/dL. 8 The international unit (IU) for hFIX is defined as the 
activity of hFIX in 1 mL of normal plasma, and normal hFIX plasma concentrations are 
2.5-5 µg/mL, and therefore 1 IU equals 2.5-5 µg. The reciprocal of observed recovery is 
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commonly defined as 1 IU/kg per IU/dL; however, this value can vary with age and on an 
individual basis.  
Prophylactic treatment regimens are given on a regular weekly basis as a 
preventative measure for patients with severe (<1%) hemophilia B. The common 
prophylactic dosage is 25-40% increase in FIX, administered twice per week.9 However, 
studies have shown that tailoring the dosing of FIX according to an individual patient and 
increasing the dosage intervals to determine the minimum effective dose can markedly 
improve the cost-effectiveness of the prophylactic treatment, as well as maintain a certain 
trough level. For a patient with relatively unaffected joints, a 1% increase in FIX is 
generally recommended since a 1% activity level can eliminate spontaneous bleeding 
episodes.9 However, an individual with joint damage typically require a high target level, 
where a 3% increase has been suggested for preventing further joint function deterioration. 
Another study found at a 2% increase in FIX for prophylactic treatments is clinically 
effective and cost-effective.10  For a minimum effective prophylactic treatment, requiring 
1% hFIX increase, an average 10 year old male (35 kg) requires 35 IU or 1750 µg of hFIX, 
assuming a conversion of 2.5 µg per IU.  Based on our results, we can assume an intestinal 
release of 3 µg hFIX/mg particle and 5% bioavailability, meaning that 583 mg of particles 
would need to be administered. This dose of particles will fit approximately into two size 
2 capsules.  
5.3.4 Factor IX Transport Studies 
In vitro transport studies are used to screen for potentially successful candidates 
and determine the effect of the presence of microparticles on the hFIX absorption. We 
evaluated the transport of hFIX using two intestinal epithelial monolayers of Caco-2 cells 
only or a co-culture of Caco-2 and HT29-MTX cells. The Caco-2 cell line is well-
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characterized intestinal epithelial model that is the most widely used standard in the 
pharmaceutical industry to predict oral drug absorption. Permeability data obtained using 
Caco-2 cells often correlates well with in vivo results. However, Caco-2 cells do not secret 
mucus, a key component of the intestinal epithelial layer. Co-cultures of Caco-2 cells and 
mucus-secreting goblet-like HT29-MTX cells are commonly used as an intestinal epithelial 
model for predicting oral drug absorption, particularly paracellular transport in vivo.11 A 
co-culture model better mimics the physiological conditions of the intestine, containing 
three major absorption barriers—tight junctions, membranes of absorptive epithelia, and a 
mucus layer. Additionally, HT29-MTX cells modulate the tight junction geometry, 
resulting in a “tightness”,  indicated by TEER values (~300 Ω cm2), closer to in vivo 
conditions which range from 20 to 100 Ω cm2 (Figure 5-14).11 While the co-culture model 
is more physiologically relevant, the drug permeability is typically lower due to higher 
TEER values. 
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Figure 5-14. TEER of in vitro epithelial monolayers during culturing. (n=12, mean ± SE). 
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Transport studies were conducted to determine the permeability of hFIX across an 
intestinal epithelial monolayer. Prior to the transport studies, hFIX was endotoxin depleted 
(final endotoxin concentration < 2.5 EU mL-1). For experimental groups, a suspension of 
0.04 mg mL-1 hFIX and 0.875 mg mL-1 microparticles (the same surface area coverage of 
0.391 mg cm-2 as the 1.25 mg mL-1 concentration used in the cytocompatibility studies and 
determined as non-cytotoxic) was initially added to the apical chamber, and a 0.04 mg mL-
1 hFIX solution was also included as a control. The presence of the P(MAA-g-EG) 
microparticles promoted the apical-to-basolateral transport of hFIX as compared to the 
hFIX only for both culture types (Figures 5-15 and 5-16).  For the Caco-2 only monolayers, 
PEGDMA1000 formulation resulted in the highest amount of hFIX transported to the 
basolateral side (Figure 5-15). For the co-culture model, there was no significant difference 
in hFIX transported among the microparticle formulations (Figure 5-16). Overall, the 
amount of hFIX transported was higher in the co-culture model. 
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Figure 5-15. The amount of hFIX transported across the Caco-2 intestinal epithelial 
monolayer over time shows that the presence of the microparticles improved 
hFIX transport. The PEGDMA1000 formulation resulted in the highest 
levels of hFIX transported. (n=3, mean ± SE, *p<0.05). 
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Figure 5-16. The amount of hFIX transported across the co-culture intestinal epithelial 
monolayer over time shows that the presence of the microparticles improved 
hFIX transport. (n=3, mean ± SE, *p<0.05).  
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The permeability of the protein across the monolayer was calculated by: 
 
𝑃𝑎𝑝𝑝 =
𝑑𝑄(𝑡)
𝑑𝑡
×
1
𝐴×𝐶𝐴𝑂
                (Eq. 5-3) 
where Q(t) is the cumulative protein release (ng) at time t (s), A is the area of the cell 
monolayer (cm2), and CAO is the initial protein concentration (ng/mL). hFIX permeability 
was calculated after the first 2 hours, where the amount of hFIX transported over time 
follows a linear relationship. The overall permeability (4 hours) was also calculated; 
however, values are decreased due to the plateauing of hFIX transported after 2 hours, 
similar to previous reported trends.12  The presence of the microparticles resulted in 
permeability values at least 2.4-fold higher than hFIX only (Figures 5-17 and 5-18). For 
the Caco-2 model, increasing the PEGDMA crosslinking length resulted in increased hFIX 
permeability (Figure 5-17). However, results with the co-culture model did not show a 
significant distinction among formulations (Figure 5-18). Previous studies showed the 
same trends for insulin, where microparticle presence improved permeability, possibly due 
to Ca2+ chelation.13  Ichikawa et al. hypothesized that PMAA-based microparticles can 
chelate Ca2+, leading to an opening of tight junctions and increasing permeability.14  
 
 102 
2  h 4  h
0
1 0 0
2 0 0
3 0 0
4 0 0
P
e
r
m
e
a
b
il
it
y
 (
x
1
0
6
 c
m
-2
s
-1
)
P E G D M A 4 0 0
P E G D M A 6 0 0
P E G D M A 1 0 0 0
h F IX  o n ly
*
****
*
 
Figure 5-17. The presence of the microparticles enhances the permeability of hFIX (2h 
and 4h) as compared to hFIX only for the Caco-2 model. Increasing the 
PEGDMA crosslinking length increased hFIX permeability. (n=3, mean ± 
SE, *p<0.05, **p<0.01).  
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Figure 5-18. The presence of the microparticles enhances the permeability of hFIX (2h 
and 4h) as compared to hFIX only for the co-culture model. (n=3, mean ± 
SE, *p<0.05, **p<0.01).  
 
Additionally, the TEER was monitored for the study duration to determine the 
effect of the microparticles on the monolayer integrity. Similar to previous studies,13 the 
TEER values remained relatively constant over the 4-hour exposure for both the Caco-2 
and co-culture model, indicating that the tight junctions remained intact (Figures 5-19 and 
5-20). As hypothesized by Wood et al., the microparticles may have a Ca2+ chelating effect, 
but the mucus layer provides barrier between the cells and microparticles, reducing the 
effect of the microparticles on TEER.13 The monolayers also recovered after the removal 
of the microparticles, as indicated by the 24-hour TEER measurements.   
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Figure 5-19. TEER remained constant during the transport study, indicating that the tight 
junctions remained intact for the Caco-2 model. TEER measurements at 24 
h post study showed that the monolayers fully recovered after removal of 
microparticles. (n=4, mean ± SE, *p<0.05, and **p<0.01). 
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Figure 5-20. TEER remained constant during the transport study, indicating that the tight 
junctions remained intact for the co-culture model. TEER measurements at 
24 h post study showed that the monolayers fully recovered after removal of 
microparticles. (n=4, mean ± SE, *p<0.05, and **p<0.01). 
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5.4 CONCLUSIONS 
Addressing the medical need, we have developed a delivery system based on pH-
responsive P(MAA-g-EG) hydrogel networks for the oral delivery of hematological factor 
IX. Tailoring the biomaterial formulation by varying the length of the PEGDMA 
crosslinking agent resulted in improved performance of the microcarriers. Increasing the 
mesh size increased loading and distribution of hFIX within the microparticles, offering 
more protection in gastric conditions. Furthermore, improved hFIX protection resulted in 
higher release of active protein in intestinal conditions. Based on the results presented, 
P(MAA-g-EG) crosslinked with 1 mol% of PEGDMA1000 is the best performing 
formulation. Further optimization of loading conditions (i.e., reduced ionic strength of 
buffer and increased time to 5 days at 4°C) significantly improved the loading efficiency 
and the amount of active hFIX released.  
The ability of the microcarriers to modulate the oral absorption of hFIX further 
shows the potential of such oral delivery systems. The presence of the microparticles 
increased hFIX permeability without causing damage to the in vitro intestinal epithelial 
layer. The combination of well-maintained hFIX activity and its enhanced permeability is 
expected to promote overall bioavailability.  
The promising work presented here can lead to an orally administered treatment for 
hemophilia that can replace needle-based options, offering improved quality of life for 
patients and global access to therapy.  
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Chapter 6: Stability Testing 
6.1 INTRODUCTION 
Stability testing is critical for predicting shelf life of a drug substance or drug 
product and determining recommended storage conditions. The FDA provides guidelines 
for storage conditions of a drug substance to test its thermal stability and its sensitivity to 
moisture, as well as additional stress testing.1 In general, stability testing studies are 
designed to cover storage, shipment, and subsequent use for a new drug substance/product.  
For the general case, the FDA guidelines for stability testing of a drug substance/product 
are outlined in Table 6-1. The FDA guidelines also include stability testing conditions for 
drug substances intended for storage in a refrigerator (Table 6-2).  
 
Table 6-1. FDA guidelines for stability testing for the general case.1 
Study Storage Conditions Minimum Time Period 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
Intermediate 30°C/± 2°C/65% RH ± 5% RH 6 months 
Long-term 25°C/± 2°C/60% RH ± 5% RH 12 months 
 
Table 6-2. FDA guidelines for stability testing of a drug substance intended for storage in 
a refrigerator.1 
Study Storage Conditions Minimum Time Period 
Accelerated 25°C ± 2°C/60% RH ± 5% RH 6 months 
Long-term 5°C± 3°C 12 months 
 
According to the FDA guidelines, for drug substances intended for storage in a 
freezer, long-term storage at -20°C ± 5°C should be included in addition to the storage 
conditions in Table 6-2 for obtaining data at elevated temperatures. The recommended 
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testing frequency is every 3 months with a minimum of three time points for the accelerated 
study and four time points for the intermediate study. At the long-term storage conditions, 
the frequency of testing should be every 3 months over the first year, followed by every 6 
months over the second year, and annually thereafter.1  
In assessing acceptance criteria for a solid oral drug product, the stability testing 
procedures included several tests as listed:  
 Dissolution- Measure the release of drug substance from the drug product  
 Disintegration- Substitute for dissolution for rapidly dissolving products only 
 Hardness/friability- Only if critical impact on drug product quality (e.g., chewable 
tablet) 
 Uniformity of dosage unit- Mass of dosage form and the content of the active 
substance 
 Water content- Measure amount of water to determine effects of hydration or water 
absorption on the drug product 
 Microbial limits- Measure the amounts of aerobic microorganisms, yeasts and 
molds, and specific objectionable bacteria (e.g., E. coli, Salmonella, etc.).2  
For biological products, an assessment of the biological activity is an essential step in 
determining shelf life. The capacity of a product to achieve a defined biological effect relies 
on a biologically active therapeutic. Examples of recommended procedures to measure 
biological activity include:  
 Biochemical assays- Measure enzymatic reaction rates or biological responses 
induced by immunological interactions 
 Cell culture-based assays- Measure biochemical or physiological response at 
cellular level 
 Animal-based assays- Measure an organism’s biological response to the product.3 
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The potency of the drug during stability testing is critical in determining the recommended 
storage conditions and predicting shelf life.  
A pharmaceutical product is expected to have adequate stability over at least an 18-
month shelf life. The stability of most molecules normally increases in the order of solution 
< glassy solid < crystalline solid due to the increasingly restricted mobility of reacting 
species.4, 5 Drying techniques include lyophilization, spray drying, spray freeze drying, 
vacuum drying, and supercritical fluid technology.  
Due to slowed rates of the reactions that involve water as a reactant, lyophilization 
can enhance pharmaceutical stability and desired shelf life. Lyophilization is the general 
method of choice due to the following advantages:  
 Low temperature process, less thermal degradation 
 No terminal sterilization step necessary as it maintains sterility and particle free 
characteristics of product 
 Controlled residual moisture content and headspace gas composition in the vial 
 Easy scale-up and reasonable yield process.4  
We have selected to use lyophilization for drying the hFIX-loaded microparticles due to 
the aforementioned advantages.  
 In this Chapter, we outline the stability testing of lyophilized hFIX-loaded 
microparticles composed of P(MAA-g-EG) crosslinked with 1 mol% PEGDMA1000, 
previously described in Chapters 4 and 5. The storage conditions tested were selected based 
on the FDA guidelines for the general case and refrigerated storage. In order to gain an 
understanding of the drug product stability, we evaluated the effect of temperature and 
humidity on the dissolution, biological activity, and water content after storage at a 
maximum of 3 months. This short-term study was designed to assess the stability of the 
hFIX-loaded microparticles only without additional stabilizing agents.  
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6.2 MATERIALS AND METHODS 
6.2.1 Polymer Synthesis 
P(MAA-g-EG) hydrogels were synthesized by bulk UV-polymerization as 
previously described in Chapter 4. Briefly, the feed composition of the pre-polymer was 
MAA and PEGMMA1000 at a 2:1 molar ratio of hydrogen bonding groups, 
PEGDMA1000 at 1.0 mol% of total monomers, and Irgacure 184® at 1.0 wt. % of total 
monomers in a 1:1 (w/w) mixture of deionized water and ethanol. After sonicating for 20 
minutes, the pre-polymer mixture was needle purged with nitrogen for 5 minutes in the 
nitrogen-rich environment of a glove box. The mixture was then dispensed between two 
quartz glass plates, separated with a 0.7 mm Teflon® spacer, and then polymerized for 30 
minutes under 35 mW cm-2 UV light using a UV flood source. After synthesis, the resulting 
polymer was removed from the plates, and then washed in deionized water for a total of 10 
water exchanges. The polymer was dried for 3 days in air and then for 3 additional days 
under vacuum at 37°C. Dried films were crushed and sieved into microparticles, sized 30-
45 µm. 
6.2.2 Protein Loading Studies 
Loading studies were conducted using the optimized loading conditions as 
described in Chapter 5. Dried particles were added to a 0.5 mg mL-1 hFIX solution (5 mM 
NaH2PO4) to a final concentration of 5 mg mL
-1 and pH of 7.4. hFIX loading was carried 
out by equilibrium partitioning for 5 days with particle/protein suspensions under constant 
end-to-end rotation at 4°C. After 5 days, particles were collected by Buchner filtration 
using Whatman 50 filter paper. Particles were then collapsed with 0.1 N HCl and then triple 
rinsed with 0.1 N HCl, DI water, and 0.1 N HCl. Samples were collected after each step—
end of loading, collapse, and rinse—for protein quantification using hFIX ELISAs. 
 112 
Protein-loaded particles were then lyophilized overnight. Three separate batches of loaded 
microparticles were prepared. 
6.2.3 Storage Conditions 
For stability testing, samples included hFIX-loaded particles to determine drug 
release and activity after storage and empty particles to determine water uptake during 
storage. All samples (5-6 mg) of either hFIX-loaded particles or empty particles (n=3 for 
each sample type and storage condition) were placed in Type I borosilicate glass E-C 
sample vials with PTFE faced 14B Rubber-lined black phenolic caps (Wheaton, VWR, 
Radnor, PA).  
Prior to use, the glass vials and caps were autoclaved. These Type I borosilicate 
vials conform to USP requirements.6 Type I borosilicate glass, which has a high hydrolytic 
resistance and a high thermal shock resistance, is recommended for most products for 
parenteral and nonparenteral use.  
For this stability testing study, we selected three storage conditions according to 
USP and FDA guidelines. Table 6-3 outlines the conditions for the stability testing, which 
were adapted based on recommendations for general drug products and drug substances 
intended for storage in a refrigerator. 
 
Table 6-3. Stability testing conditions.  
Study Storage Conditions Time Period 
Accelerated 40°C/75% RH 30 days (1 month) 
Long-term 25°C/60% RH 90 days (3 months) 
Long-term, Refrigerated 4°C 90 days (3 months) 
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The vials with samples were stored protected from light in all conditions. For the 
accelerated and long-term studies, the samples with loosened caps were stored in the 
Darwin Chamber Company stability chambers (St. Louis, MO) at the specified conditions. 
The stability chambers are strictly maintained and monitored by THERAPEUTEX of the 
Drug Dynamics Institute at the UT Austin Dell Pediatric Research Institute. For the long-
term, refrigerated study, samples with the caps tightened were stored in a refrigerator.  At 
the end of the storage time period, samples were immediately tested for drug release and 
water content.  
6.2.4 Dissolution and Biological Activity 
In order to determine the release profile, the total amount of drug released, and the 
total amount of active drug released, protein release studies were conducted immediately 
following storage. For the t=0 condition, release studies were performed immediately after 
loading and lyophilization. Protein release studies were conducted following a two-stage 
dissolution procedure using biorelevant media as previously described in Chapter 5. 
Biorelevant media were prepared using a FaSSIF, FeSSIF & FaSSGF powder which 
contains bile salts and phospholipids. Fasted-state simulated gastric fluid (FaSSGF) was 
prepared at a 1x concentration with a final pH of 1.6 according to the manufacturer’s 
protocol (Biorelevant).  Fasted-state simulated intestinal fluid (FaSSIF) was prepared at 2x 
concentration with a final pH of 6.9. For the two-stage dissolution procedure, a 1:1 (v/v) 
FaSSGF:FaSSIF mixture at a final pH of 6.5 is required for the intestinal condition.  
Dissolution testing was performed using an USP apparatus 2 (paddles) setup for 
small volume (100 mL vessel) with low evaporation mini vessel covers using a Distek 
2100B dissolution apparatus (North Brunswick, NJ). A 5 mg sample of hFIX-loaded 
microparticles was added to a Sigmacoted (i.e., siliconized) vessel containing 30 mL of 
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SGF (1x, pH 1.6) at 37°C. After 30 minutes, 30 mL of FaSSIF (2x) at 37°C was added, 
raising the pH to 6.5. The solution was continuously stirred at 75 rpm and maintained at 
37°C for both stages. The FaSSIF stage was carried out for up to 2 h. Over the course of 
the dissolution, 1 mL samples were taken using a 1/8 cannula sample probe (Distek, Inc.) 
with a 10 micron polyethylene filter tip (Agilent Technologies, Santa Clara, CA). Samples 
were replaced with an equal volume of appropriate prewarmed media. hFIX released was 
quantified by hFIX ELISAs. The biological activity of the released hFIX was measured by 
hFIX chromogenic activity assays for the 2 h FaSSIF sample only.  
6.2.5 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was conducted using a TA Instruments TGA 
Q500 (New Castle, DE) to determine the water content of the empty particles (2-5 mg) 
after storage.  For the t=0 condition, vacuum dried particles were tested to determine the 
initial water content. Decomposition profiles were recorded from 25°C ramped at 
10°C/min to 550°C in nitrogen and then isothermal at 550°C for 5 minutes.  
6.2.6 Statistical Analysis 
Data are reported as mean ± standard error. Comparisons between groups were 
performed using a Student’s two-tailed t-test, and comparisons among multiple groups 
were performed using an ANOVA. Significant differences were considered when *p < 0.05 
and **p < 0.01. All statistical analysis was computed using GraphPad Prism 6.  
 
 115 
6.3 RESULTS AND DISCUSSION 
6.3.1 Protein Loading  
Microparticles (30-45 µm) of P(MAA-g-EG) crosslinked with 1 mol% 
PEGDM1000 were loaded with hFIX using optimized loading conditions.7 The final 
amount of protein loaded was calculated based on the concentration of the supernatant after 
incubation, collapse, and triple rinse. Protein lost during the collapse and rinse was likely 
surface loaded. The loading level (µg hFIX mg-1 particles) was calculated as:  
 
 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑐0𝑉0−𝑐𝑓𝑉𝑓
𝑐𝑝𝑉0
                 (Eq. 6-1) 
where c0 is the initial protein concentration (µg mL
-1), V0 is the initial volume (mL), cf is 
the final protein concentration (µg mL-1) after rinsing, Vf is the final volume (mL) after 
rinsing, and cp is the particle concentration (mg mL
-1). The average loading level for the 
three batches of particles is 50.9 ± 2.5 µg hFIX/mg particle.  
6.3.2 Effect of Storage Conditions on Drug Release and Activity 
Release studies were conducted to quantify the effects of storage on the stability of 
hFIX. The release of hFIX from microparticles of P(MAA-g-EG) crosslinked with 1 mol% 
PEGDMA1000 was tested using a two-stage dissolution procedure in biorelevant media. 
As shown in Figure 6-1, the initial release profile of hFIX from the t=0 samples matches 
the trends of previously reported hFIX release curves in Chapter 5. In the t=0 curve, the 
release is minimal in the fasted-state simulated gastric fluid (FaSSGF) and is significantly 
increased in the fasted-state simulated intestinal fluid (FaSSIF) as desired. The activity of 
hFIX released is well maintained (Figure 6-2), which allow agrees with previously reported 
results.  
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Based on the hFIX stability study reported in Chapter 5, we expect increased 
temperature and time to result decreased hFIX activity and stability. The previously 
reported study was conducted in solution, and the stability is expected to increase for the 
lyophilized form.4 Based on the release profiles in Figure 6-1, hFIX was significantly 
affected by the storage conditions. Samples in both the long-term (25°C/60% RH for 90 
days) and the accelerated (40°C/75% for 30 days) studies have significantly reduced 
release which may be attributed to the degradation of hFIX due to elevated temperature 
and humidity. However, the release profile from samples in the long-term, accelerated (5°C 
for 90 days) closely matches that of the initial release profile at t=0. The amount of hFIX 
released was quantified by hFIX-specific ELISAs. Detection by ELISA required antibodies 
to bind to hFIX, which confers the native conformation to a degree. In the case of the long-
term, refrigerated study, the hFIX likely remained stability in structure. However, the 
activity of hFIX released from particles stored at 5°C for 90 days is significantly reduced 
likely due to instability in the Gla domain and its function to bind Ca2+ ions (Figure 6-2).8 
Maintenance of the biological activity of hFIX is critical for its therapeutic use in protein 
replacement therapy.  
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Figure 6-1. Release profile of hFIX from P(MAA-g-EG) microparticles after various 
storage conditions.  
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Figure 6-2. Activity (%) of hFIX released (150 min in FaSSIF samples) from P(MAA-g-
EG) after various storage conditions.  
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6.3.3 Effect of Storage Conditions on Sample Water Uptake 
 During storage, the dried hydrogel particles are susceptible to water uptake, 
especially in elevated humidity. Water uptake in the sample can lead to protein instability 
due to hydrolysis. Hydrolytic reactions that occur in proteins include deamidation, 
aspartate (Asp) isomerization, proteolysis, and β elimination,9 all of which can affect hFIX 
(see amino acid sequence in Chapter 2). Deamidation, one of the most common hydrolytic 
reactions of proteins, occurs primarily at asparagine (Asn) residues, converting them to 
Asp. Isomerization at Asp sites produces isoAsp, which introduces a methylene group into 
the peptide backbone and perturbs the local conformation.  
Proteolysis is the hydrolysis of amide bonds connecting amino acids in the protein 
backbone. A single proteolytic reaction splits the protein backbone in two pieces. β-
elimination can result in the thermal decomposition of cysteine residues which can lead to 
additional reactions contributing to intermolecular crosslinking and formulation of 
covalent protein aggregates.10 However, β-elimination typically occurs at alkaline 
conditions, meaning this hydrolytic reaction is unlikely in the present case. The rates of 
hydrolytic reactions are accelerated at increased temperatures. In addition to chemical 
degradation by hydrolysis, water uptake in the sample may result in phase separation. At 
interfaces, proteins tend to denature, losing tertiary and secondary structure.  
 The water uptake in the sample was quantified by a thermal decomposition analysis 
using TGA. Representative decomposition curves of empty microparticles from each study 
show differences in the amount of water removed at 100°C (Figure 6-3). The weight % of 
the sample was determined at 100°C (averaged over 99.50°C < T < 100.50°C) to quantify 
the amount of water in the sample (the weight % removed at 100°C). During storage for 
all conditions, the microparticle samples did uptake water, and those stored at elevated 
humidity resulted in at least 2.3-fold increase in water content (Figure 6-4).  
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Figure 6-3. Representative decomposition curves of P(MAA-g-EG) microparticles after 
storage at various conditions.  
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Figure 6-4. Water content (wt. %) of P(MAA-g-EG) microparticles show water uptake 
during storage under various conditions.  
 
6.3.4 Stability Analysis 
In order to predict shelf-life, stability testing is conducted at various temperatures, 
particularly higher values, to calculate long-term product stability at lower temperatures. 
The effect of temperature on reaction rates is given by the Arrhenius equation as: 
𝑘 = 𝐴𝑒−𝐸𝑎 𝑅𝑇⁄                  (Eq. 6-1) 
Where k is the reaction rate constant, A is the Arrhenius factor, Ea is the energy of activation 
(cal mol-1), R is the ideal gas constant (1.987 cal K-1 mol-1), and T is the absolute 
temperature (K). The Arrhenius equation can be applied regardless of the order of the 
reaction kinetics.  
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 The reaction rate constant k can be determined based on the percent of drug 
remaining as a function of time. The drug loss as a function of time shows zero-order 
degradation kinetics for each isotherm. In this case, the reaction rate k is defined as:  
 
𝑘 =
𝑑(𝑑𝑟𝑢𝑔 %)
𝑑𝑡
                 (Eq. 6-2) 
which is the slope of the drug % versus time plot. One limitation of this study is the reaction 
rate k was calculated using only two time points due to limited resources. The reaction rate 
constant was calculated based on both the total amount of hFIX released and the amount 
of active hFIX released for each temperature (Table 6-4).  
 
Table 6-4. Drug loss and reaction rate constants k based on total hFIX released and active 
hFIX released for three temperatures.  
Temperature Time (days) Drug (%) 
k (drug 
%/day) 
Active Drug 
(%) 
k (drug 
%/day) 
--- 0 100.00 --- 100.0 --- 
40°C (313 K) 30 4.67 -3.17 3.34 -3.22 
25°C (298 K) 90 0.88 -1.10 0.45 -1.11 
4°C (277 K) 90 97.67 -0.03 30.86 -0.77 
 
 The energy of activation is critical to applying accelerated stability testing data to 
predict the product shelf life. To determine the energy of activation, the Arrhenius equation 
can be rearranged in a linear form as:  
ln(𝑘) =
−𝐸𝑎
𝑅𝑇
+ ln (𝐴)                               (Eq. 6-3) 
and an Arrhenius plot of ln(k) versus 1/T has a slope of –Ea/R and an x-intercept of ln(A). 
Based on the Arrhenius plot using the total hFIX released, the energy of activation Ea is 
23.60 ± 4.39 kcal mol-1 (Figure 6-5), while the energy of activation Ea is 6.50 ± 2.79 kcal 
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mol-1 for the active hFIX released (Figure 6-6). The Ea for drug decomposition is generally 
in the range of 12 to 24 kcal mol-1.11, 12  
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Figure 6-5. Arrhenius plot for the total hFIX released.  
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Figure 6-6. Arrhenius plot for the active hFIX released.  
 123 
 
6.4 RECOMMENDATIONS FOR IMPROVING STABILITY 
Based on the Arrhenius kinetic analysis, the lyophilized hFIX drug product requires 
additional stabilizing agents to enhance its shelf life. While lyophilization can improve 
pharmaceutical stability, this process consists of three phases—freezing, drying, and 
storage—during which stresses can cause product instabilities.  
In the freezing phase, the two common mechanisms of denaturation are 
cryoconcentration13 and ice-liquid surface denaturation.14 In the cryoconcentration 
mechanism, as the water freezes, turning into ice, the solutes can reach concentrations as 
high as 20-50 times their initial concentration.4, 13 Despite the reduced temperature, 
increased protein concentrations can promote degradation. Additionally, increased salt 
concentrations can contribute to protein instability due to exposure to high ionic 
strengths.15 Furthermore, increased salt concentrations at decreased temperatures can lead 
to selective crystallization, causing pH shifts.16 While possible pH effect is not evident for 
use immediately after lyophilization, we recommend monitoring the pH during 
lyophilization and assessing the potential pH effect on long-term stability.17 
Ice-liquid surface is a potential site for protein denaturation, as proteins tend to 
denature at interfaces, losing tertiary and secondary structure. However, increasing the 
cooling rate, decreasing the time for the system to phase separate, can reduce interface 
denaturation. In order to minimize degradation due to phase separation, we remove water 
and buffer by filtration, leaving the microparticles in a collapsed state with minimal liquid 
remaining. These microparticles are then flash frozen in liquid nitrogen. Additionally, 
some proteins undergo cold denaturation (i.e., spontaneous unfolding at low 
temperatures).18  While hFIX is not a known cold-labile protein, degradation studies at low 
temperatures could be performed to assess potential instabilities and denaturation. 
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In the drying phase, additional stresses due to the removal of bound water and 
elevated temperatures can lead to further protein instability. Reducing moisture levels to 
≤1%-2% can unbalance the hydrogen bonding in the protein’s native conformation, leading 
to reversible or irreversible unfolding.19, 20 Incorporating hydrogen-bonding excipients in 
the formulation is a common approach to enhancing the stabilization of the protein’s 
structure in the solid state.21 While no new stresses develop during the storage phase, the 
stress developed in the lyophilization process will continue to pose challenges to the 
storage stability.4 We recommend incorporating additional stabilizing agents, such as 
cryoprotectants and lyoprotectants, to reduce protein denaturation.  
Cryoprotectants are solutes, such as sugars, polyols, certain amino acids, 
methylamines, and “salting out” salts, used to prevent conformational changes and 
degradation during freezing.4 At concentrations of 300-600 mM, these cryoprotectants 
work by a mechanism called preferential exclusion of solutes.22 The solutes are excluded 
from the vicinity of protein, and therefore, their presence increases the chemical potential 
of the protein. Chemical potential is directly related to surface area. As a protein unfolds, 
the surface area increases, which in turn increases the chemical potential. Due to the lower 
chemical potential in the native form, the native form is more thermodynamically stable 
than the denatured form.4   
Polymers, particularly poly(ethylene glycol) (PEG), are included in formulations to 
stabilize biotherapeutics. PEG is a cryoprotectant that stabilizes proteins during freezing 
through preferential exclusion of PEG from the surface of the protein.23, 24 The inclusion 
of PEG in polymer formulation may attribute to the stabilization of hFIX. However, 
polymers are less effective lyoprotectants, as they are sterically hindered in forming 
hydrogen-bonds with proteins.  
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Lyoprotectants serve as “water substitutes” that allow for hydrogen-bonding 
interactions with the protein similar to such interactions between water and the protein.4 
The stabilization mechanism of lyoprotectants has been interpreted both 
thermodynamically and kinetically. Thermodynamically, stabilization by hydrogen 
bonding maintains or restores the free energy of unfolding such that the native 
conformation is preferred over the unfolded form. In the kinetic interpretation, the protein 
has restricted mobility due to being dispersed in a viscous microenvironment of the 
stabilizer. The protein is stabilized due to the significantly reduced or arrest rate of 
conformational changes leading to protein unfolding.4  
Nonreducing di- and tri-saccharides, such as sucrose, trehalose, or raffinose, are 
typically good lyoprotectants that can function as water substitutes and good glass 
formers.19, 20  These sugars can replace the hydrogen bonds at the exposed polar groups of 
the protein, which preserves the native structures of proteins in the dried state and during 
subsequent storage.13, 19, 22 Inert stabilizers are critical, where reducing sugars, such as 
lactose, maltose, and glucose, can chemically react with the protein. Sucrose at a level of 
approximately 1-9% is widely accepted as a cryoprotectant for lyophilized protein 
formulations.4 However, trehalose is a more effective stabilizer under acidic conditions, 
especially below pH 5, as it is less susceptible to hydrolysis. Since the hFIX-loaded 
microparticles are in the collapsed state, the microenvironment in the polymer is acidic. 
We would recommend testing several sugars, particularly trehalose which is an effective 
stabilizer under acidic conditions, as a lyoprotectant. The desired weight ratio of saccharide 
to protein is between 1:1 and 10:1 for stabilization during drying and storage. However, 
one issue that may arise is freeze-concentration-induced phase separation, which could 
result in protein denaturation.25 Phase separation can be reduced by increasing the cooling 
rate.  
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Commercially available lyophilized hFIX products include trehalose to enhance 
stability.26 The addition of 1% trehalose stabilized the calcium binding ability of hFIX and 
maintained its biological activity. The Gla domain of hFIX is responsible for Ca2+ binding 
which is required for its clotting activity. Binding to Ca2+ ions induces a conformational 
change in the protein that exposes the previously buried hydrophobic binding sites to 
facilitate binding to phospholipids to achieve efficient coagulation.8 Previous results show 
that trehalose decreases the rate of decay at 40°C/75% RH by almost 20-fold and the rate 
of decay at 25°C/60% by 5-fold for lyophilized hFIX. Likewise, trehalose reduces the rate 
of decay in biological function to a similar extent. Furthermore, trehalose (1 vol. %) 
substantially prevents hFIX aggregation during storage of the lyophilized product.26 We 
recommend testing the addition of trehalose at 0.5 to 5 vol. % to determine an optimal 
formulation for lyophilized hFIX-loaded microparticles.  
Other components in commercially available lyophilized hFIX products are a 
buffering agent, a bulking agent, and surfactant. In the patent, the optimal formulation 
contained 10 mM histidine as a buffering agent, 3 vol. % mannitol as a bulking agent, and 
0.0075 vol. % polysorbate 80 as a surfactant. Lyophilized hFIX prepared using this 
formulation (including 1 vol. % trehalose) maintained at least 90% of its activity when 
stored at 2-8°C for at least two years and at 25°C/60% RH for 6 months.26 While results 
showed that trehalose was key in stabilizing lyophilized hFIX and preserving its activity, 
we also recommend testing the other additives used in this patented formulation 
composition.  
Gaining a better understanding of the structure and stability of hFIX will be critical 
for improving drug product stability. FTIR is often used as an analytical tool for identifying 
the ideal sugar stabilizer for dry powder formulations.4, 27 Additionally, differential 
scanning calorimetry (DSC) is a technique used to study the unfolding of secondary 
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structures of proteins and to characterize the conformational stability of proteins in 
different conditions (solid and liquid states). Protein unfolding is detected as an 
endothermic event by DSC, while protein aggregation produces an exothermic peak. DSC 
analysis can be used to determine the optimal freezing and annealing temperatures during 
a lyophilization cycle.4 In formulation development, DSC can be used to measure the effect 
of an additive on the protein’s thermal stability. An increase in the protein’s melting 
temperature indicates that the additive improves protection.  
 
6.5 CONCLUSIONS 
Stability testing of a drug product, which in this case is lyophilized hFIX-loaded 
P(MAA-g-EG) microparticles, is critical for predicting shelf life. After storage, the 
dissolution, biological activity, and water content were evaluated. Based on these stability 
testing results, we determined that elevated temperature and humidity can lead to drug loss 
and water uptake. While the hFIX release profile after storage at 4°C for 90 days nearly 
matched that of t=0, the biological activity of released hFIX was significantly reduced. 
Based on these exploratory studies, we recommend storage at 4°C with humidity control. 
However, enhancing the biological activity of hFIX, which could be achieved by the 
addition of trehalose,26 is critical for lyophilized hFIX-loaded microparticles. Further 
investigations of the effects of additives, particularly trehalose, are recommended to 
stabilize hFIX in the lyophilized formulation, leading to an improved shelf life. 
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Chapter 7: Enzymatically Degradable Delivery Systems3 
7.1 INTRODUCTION 
Current treatments for hemophilia B, a hereditary bleeding disorder, require painful 
IV injections of coagulation factor IX. To overcome the issues with current treatment 
options, our goal is to develop an oral delivery system for human FIX (hFIX) as a 
convenient prophylactic treatment for hemophilia B.  
We have successfully designed a pH-responsive P(MAA-g-EG) microcarrier 
system to enable the oral route of factor IX.1 However, modifications of this delivery 
system became necessary to improve the oral bioavailability of hFIX.  We have 
incorporated an enzymatically degradable peptide-based crosslinking agent into the pH-
responsive P(MAA-g-EG) system to increase release of hFIX in the small intestine. Using 
enzyme-degradable components in hydrogel systems has been recently explored for oral 
delivery systems of biologics targeted for delivery to the small intestine.2-4  Previous work 
showed promising applications of enzymatically degradable systems for delivering siRNA 
to treat inflammation of the small intestine.3  
Enzymatic degradation is an attractive method for site-specific delivery systems 
due to the localized enzyme concentrations in the GI tract and the specificity of enzyme-
catalyzed reactions (Figure 7-1).2, 3, 5  In the stomach, the primary proteolytic enzyme is 
pepsin. The human small intestine contains gram quantities of peptidases (e.g. trypsin, α-
chymotrypsin, pancreatic elastase, etc.) secreted from the pancreas and cellular peptidases 
from the mucosal cells.6, 7 In order to achieve targeted degradation in the small intestine, 
the peptide crosslinking agent can be designed with cleavage sites specific to intestinal 
                                                 
3 Portions of this chapter have been previously published in Horava, S. D.; Moy, K.J.; Peppas, N. A., 
Biodegradable Hydrophilic Carriers for Delivering Hematological Factor IX for Hemophilia B Treatment. 
International Journal of Pharmaceutics 2016. 
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enzymes, while avoiding sites for pepsin (see Table 1 for enzyme cleavage sites).7 We have 
selected a peptide crosslinking agent composed primarily of arginine (Arg, R) residues, as 
well as glycine (Gly, G) and lysine (Lys, K), for targeted cleavage by trypsin and resistance 
to degradation by pepsin.  
 
 
Figure 7-1. Schematic of a biodegradable microcarrier containing peptide crosslinks 
shows the enzyme-specific degradation. In the stomach, the peptide 
crosslinking agent is not degraded by pepsin, and the particle remains intact, 
protecting the drug. In the small intestine, the peptide crosslinking agent is 
degraded by trypsin, which allows for the release of the drug. 
 
Table 7-1. Cleavage sites of the primary proteolytic enzymes in the stomach and small 
intestine. (Note: Xaa = amino acid).7 
 Enzyme Cleavage sites 
Stomach pepsin 
Phe-|-Xaa, Tyr-|-Xaa, Leu-|-Xaa, Trp-|-
Xaa, ideally Xaa = Phe, Trp, Tyr 
Small intestine 
trypsin Arg-|-Xaa, Lys-|-Xaa 
α-chymotrypsin 
Tyr-|-Xaa, Trp-|-Xaa, Phe-|-Xaa, Leu-|-
Xaa, Met-|-Xaa 
pancreatic elastase Ala-|-Xaa, Gly-|-Xaa, Val-|-Xaa, Ser-|-Xaa 
 
 132 
Here, we describe the design and development of an enzymatically degradable and 
pH-responsive P(MAA-g-EG) system for the oral delivery of hFIX. As previously 
described, the pH-responsive swelling behavior allows for protection of the protein in the 
stomach and release in the small intestine. Additionally, the release of protein is triggered 
by enzymatic degradation by trypsin in the small intestine. Degradation of the microcarriers 
is expected to improve the release of hFIX as compared to the diffusion-based release of 
crosslinked P(MAA-g-EG) systems. Increased release is expected to promote the overall 
bioavailability of orally administered hFIX. Synthesis, characterization, and 
cytocompatibility of biodegradable P(MAA-g-EG), as well as an evaluation of hFIX 
loading, release, and in vitro transport, are detailed herein.  
 
7.2 METHODS 
7.2.1 Materials 
Methacrylic acid (MAA), Irgacure 184® (1-hydroxy-cyclohexyl-phenylketone), 
N-(3-dimethylaminopropyl)-Nʹ-ethylcarbodiimide (EDC), N-hydroxysulfosuccinimide 
(NHS), trypsin from bovine pancreas, and trypsin inhibitor type III-O (free of ovoinhibitor) 
were purchased from Sigma-Aldrich (St. Louis, MO). Poly(ethylene glycol) (MW=1000) 
mono methyl ether monomethacrylate (PEGMMA1000) was purchased from Polysciences 
(Warrington, PA). The custom sequence oligopeptide was synthesized by CHI Scientific 
(Maynard, MA). Plasma-derived human factor IX (hFIX) was purchased from 
Haematologic Technologies Inc. (Essex Junction, VT). Human factor IX ELISA kits were 
purchased from AssayPro LLC. (St. Charles, MO), and the BIOPHEN factor IX activity 
assays were purchased from HYPHEN Biomed SAS (Neuville-sur-Oise, France). FaSSIF, 
FeSSIF & FaSSGF Powder was purchased from Biorelevant.com (London, England, UK). 
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All reagents were used as received. All other solvents and buffers were purchased from 
Fisher Scientific (Waltham, MA).  
7.2.2 Uncrosslinked Polymer Synthesis, Purification, and Characterization 
Uncrosslinked P(MAA-g-EG) polymer was synthesized by bulk UV 
polymerization (Figure 7-2). MAA and PEGMMA1000 were added at 2:1 molar ratio of 
hydrogen bonding groups to a 1:1 (w/w) mixture of deionized water and ethanol to result 
in a 1:1 (w/w) ratio of total monomer to solvent in a 10 mL round bottom flask. Irgacure 
184® photoinitiator was added at 1 wt. % of the total monomers, and then the prepolymer 
mixture was sonicated for 20 minutes in a Bransonic® CPX3800 ultrasonic digital bath 
(Branson Ultrasonics Corporation, Danbury, CT). After sealing the flask with a rubber 
septum, the prepolymer mixture was nitrogen purged for 20 minutes to remove oxygen, 
which is a free radical scavenger, while stirring. With constant stirring, the mixture was 
polymerized for 90 minutes under 100 mW/cm2 UV light using a Dymax BlueWave 200 
UV point source (Dymax, Torrington, CT).  
In order to purify the polymer from any unreacted monomers, the uncrosslinked 
polymer was purified by precipitation with acetone and then dialyzed. In order to 
precipitation of the polymer, 1 N NaOH was added to ionize the polymer and acetone 
(dielectric constant ε=20.7) was added to induce ionomer collapse.8 The precipitated 
polymer suspension was then centrifuged at 20,000 x g and then resuspended in deionized 
water. This precipitation procedure was carried out a total of three times, followed by 
dialysis using 3.5 kDa MWCO Spectra/Por Regenerated Cellulose Dialysis Tubing 
(Spectrum Laboratories Inc.) in 1 mL of deionized water, changed daily 10 times. After 
purification, the polymer was frozen with liquid nitrogen and then lyophilized for at least 
72 hours.   
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Potentiometric titration was used to quantify the MAA content of the uncrosslinked 
polymer. Uncrosslinked P(MAA-g-EG) was dissolved in 10 mM NaCl at a concentration 
of 1 mg/mL, and then titrated to a pH of 2.5 using 0.05 N HCl at 25°C with constant stirring. 
HCl was added (10-60 µL) to the polymer solution, and the pH was measured until reaching 
a steady value (three consecutive readings within ± 0.02) at each step using a Thermo 
Scientific Orion Star A211 pH benchtop meter (Waltham, MA). The molar amount of 
MAA was calculated based on equivalence point and a charge balance. 
The composition of the uncrosslinked polymer was further analyzed using proton 
nuclear magnetic resonance (1H NMR) spectroscopy and Fourier transform infrared (FTIR) 
spectroscopy (see section 2.4). For NMR, a sample of uncrosslinked polymer was prepared 
in deuterium oxide (D2O) at 10 mg/mL. The 
1H NMR spectra were collected using an 
Agilent Technologies 400-MR NMR spectrometer (Santa Clara, CA) with a resonance 
frequency of 400 MHz, with 64 scans collected at 1 second relaxation delay and 90° pulse 
angle.   
7.2.3 Crosslinking via EDC-NHS Chemistry 
Post polymerization, P(MAA-g-EG) polymer was crosslinked with a GRRRGK 
peptide via EDC-NHS chemistry (Figure 7-2). Uncrosslinked polymer was dissolved in a 
1:1 (v/v) mixture of deionized water and ethanol. To activate the carboxyl groups, EDC 
(50 mg/mL in ethanol) and NHS (16.66 mg/mL in ethanol) were added at a mass ratio of 
6:3:1 polymer: EDC: NHS, which is an approximate molar ratio of 2.2:1 MAA 
groups:EDC and 1.8:1 EDC:NHS. The mixture was then allowed to react for 3 minutes at 
room temperature while under constant rotation. The activated polymer was then titrated 
to pH 7 by adding 1 N NaOH. To crosslink the activated polymer, GRRRGK peptide (100 
mg/mL in ethanol) was added at a mass ratio of 2:1 polymer: peptide. To further facilitate 
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the reaction, the pH was reduced to 4.5-5 using 1 N HCl. The reaction was then allowed to 
proceed for 24 hours at room temperature under constant rotation.  
The peptide crosslinked polymer was purified by washing with deionized water and 
centrifuging at 10,000 x g for 5 minutes for three times, and then lyophilized overnight. 
The resulting P(MAA-g-EG) polymer crosslinked with GRRRGK peptide was then 
crushed and sieved into microparticles of the desired size range, and then stored at 4°C in 
a desiccator.  
To quantify the amount of GRRRGK peptide crosslinking agent in the final 
polymer, the peptide content in the supernatant after the reaction and after each wash was 
quantified using a fluorescamine assay. Briefly, the fluorescamine reagent (3 mg/mL 
fluorescamine dissolved in filtered acetone) was add at a 1:3 ratio by volume to supernatant 
samples, and then samples were mixed for 15 minutes at room temperature. The 
fluorescence was measured at an excitation of 400 nm and an emission of 430 nm using a 
BioTek Cytation 3 multi-mode reader (Winooski, VT). 
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Figure 7-2. (A) Synthesis of uncrosslinked P(MAA-g-EG) polymer by UV 
polymerization. (B) Crosslinking reaction of P(MAA-g-EG) via EDC-NHS 
chemistry. EDC reacts with the carboxylic acid groups of the PMAA 
backbone to form an active O-acylisourea intermediate which is easily 
displace by nucleophilic attack from a primary amine groups of the 
GRRRGK peptide. The primary amine forms an amide bond with the 
original carboxyl group, releasing an isourea by-product. (Figure adapted 
from Knipe et al.3) 
 
7.2.4 FTIR-ATR Spectroscopy 
Fourier transform infrared-attenuated total reflectance (FTIR-ATR) spectroscopy 
was used to determine the composition of peptide crosslinked microparticles as compared 
to the uncrosslinked P(MAA-g-EG) polymer and the GRRRGK peptide. FTIR-ATR 
spectra were collected using a Thermo Scientific NicoletTM iS10 FT-IR spectrometer 
(Waltham, MA) with an accessory germanium crystal at an incidence angle of 45°C. A 
background spectra was acquired immediately prior to each individual sample. Prior to 
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analysis, the uncrosslinked polymer and the microparticles were dried in a vacuum at 37°C 
for at least 24 hours. The GRRRGK peptide was used as provided from the manufacturer. 
For each sample, 128 scans were performed with a resolution of 4 cm-1 and a gain of four.  
7.2.5 SEM 
Scanning electron microscopy was used to examine the morphology and size 
distribution of the peptide crosslinked microparticles. For sample preparation, dried 
microparticles were dusted onto carbon tape-covered aluminum stubs and then coated with 
12 nm of Pt/Pd using a Cressington 208 Benchtop sputter coater (Watford, England, UK). 
SEM images were obtained using a Zeiss Supra 40VP Scanning Electron Microscope 
(Oberkochen, Germany).  
7.2.6 Microparticle Swelling Studies and Enzyme Degradation 
The time scale of microparticle swelling and degradation is determined by kinetic 
turbidimetric studies in biorelevant media. Biorelevant media were prepared using FaSSIF, 
FeSSIF & FaSSIF Powder (Biorelevent.com, London, England, UK). Fasted-state 
simulated gastric fluid (FaSSGF) was prepared at a 1x concentration according to the 
manufacturer’s protocol, while fasted-state simulated intestinal fluid (FaSSIF) was 
prepared at a 2x concentration. For all turbidity, microscopy, and release studies, a 1:1 (v/v) 
mixture of FaSSGF and FaSSIF buffers at a final pH of 6.5 were used for intestinal 
conditions.  
Microparticle suspensions (5 mg/mL) were prepared with FaSSGF buffer (pH 1.6), 
3.2 mg/mL pepsin in FaSSGF buffer, 1:1 FaSSGF:FaSSIF buffer (pH 6.5), and 0.625 
mg/mL trypsin in FaSSGF:FaSSIF buffer. Immediately following suspension, 200 µL of 
either particle suspension or buffer only was added in triplicate to a 96-well plate. The 
absorbance was then measured at 520 nm in 1 minute intervals with 20 seconds of shaking 
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prior to each read at 37°C for 2 hours using a BioTek Cytation 3 multi-mode reader 
(Winooski, VT).  
To further confirm the pH-responsive swelling behavior, microparticles in the 
FaSSGF and FaSSIF buffers were visually examined by bright-field microscopy. 
Additionally, bright-field microscopy is used to visualize degradation of the microparticles 
by trypsin and resistance to degradation by pepsin. Bright-field images were captured using 
an Olympus IX 73 inverted microscope using the 10x objective.  
7.2.7 Cytocompatibility Studies 
To determine the cytocompatibility of the peptide crosslinked microparticles and 
the degradation products, cell proliferation (MTS) assays were conducted using two 
intestinal epithelial model cell lines. Human epithelial colorectal adenocarcinoma (Caco-
2) and mucus-secreting goblet-like human colorectal adenocarcinoma (HT29-MTX) were 
cultured in modified Dulbecco’s Eagle Medium (DME) supplemented with 10% fetal 
bovine serum (FBS). Caco-2 cells (at passages 65-75) or HT29-MTX cells (at passages 15-
20) were plated on a 96-well plate, coated with fibronectin, at an initial seeding density of 
5x106 cells per well and then cultured to 80% confluence.  
Prior to use, microparticles (30-45 µm) were added to DMEM without phenol red 
with 10% FBS at concentrations of 0.625, 1.25, and 2.5 mg/mL and allowed to swell for 1 
hour at 37°C under constant rotation. To prepare the degradation products, microparticles 
were added to 0.625 mg/mL of trypsin in 1X PBS (sterile filtered) and then allowed to 
degrade for 6 hours at 37°C under constant rotation. To quench trypsin activity, trypsin 
inhibitor Type III-O (free of ovoinhibitor) was added 1:1 mass ratio to trypsin, and then 
further incubated for 1 hour at 37°C under constant rotation. The degradation products 
were further diluted 1:6 with DMEM with 10% FBS to final concentrations of 0.625, 1.25, 
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and 2.5 mg/mL. Samples of trypsin and inhibitor in media at the same ratios were prepared 
as a control.  
For the cytocompatibility study, growth media was removed from the cell and 
replaced with 100 µL of solution—microparticle suspensions, degradation product 
suspensions, media (positive control), media with trypsin and inhibitor, or lysis buffer 
(negative control). The cells were incubated for 6 hours. For the CellTiter 96® Aqueous 
One Solution Cell Proliferation (MTS) assay (Promega Corporation, Madison, WI),  MTS 
reagent (20 µL/well) for was added after 6 h exposure, and then incubated for an additional 
90 minutes. The absorbance was measured at 490 nm for the MTS and 690 nm for the 
background using a BioTek Cytation 3 multi-mode reader (Winooski, VT).  
7.2.8 Factor IX Loading Studies 
Previously optimized loading conditions for hFIX were used with the peptide 
crosslinked P(MAA-g-EG) microparticles. Dried particles (5 mg/mL) and hFIX (0.5 
mg/mL) were suspended in 5 mM NaH2PO4 buffer, adjusted to a final pH of 7.4. hFIX was 
loaded by equilibrium partitioning for 5 days at 4°C under constant rotation. After 
incubation, particles were collected by Buchner filtration using Whatman 50 filter paper, 
then collapsed with 0.1 N HCl, and then triple rinsed with 0.1 N HCl, then water, and lastly 
0.1 N HCl. Samples were collected after each step for analysis using hFIX ELISAs. The 
hFIX-loaded particles were then lyophilized overnight.  
7.2.9 Factor IX Release Studies 
Release studies were conducted using two-stage dissolution in biorelevant media 
(prepared described above). Dissolution testing was performed using a Distek 2100B 
dissolution apparatus (North Brunswick, NJ) with a USP apparatus 2 (with paddles) setup 
for small volumes (100 mL vessels) with low evaporation mini vessel covers. A 5 mg 
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sample of hFIX-loaded microparticles was added to a Sigmacoted (i.e., siliconized) vessel 
containing 30 mL of FaSSGF buffer (pH 1.6) at 37°C with continuous stirring at 75 rpm. 
At 10 minute intervals, three 1 mL samples were taken using a 1/8 cannula sample probe 
(Distek, Inc.) with a 10 micron polyethylene filter tip (Agilent Technologies, Santa Clara, 
CA). Samples were replaces with an equal volume of appropriate pre-warmed media. After 
30 minutes for the FaSSGF stage, 30 mL of 1.25 mg/mL trypsin in FaSSIF (2x) at 37°C 
was added, raising the pH to 6.5 ad bringing the final trypsin concentration to 0.625 
mg/mL. Similarly, samples were taken over the course of the 2 hour FaSSIF stage. Release 
samples were analyzed by hFIX ELISAs.  
7.2.10 Factor IX Transport Studies 
In order to determine the effect of the microparticles and degradation products on 
the transport of factor IX across an intestinal epithelium, in vitro transport studies were 
conducted using an intestinal epithelial model. Caco-2 and HT29-MTX cells at 1:1 mixture 
were seeded on the apical side of 12-well Transwell® plates (12 mm diameter, 0.4 µm 
pores, Corning, Corning, NY) at 105 cells per well. Monolayers were cultures for 17-21 
days with media (DMEM with 10% FBS) changes every other day. The transepithelial 
electrical resistance (TEER) was measured 2 hours post media change using an EVOM2 
epithelial voltohmmeter and chopstick electrode (World Precision Instruments, Sarasota, 
FL).  
Prior to in vitro use, hFIX was endotoxin-depleted for cell culture standards. 
Endotoxins were removed using Thermo ScientificTM PierceTM High-Capacity Endotoxin 
Removal Spin Columns according to the manufacturer’s protocol. For maximum endotoxin 
removal, the hFIX was incubated in the spin column for 24 hours at 4°C. After endotoxin 
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depletion, a Thermo ScientificTM PierceTM LAL (limulus amebocyte lysate) was used to 
measure the amount of endotoxin in hFIX samples.  
Prior to the start of the transport study, microparticle samples were added to Hank’s 
balanced salt solution (HBSS) with 0.5 mg/ml bovine serum albumin (BSA) (HBSS/BSA) 
and allowed to swell for 1 hour at 37°C under constant rotation. To prepare the degradation 
products, microparticles were added to 0.625 mg/mL of trypsin in 1X PBS (sterile filtered) 
and then allowed to degrade for 6 hours at 37°C under constant rotation. To quench trypsin 
activity, trypsin inhibitor Type III-O (free of ovoinhibitor) was added 1:1 mass ratio to 
trypsin, and then further incubated for 1 hour at 37°C under constant rotation. The 
degradation products were further diluted 1:6 with HBSS/BSA with 10% FBS to final 
concentrations of 0.625, 1.25, and 2.5 mg/mL. Samples of trypsin and inhibitor in 
HBSS/BSA at the same ratios were prepared as a control. 
One hour before the transport study, media was removed and replaced with 
HBSS/BSA at 37°C to allow the cells to equilibrate. The TEER was measured in 
HBSS/BSA after the 1 hour incubation, and then HBSS/BSA was removed from the apical 
side. Microparticles (0.875 mg/mL = 0.391 mg/cm2) with hFIX, degradation products 
(0.875 mg/mL) with hFIX, neat hFIX, HBSS/BSA, or trypsin and inhibitor in HBSS/BSA 
were added to the apical side. hFIX was tested at two different concentrations—0.04 
mg/mL and 0.4 mg/mL (10x)—for the microparticles, degradation products, and neat hFIX 
samples. In addition to the HBSS/BSA control, samples with trypsin and inhibitor in 
HBSS/BSA were also included to determine if trypsin and inhibitor affected TEER 
measurements. For the duration of the 4 hour study, TEER was measured, and then 200 µL 
samples were collected from the basolateral side and replaced with HBSS/BSA at 37°C for 
each time point. After 4 hours, final apical and basolateral samples were collected, then 
cells were rinsed with media, and fresh media was added to both sides. To monitor the 
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recovery of the monolayers, final TEER measurements were taken 24 hours post study 
completion. The amount of hFIX transported to the basolateral side was quantified by hFIX 
ELISAs.  
7.2.11 Statistical Analysis 
Data are reported as mean ± standard error. All statistical analysis, either a 
Student’s two-tailed t-test for two groups or an ANOVA for multiple groups, were 
computed using GraphPad Prism 6. Significant differences were considered when *p < 
0.05 and **p < 0.01.  
 
7.3 RESULTS AND DISCUSSION 
7.3.1 Uncrosslinked Polymer Synthesis, Purification, and Characterization 
The composition of the resulting uncrosslinked P(MAA-g-EG) polymer was 
confirmed by titration and FTIR (see Section 7.3.3). Based on titration, the uncrosslinked 
polymer is composed of 93 ± 0.5 mol % MAA.  Similarly, the uncrosslinked polymer is 
composed of 6.60 mol% PEG and therefore 93.5 mol% MAA as calculated from peak 
ratios of the 1H NMR spectrum (Figure 7-3). Both results agree closely of the monomer 
feed of 97 mol % MAA. 
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Figure 7-3. 1H NMR spectrum of P(MAA-g-EG) polymer dissolved in d2O shows the 
integration of the peaks of interest. 
 
7.3.2 Peptide Crosslinking via EDC-NHS Chemistry 
Immediately following the addition of GRRRGK peptide, the mixture became 
cloudy, indicating crosslinking of the P(MAA-g-EG). After the 24 hour incubation, a single 
opaque mass had formed and the remaining liquid was clear. After each wash step, the 
mass of crosslinked polymer slightly decreased due to the removal of uncrosslinked 
polymer. The resultant lyophilized crosslinked polymer was white and denser than 
lyophilized uncrosslinked polymer. Based on results from the fluorescamine assay, the 
final amount of peptide incorporated was 1.32 ± 0.24 mol % of total moles of polymer. The 
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dried peptide crosslinked polymer was crushed into microparticles of 30-45 µm, and the 
particles showed irregular morphology due to the crushing process (Figure 7-4). 
 
 
Figure 7-4. A representative SEM image shows the irregular morphology of a 30-45 µm 
peptide crosslinked P(MAA-g-EG) microparticle (scale bar = 20 µm).  
 
7.3.3 FTIR-ATR Spectroscopy 
In order to confirm the incorporation of the GRRRGK peptide into the 
microparticles, FTIR-ATR spectra were collected for uncrosslinked P(MAA-g-EG) 
polymer, GRRRGK peptide, and peptide crosslinked microparticles.  As shown in Figure 
7-2, the peptide spectrum shows the amide I region (1700-1600 cm-1), corresponding to the 
carbonyl (C=O) stretching vibration of a peptide bond, and the amide II region (1575-1480 
cm-1) due to CN stretching and NH bending.9, 10 Additional characteristic bands of the 
peptide can be attributed to CN stretching (1250 and 1140 cm-1) and NH2 stretching (800 
cm-1).2  For  the  uncrosslinked P(MAA-g-EG) spectra, peaks are characteristic of COOH 
stretching (1730 cm-1), C-O stretching (1200 cm-1), and asymmetric stretching of the ether 
group (C-O-C) of PEG (1100 cm-1).11 The spectra of P(MAA-g-EG) crosslinked with 
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peptide shows characteristic peaks from both the uncrosslinked P(MAA-g-EG) polymer 
and the GRRRGK peptide, notably the broadening of the peak at 1750-1600 cm-1 and 1250-
1140 cm-1 (Figure 7-5). 
 
 
Figure 7-5. FTIR-ATR spectra of uncrosslinked P(MAA-g-EG), GRRRGK peptide, and 
peptide crosslinked P(MAA-g-EG).  
 
7.3.4 Microparticle Swelling and Enzyme Degradation 
Kinetic turbidimetric studies were conducted to determine the timescale of 
microparticle swelling and degradation. Previous studies have demonstrated the use of 
turbidity for analysis of microparticle swelling1 and microparticle degradation.2  The 
turbidity of a microparticle dispersion decreases as a result of microparticle swelling due 
to the increased transparency of the microparticles. Similarly, as microparticles degrade, 
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the turbidity of the dispersion decreases. In the case of microparticle swelling and 
degradation, the relative refractive index of the particles to the solvent decreases and 
reduces the turbidity measurement. As previously derived by Klinger et al., turbidity can 
be expressed as:  
𝜏 = [𝐴𝑡 − 𝐴0]  ln10                (Eq. 7-1) 
where At is the absorbance of the sample and A0 is the absorbance of the pure solvent. 
12 
For kinetic turbidity measures for an individual sample, the relative turbidity is defined as: 
𝜏𝑟𝑒𝑙 =
𝜏𝑡
𝜏𝑡=0
                 (Eq. 7-2) 
where τt is the turbidity at time, t, and τt is the initial turbidity.  
The kinetics of degradation and swelling are shown in Figure 7-6 where the rate of 
degradation (sample in FaSSIF with 0.625 mg/mL trypsin) is occurs more rapidly than the 
rate of swelling (samples in FaSSIF). The microparticles (90-150 µm) are nearly completed 
degraded by one hour. The turbidity of samples in FaSSGF with 3.2 mg/mL pepsin remain 
relatively constant indicating that the particles remain intact and do not swell. The kinetic 
turbidity results are as expected since this system is designed for targeted degradation by 
trypsin (prominent in the small intestine), not by pepsin (prominent in the stomach). 
In addition to turbidity results, microscopy was used to visually confirm the pH-responsive 
swelling behavior of peptide-crosslinked P(MAA-g-EG). At intestinal conditions (pH 6.5), 
the microparticles were swollen as shown by the increase in size compared to 
microparticles at gastric conditions (pH 1.6). In addition, the microparticles remained intact 
at pH 6.5 confirming that the P(MAA-g-EG) polymer was crosslinked by the GRRRGK 
peptide (Figure 7-7). Uncrosslinked polymer would dissociate at a pH above 4.8, which is 
the pKa of MAA.  
Microscopy was further used to confirm the specificity of the enzymatic 
degradation and the corresponding timescale. As visually confirmed, the microparticles 
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were not degraded by pepsin in FaSSGF medium, while microparticles were degraded by 
trypsin (0.625 mg/mL) in FaSSIF medium (Figure 7-7). The majority of microparticles 
were degraded within 30 minutes with small pieces remaining, and within an hour, the 
microparticles were fully degraded.  
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Figure 7-6. Kinetic turbidimetric measurements show the timescale of microparticle 
swelling and degradation by trypsin, while confirming that the 
microparticles are not degraded by pepsin (mean ± SE, n=3). 
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Figure 7-7. Bright-field images of microparticles (90-150 µm) after 30 minutes in 
biorelevant conditions (scale bar = 100 µm).  Microparticles in the gastric 
conditions with pepsin remained intact. In the intestinal conditions with 
enzymes, the microparticles are swollen and intact. The microparticles are 
degraded by trypsin, leaving some debris behind.  
 
7.3.5 Cytocompatibility  
The cytocompatibility of the microparticles and degradation products was 
determined using an MTS cell proliferation assay. The cytocompatibility was found to be 
concentration dependent with the effect more profound for Caco-2 cells (Figure 7-8) 
compared to HT29-MTX (Figure 7-9). At all concentrations, both the microparticles and 
the degradation products are cytocompatible (80% cell viability) in both cell lines. As the 
microparticles degrade in the small intestine, the degradation products are also 
cytocompatible as there is no significant difference between the two groups.  Additionally, 
the presence of trypsin and inhibitor in the media showed no negative effects on cell 
viability (103.5 ± 5.1% for Caco-2 cells and 100.2 ± 1.9% for HT29-MTX cells).  
 
FaSSGF + pepsin (pH 1.6) FaSSIF (pH 6.5) FaSSIF + trypsin (pH 6.5) 
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Figure 7-8. Cytocompatibility of peptide crosslinked P(MAA-g-EG) particles and 
degradation products (6 h exposure) was evaluated in Caco-2 cells using a 
cellular metabolic activity MTS assay. (n=3, mean ± SE, *p<0.5). 
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Figure 7-9. Cytocompatibility of peptide crosslinked P(MAA-g-EG) particles and 
degradation products (6 h exposure) was evaluated in HT29-MTX cells 
using a cellular metabolic activity MTS assay. (n=3, mean ± SE, *p<0.5). 
  
7.3.6 Factor IX Loading and Release 
We designed a biodegradable system for improved release of hFIX as compared to 
previously tested systems using P(MAA-g-EG) crosslinked with PEGDMA (MW of PEG 
ranging from 400 to 1000).  The final amount of protein loaded takes into account the 
concentration of supernatant after incubation, collapse, and triple rinse. Protein lost during 
collapse and rinse was likely surface loaded. The loading level tor the peptide-crosslinked 
P(MAA-g-EG) microparticles is 37.02 ± 0.21 µg hFIX/mg particles, which is similar to the 
loading amount (39.91 ± 1.91 µg hFIX/mg particles) for P(MAA-g-EG) crosslinked with 
1% PEGDMA1000 using the same loading conditions.1  
Release from the biodegradable system showed the desired trends with minimal 
release in gastric conditions (FaSSGF) and increased release in intestinal conditions 
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(FaSSIF), as shown in Figure 7-10. hFIX release from the biodegradable system continued 
to increase over the first hour in FaSSIF conditions which may be attributed to both the 
pH-responsive swelling and enzymatic degradation. As the microparticles swell, the 
peptide crosslinks become more accessible to trypsin, which can increase the rate of 
degradation of the microparticle and allow for increased release of hFIX from the internal 
sections of the microparticle. By combining pH-responsive behavior and enzymatic 
degradation, we have improved the amount of hFIX released in intestinal conditions by 
1.7-fold as compared to PEGDMA crosslinked pH-responsive systems. 
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Figure 7-10. Release profile of hFIX from P(MAA-g-EG) microparticles using two-stage 
dissolution in biorelevant media. Enzymatically degradable particles 
crosslinked with peptide showed increased hFIX release compared to 
particles crosslinked with PEGMDA1000 (data from Horava and Peppas1). 
Note that FaSSGF = fasted-state simulated gastric fluid and FaSSIF = 
fasted-stated simulated intestinal fluid. (n=3, mean ± SE, *p<0.05). 
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7.3.7 Transport Studies 
In vitro transport studies using an intestinal epithelial model are used as a tool to 
predict the oral drug absorption. Co-cultures of Caco-2 cells and mucus-secreting goblet-
like HT29-MTX cells are a commonly used as physiologically relevant intestinal epithelial 
models for predicting oral drug absorption.13 As previously noted, co-culture models 
contain three major absorption barriers—tight junctions, membranes of absorptive 
epithelia, and a mucus layer. While the tight junctions (in vitro TEER values of ~250-300 
Ω cm2, Figure 7-11) are closer to in vivo values (20-100 Ω cm2), the in vitro drug 
permeability is typically lower than in vivo.13  
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Figure 7-11. TEER of in vitro intestinal epithelial monolayers (co-culture of Caco-2 and 
HT29-MTX cells) during culturing. (n=24, mean ± SE). 
 
Transport studies using an in vitro intestinal epithelial model were conducted to 
determine the effect of the microparticles and degradation products on the transport of 
hFIX. We further examined the effect of apical hFIX concentration on absorption. Prior to 
 153 
in vitro use, hFIX was endotoxin depleted to a final concentration of < 1.5 EU/mL, as 
quantified by LAL assay. Suspensions of microparticles and degradation products were 
added at a concentration of 0.875 mg/mL, which is the same surface coverage of 0.391 
mg/cm2 as the 1.25 mg/mL concentration tested in cytocompatibility studied and found as 
non-cytotoxic. Two hFIX concentrations, 0.04 mg/mL and 0.40 mg/mL (10x), were tested. 
For both hFIX concentrations, the presence of the microparticles and degradation products 
significantly increased the apical-to-basolateral transport of hFIX as compared to hFIX 
only (Figures 7-12 and 7-13). Similar to previously reported results,1, 14 protein transport 
begins to plateau after 2 hours. For an initial hFIX concentration of 0.04 mg/mL at the 
apical side, the microparticles and degradation products have the same effect on the 
transport of hFIX (Figure 7-12). At the higher initial hFIX concentration of 0.40 mg/mL, 
the effect of the microparticles and degradation products deviate at times greater than 2 
hours (Figure 7-13). The decreased transport at later times for the microparticles may be 
attributed to hFIX loading into the microparticles on the apical side. In order to improve 
bioavailability, increasing the initial amount of hFIX can drive the transport of hFIX by 
increasing the protein gradient across the monolayer.  
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Figure 7-12. The amount of hFIX transported across the co-culture intestinal epithelial 
monolayer over time shows that the presence of the microparticles and 
degradation products improved hFIX transport. (n=3, mean ± SE, 
**p<0.001). 
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Figure 7-13. The amount of hFIX transported across the co-culture intestinal epithelial 
monolayer over time shows that the presence of the microparticles and 
degradation products improved hFIX transport. (n=3, mean ± SE, *p<0.05, 
**p<0.01). 
 
We further evaluated the effect of the microparticles and degradation products, as 
well as the initial hFIX concentration, on the permeability of hFIX. The permeability of 
protein across the monolayer was calculated by:  
𝑃𝑎𝑝𝑝 =
𝑑𝑄(𝑡)
𝑑𝑡
×
1
𝐴×𝐶𝐴𝑂
                (Eq. 3-1) 
where Q(t) is the cumulative protein release (ng) at time t (s), A is the area of the cell 
monolayer (cm2), and CAO is the initial protein concentration (ng/cm
3) at the apical side. 
The permeability of hFIX was calculated over 1 hour, 2 hours, and 4 hours (Table 7-2). 
We examined the permeability at these time points, since the amount of hFIX transported 
over time (dQ(t)/dt) follows a linear relationship for 1 hour at the initial concentration of 
0.04 mg/mL and for 2 hours at the initial concentration of 0.04 mg/mL. The permeability 
of hFIX is significantly increased by the presence of microparticles and degradation 
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products as compared to hFIX only for all cases. These trends are the same as previously 
reported results where PMAA-based microparticles improve protein permeability, which 
may be due to Ca2+ chelation.1, 15 While higher initial hFIX concentrated improved 
transport, the amount of hFIX transported was only two-fold higher for a 10x initial 
concentration, resulting in reduced permeability values.  
 
Table 7-2. In vitro permeability of hFIX across the intestinal epithelial monolayer is 
improved by the presence of the microparticles and degradation products.  
 For ChFIX,0 =0.04 mg/mL For ChFIX,0 =0.40 mg/mL 
 
Micro-
particles 
Degradation 
Products 
hFIX 
only 
Micro-
particles 
Degradation 
Products 
hFIX only 
Papp, 1 h 513.7±101.8 600.8±43.2 24.9±7.2 164.7±15.0 191.5±21.0 6.5±5.1 
Papp, 1 h 326.4±59.8 404.3±77.0 25.4±12.7 74.4±3.2 93.2±5.8 14.4±8.4 
Papp, 1 h 210.9±42.1 171.2±20.8 30.7±7.2 28.4±3.5 47.7±0.8 6.8±2.9 
 
To evaluate the integrity of the intestinal epithelial monolayers, the TEER was 
measured for the study duration (Figure 7-140. As previously reported,1 the TEER values 
for all conditions were relatively constant over the 4-hour study, indicating that the tight 
junctions remained intact. Exposure to trypsin and inhibitor did not affect the TEER 
measurements. Furthermore, the presence of the microparticles and degradation products 
did not have negative effects on the monolayer integrity. While the Ca2+ chelating effect is 
expected to open the tight junctions, the mucus layer is hypothesized to act as a barrier 
between the cells and microparticles and therefore reduce the effect on TEER 
measurements. Additionally, the monolayers fully recovered 24 hours after the removal of 
the microparticles and degradation products. In an oral delivery system application, any 
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effect of the particles and their degradation products is expected to only be temporary and 
not cause any permanent damage to the intestinal tract.  
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Figure 7-14. TEER remained constant during the transport study, indicating that the tight 
junctions remained intact with when exposed to microparticles and 
degradation products. TEER measurements at 24 h post study showed that 
the monolayers fully recovered after removal of microparticles. (n=6, mean 
± SE). 
 
7.4 CONCLUSIONS 
We have successfully developed a microcarrier system based on an enzymatically 
degradable and pH-responsive P(MAA-g-EG) hydrogel for the oral delivery of hFIX. In 
order to improve upon previously described pH-responsive systems, we incorporated an 
enzymatically degradable peptide crosslinking agent to achieve a higher delivery potential. 
We have demonstrated the enzyme-specific degradation reaction of such microcarriers on 
a physiologically relevant time scale. Both the microparticles and degradation products 
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were found to be cytocompatibility which is necessary for the end use in therapeutic 
applications.  
The peptide crosslinked P(MAA-g-EG) microparticles are capable of loading hFIX 
and releasing it in response to environmental stimuli. Incorporation of a biodegradable 
component allowed for increased levels of hFIX released under intestinal conditions. 
Improving the delivery potential of hFIX is important for promoting the oral bioavailability 
of hFIX. Additionally, we have demonstrated that the presence of the microparticles and 
degradation products enhances the in vitro absorption of hFIX. Based on the result reported 
here, enzymatically degradable and pH-responsive P(MAA-g-EG) microcarriers are an 
ideal candidate for an oral drug delivery system for hFIX.  
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Chapter 8: In Vivo Safety of P(MAA-g-EG) Microcarriers4 
8.1 INTRODUCTION 
The oral delivery of factor IX for the treatment of hemophilia B is a highly desirable 
alternative to needle-based treatment options, especially for patients with moderate and 
severe hemophilia B taking multiple injections per week for prophylaxis.  We have 
developed pH-responsive P(MAA-g-EG) microcarriers to enable the oral route of factor 
IX.1, 2 However, before safe use of these P(MAA-g-EG) in a clinical setting, their 
biocompatibility must be evaluated in preclinical studies.3 As previously reported, the in 
vivo safety of oral delivery systems has been tested in rodent models and assessed by 
clinical biochemical tests and tissue examination.4, 5 
In this Chapter, we investigated the acute and long-term in vivo safety of P(MAA-
g-EG) microcarriers. The safety study consisted of two separate studies: (1) acute and (2) 
long-term. The goal of the acute study was to evaluate the acute inflammatory response 24 
hours post administration of the P(MAA-g-EG) microcarriers. The second study evaluated 
the long-term effects of dosing microparticles every other day for 14 days to mimic a 
prophylactic regimen with the shortest dosing intervals (and therefore, maximum exposure 
to the P(MAA-g-EG) microparticles). For both studies, the P(MAA-g-EG) microparticles 
were administered by oral gavage. The control group received sterile distilled water by oral 
gavage, which should cause no adverse effects. To establish the biocompatibility of 
P(MAA-g-EG) microparticles, we evaluated cytokine levels for inflammatory and immune 
responses, performed biochemical analysis of serum and urine for kidney and liver 
function, and examined tissue morphology for damage and inflammation. 
                                                 
4 The in vivo safety studies presented here were conducted as part of a study testing the safety of three 
hydrogel formulations. The safety studies were performed by the author and Stephanie Steichen. 
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8.2 MATERIALS AND METHODS 
8.2.1 Polymer Synthesis 
P(MAA-g-EG) hydrogels were synthesized by bulk UV-polymerization as 
previously described in Chapter 4. Briefly, the feed composition of the pre-polymer was 
MAA and PEGMMA1000 at a 2:1 molar ratio of hydrogen bonding groups, 
PEGDMA1000 at 1.0 mol% of total monomers, and Irgacure 184® at 1.0 wt. % of total 
monomers in a 1:1 (w/w) mixture of deionized water and ethanol. After sonicating for 20 
minutes, the pre-polymer mixture was needle purged with nitrogen for 5 minutes in the 
nitrogen-rich environment of a glove box. The mixture was then dispensed between two 
quartz glass plates, separated with a 0.7 mm Teflon® spacer, and then polymerized for 30 
minutes under 35 mW cm-2 UV light using a UV flood source. After synthesis, the resulting 
polymer was removed from the plates, and then washed in deionized water for a total of 10 
water exchanges. The polymer was dried for 3 days in air and then for 3 additional days 
under vacuum at 37°C. Dried films were crushed and sieved into microparticles, sized 30-
45 µm. 
8.2.2 Animals and Treatment 
Female C57BL/6J mice (4-6 weeks old) were purchased from The Jackson 
Laboratory. C57BL/6J mice were selected since the hemophilia B mice are derived from 
this background. For both the acute and long-term studies, adult mice entered the UT 
animal facility in the ARC building and were given at least three days to acclimate 
themselves to their new environment. Upon arrival mice were housed four per cage, and 
mice received ear punches as an identification marker.  
One day prior to administration, a baseline blood sample was collected via 
saphenous vein. For the blood sample, the mice were restrained manually while the hind 
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leg was shaved using electric clippers and then the blood (up to 0.15 mL) was collected 
from the saphenous vein using a sterile 27G needle to puncture and a blood-collection tube.  
For the acute study, mice were fasted by the removal of solid food in the morning 
for two hours prior to administration. The P(MAA-g-EG) microparticles were suspended 
in sterile distilled water prior to administration. The microparticle suspension (6.67 mg 
particle/mL distilled water) (n=8) or the sterile distilled water (control, n=8) were 
administered via oral gavage using a 22 gauge metal feeding tube (gavage needle) about 
1.5 inches in length with a rounded tip. The dosing volume was 0.15 mL for a 15 g mouse 
(based on the recommended 10 mL/kg).  Mice were administered 30-45 µm microparticle 
suspensions at a dose of 66.7 mg particle/kg body, which was 1 mg for a 15 g mouse. This 
dosing level was based on a minimum effective prophylactic treatment requiring a 1% 
increase in factor IX and assumed 2% bioavailability and a delivery potential of 3 µg 
hFIX/mg particle. The mouse was manually restrained and the proper length of the gavage 
tube was determined. A dose of either particle suspension or water was administered by a 
syringe attached to the end of the tube.  After dosing, the tube was removed gently 
following the same angle as insertion. Each mouse was monitored for signs of labored 
breathing or distress for 5-10 minutes after oral gavage. Animals were monitored for the 
duration of the study. Twenty-four hours post administration, a urine sample was collected. 
The mice were then sacrificed by an overdose of CO2 and then exsanguinated by heart 
stick.  
For the long-term study, mice were fasted every other day in the morning for two 
hours prior to administration. As in the acute study, mice received either a microparticle 
suspension (6.67 mg particle/mL distilled water) (n=8) or the sterile distilled water 
(control, n=8) at a dosing volume of 0.15 mL via oral gavage. In addition to monitoring 
the mice for physical signs of labored breathing or distress, mice were weighted after each 
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administration. Mice received a dose of microparticle suspension or water every other day 
for 14 days (a total of seven doses). On day 15 (24 hours post the final administration), a 
urine sample was collected, and mice were then sacrificed by an overdose of CO2 and then 
exsanguinated by heart stick.  
8.2.3 Serum Cytokine Analysis 
The serum cytokine analysis was performed using a Bio-Rad Bio-Plex ProTM Assay 
(Hercules, CA) for mouse cytokines. The assay was selected for quantification of seven 
cytokines: interleukin-1β (IL-1β), IL-2, IL-6, IL-10, IL-12 (p70), interferon-γ (IFN-γ), and 
tumor necrosis factor-α (TNF-α). Serum samples were diluted 1:4 with sample diluent, and 
the assay was carried out according to the manufacturer’s protocol. The wash steps were 
automated using a Bio-Rad Bio-Plex ProTM wash station. The plate was read using low 
PMT voltage and low RPI target using the Bio-Rad Bio-Plex 200 multiplex system.  
8.2.4 Blood Urea Nitrogen (BUN) Analysis 
To assess kidney and level function, serum samples were analyzed to determine the 
blood urea nitrogen (BUN) using a Sigma-Aldrich urea assay kit. Serum samples were 
diluted 1:100 with assay buffer, and the assay was performed according to the 
manufacturer’s protocol. In the urea assay, the amount of urea was determined by a coupled 
enzyme reaction that results in a colorimetric product. The absorbance at 570 nm was read 
using a BioTek Cytation 3 multi-mode reader (Winooski, VT). 
8.2.5 Urine Creatinine Analysis 
To determine the effect of the microparticles on the kidney function, the creatinine 
levels were evaluated. The amount of creatinine in the urine was determined using a Sigma-
Aldrich creatinine assay kit. Urine samples were diluted 1:100 with assay buffer. The assay 
was performed following the manufacturer’s protocol for fluorometric detection. After 
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incubating at 37°C for 60 minutes, the fluorescence was measured at 535 nm excitation 
and 587 nm emission using a BioTek Cytation 3 multi-mode reader (Winooski, VT). 
8.2.6 Histological Analysis 
Histological studies were performed for the long-term study to determine the effect 
of repeated dosing microparticles at the tissue level. The spleen, liver, kidneys, and GI tract 
(including stomach, small intestine, cecum, and large intestine) were removed from each 
animal. Organs were immersion-fixed in formalin at room temperature for at least 24 h. 
After fixing, each organ was cleaned up by removing any remaining fat and then was placed 
in a tissue cassette, and then dehydrated in 70% ethanol. The GI tract was split up into the 
stomach, small intestine (further sectioned into three pieces of equal length of 8-9 cm to 
represent the duodenum, jejunum, and ileum), and cecum with the ascending colon.  
Tissues were embedded in paraffin, then sectioned using a microtome, and stained 
with hematoxylin and eosin (H&E). Embedding, sectioning, and staining were performed 
by the Histology/Immunohistochemistry Laboratory, Department of Pathology at UT 
Health Science Center San Antonio. The sections were also examined and scored blindly 
by Dr. Robert Reddick, MS, MD, Department of Pathology at UT Health Science Center 
San Antonio. Bright-field images of stained sections were captured using an Olympus IX 
73 inverted microscope with the 4x objective. 
8.2.7 Statistical Analysis 
Data are reported as mean ± standard error. Comparisons between groups were 
performed using a Student’s two-tailed t-test, and comparisons among multiple groups 
were performed using an ANOVA. Significant differences were considered when *p < 0.05 
and **p < 0.01. All statistical analysis was computed using GraphPad Prism 6.  
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8.3 RESULTS AND DISCUSSION 
8.3.1 Oral Administration  
The acute and long-term biocompatibility of P(MAA-g-EG) microparticles was 
assessed in vivo by the oral administration of microparticles in C57BL/6J mice. Mice were 
treated with a single dose of microparticles for the acute study and multiple doses given 
every other day for 14 days for the long-term study. The microparticles were administered 
via oral gavage to mimic the intended route of administration and to control the dose. When 
administered orally, the microparticles pass through the different regions of the GI tract 
where they are exposed to different physiological pH and enzymatic conditions. No 
differences in clinical signs (e.g. diarrhea, fever, or other systemic symptoms) between the 
experimental and control groups were observed, and no significant differences in body 
weight between the two groups were found. Additionally, there was no mortality over the 
course of the study.  
8.3.2 Cytokine Analysis 
In order to determine whether administration of P(MAA-g-EG) microparticle 
resulted in inflammation or an immune response, the serum levels of various cytokines 
(listed in Table 8-1) were quantified. No significant differences between the experimental 
and control groups were found. Based on the results from the cytokine analysis, 
administration of P(MAA-g-EG) microparticles did not cause an inflammatory or immune 
response for both a single dose and repeated doses. (See below for specific details about 
each cytokine).  
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Table 8-1. Cytokine analytes in the Bio-plex assay.  (Note that MHC = major 
histocompatibility complex.)6  
Cytokine Source Principle 
Target 
Property Principle Effects 
IL-1β Macrophages, 
LGLs, B cells, 
endothelium 
fibroblasts, 
astrocytes, etc. 
T cells, B cells, 
macrophages, 
endothelium 
tissue cells 
Pro-inflammatory Lymphocyte activation, 
macrophage simulation, ↑ 
leukocyte/endothelial 
adhesion, pyrexia, acute 
phase proteins 
IL-2 T cells T cells Hematopoietic, 
immune response, 
tolerance, 
immunity 
T cell proliferation and 
differentiation, activation 
of cytotoxic lymphocytes 
and macrophages 
IL-6 T cells, B cells, 
fibroblasts, 
macrophages 
B cells, 
hepatocytes 
Pro-
inflammatory, 
hematopoietic 
B cell differentiation, 
induces acute phase 
proteins 
IL-10 T cells Th 1 cells  Anti-
inflammatory 
(pro-
inflammatory 
from muscle) 
Inhibition of cytokine 
synthesis 
IL-12 Monocytes T cells Pro- or anti-
inflammatory, 
anti-angiogenic 
Induction of Th 1 cells 
IFN-γ T cells, NK 
cells, epithelia, 
fibroblasts 
Leukocytes, 
tissue cells, Th 
2 cells 
Innate and 
adaptive 
immunity 
MHC class I and II 
induction, macrophage 
activation, ↑ endothelial 
cell/lymphocyte adhesion. 
monocyte cytokine 
synthesis, antiviral state, 
anti-proliferation (Th2 
cells) 
TNF-α Macrophages, 
mast cells, 
lymphocytes 
Macrophages, 
granulocytes, 
tissue cells 
Pro-
inflammatory, 
innate immunity 
Activation of 
macrophages, granulocytes 
and cytotoxic cells, 
leukocyte/endothelial cell 
adhesion, cachexia, 
pyrexia, induction of acute 
phase protein, stimulation 
of angiogenesis, enhanced 
MHC class I production 
 
 167 
8.3.2.1 Interleukin-1β 
IL-1β plays an important role in the innate and adaptive immunity. As a pro-
inflammatory cytokine, IL-1 β is a crucial mediator of the host inflammatory response.7 
Results for both the acute and long-term studies show that oral administration of P(MAA-
g-EG) microparticles did not affect IL-1β serum levels as compared to the control group 
(Figure 8-1). There are no significant differences IL-1β concentrations between the 
experimental and control groups in each study.  
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Figure 8-1. Serum concentrations of IL-1β for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage. For the acute study, mice 
received a single dose and serum was collected 24 h after. For the long-term 
study, mice received a dose every other day for 14 days and serum was 
collected 24 h after the final dose. (Points represent individual mice, mean ± 
SE).  
 
8.3.2.2 Interleukin-2 
IL-2 plays a variety of roles in the immune system related to immune response, 
tolerance, immunity, and hematopoiesis. IL-2 supports the proliferation and differentiation 
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of cells with high-affinity IL-2 receptors, such as stimulated T lymphocytes and T helper 
(TH) cells. Binding of IL-2 to its specific receptors on TH cells stimulated their proliferation 
along with the release of numerous cytokines. IL-2 is required for the generation of CD8+ 
cytolytic T cells, which are important in antiviral responses. Additionally, IL-2 enhances 
the immune system’s ability to kill tumor cells and may also interfere with blood flow to 
tumors.7  
For both studies, the serum concentrations of IL-2 were not significantly different 
between the experimental and control groups (Figure 8-2). The administration of P(MAA-
g-EG) microparticles did not affect the IL-2 levels which indicates that the microparticles 
do not produce an immune response.  
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Figure 8-2. Serum concentrations of IL-2 for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.2.3 Interleukin-6 
IL-6 is a pro-inflammatory cytokine that affects various processes including the 
immune response, reproduction, bone metabolism, and aging. IL-6 is produced in response 
to trauma, tissue damage, inflammation, IL-1, and TNF-α.7 As shown in Figure 8-3, IL-6 
serum levels remained unchanged after P(MAA-g-EG) microparticle administration, with 
no significant differences between the experimental and control groups for each study. The 
IL-6 concentrations indicate that there is no tissue damage nor inflammation after dosing 
of P(MAA-g-EG) microparticles.  
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Figure 8-3. Serum concentrations of IL-2 for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.2.4 Interleukin-10 
IL-10 is an anti-inflammatory cytokine and an important immunoregulatory 
cytokine. IL-10 inhibits the production of pro-inflammatory cytokines and augments the 
production of anti-inflammatory factors. The major role of IL-10 is to regulate the Th1/Th2 
(cellular/humoral) balance. Additionally, IL-10 is involved in assisting against intestinal 
parasitic infection and local mucosal infection, and indirectly helps neutralize bacterial 
toxins.7 Serum concentrations of IL-10 were not significantly affected by the single dose 
and multiple doses of P(MAA-g-EG) microparticles as compared to the control (Figure 8-
4).   
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Figure 8-4. Serum concentrations of IL-10 for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.2.5 Interleukin-12 
IL-12 has both pro- and anti-inflammatory effects. IL-12 induces the production of 
INF-γ which can mediate the pro-inflammatory activities of IL-12. Additionally, IL-12 has 
an important role in the Th1 response where it functions as an immunoregulatory cytokine. 
IL-12 promotes the differentiation of T helper 1 (TH1) cells, forming a link between innate 
resistance and adaptive immunity.8.  IL-12 is a heterodimer formed by a 35-kDa light chain 
(p35) and a 40-kDa heavy chain (p40), and the heterodimer form is denoted IL-12 (p70).7 
Similar to other interleukin serum levels, there were no significant differences in IL-12 
concentrations between the experimental and control groups for each study (Figure 8-5).  
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Figure 8-5. Serum concentrations of IL-12 for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.2.6 Interferon-γ 
IFN-γ modulates various components in the immune response. IFN-γ is 
important for host response to intracellular pathogens by increasing cytotoxic T cell 
recognition and therefore promoting the induction of cell-mediated immunity. Produced 
from Th1 cells, IFN-γ favors a Th1 response by promoting innate cell-mediated immunity, 
specific cytotoxic immunity, and macrophage activation. IFN-γ induces Th1 differentiation 
and indirectly inhibits Th2 proliferation and differentiation. Additionally, IFN-γ induces 
key antiviral enzymes and such immunoregulatory activities of IFN-γ are important in 
establishing an antiviral state for longer term control.9 The serum levels of IFN-γ for mice 
that received P(MAA-g-EG) microparticles were not significantly different from that of 
the control group in the same study (Figure 8-6).  
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Figure 8-6. Serum concentrations of IFN-γ for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.2.7 Tumor Necrosis Factor-α 
TNF-α is another pro-inflammatory cytokine that mediates the natural and acquired 
immunity. Although the main cell source of TNF-α is macrophage, it can also be produced 
as a result of tissue damage. Increased local concentrations of TNF-α cause heat, swelling, 
redness, and pain. TNF-α further causes an inflammatory response by inducing the 
production of pro-inflammatory cytokines (IL-1, IL-6, and itself) and chemokines through 
stimulation of macrophages. In response to an infection, TNF-α induces acute-phase 
responses by activating hepatocytes.6, 7 Serum concentrations of TNF-α shown in Figure 
8-7 indicate that administration of P(MAA-g-EG) microparticles did not induce an 
inflammatory response. For each study, no significant differences between the 
experimental and control groups were found.  
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Figure 8-7. Serum concentrations of TNF-α for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (Points represent individual mice, mean ± SE). 
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8.3.3 Blood Urea Nitrogen (BUN) Analysis 
Urea is a major waste product of nitrogen metabolism and is produced from the 
urea cycle of the digestion of proteins in the liver. In the urea cycle, ammonia is converted 
to urea, which is dissolved in the blood and transported to the kidneys. Urea is then excreted 
by the kidneys as component of urine.  High levels of urea in the blood may indicate renal 
failure. Other causes of elevated urea levels include decreased kidney filtration due to 
dehydration or congestive heart failure. Additionally, decreased blood urea levels can be 
indicative of liver disease or malnutrition.10  
 A blood urea nitrogen (BUN) test is commonly used to determine kidney health 
and, to a lesser extent, liver health.10 We measured the amount of urea in serum samples 
from individual mice that were administered either P(MAA-g-EG) microparticles or water. 
The concentration of urea can be converted to BUN levels by:  
𝐵𝑈𝑁 = [𝑢𝑟𝑒𝑎] ×
2 𝑚𝑚𝑜𝑙 𝑁
1 𝑚𝑚𝑜𝑙 𝑢𝑟𝑒𝑎
× 𝑀𝑊𝑁             (Eq. 8-1) 
where BUN is in units of mg dL-1, the concentration of urea is in units of mmol dL-1, molar 
ratio of nitrogen to urea is 2, and MWN is the molar mass of nitrogen (14 mg mmol
-1).  
Based in the BUN analysis shown in Figure 8-8, the oral administration of P(MAA-
g-EG) microparticles does not affect renal function. Furthermore, repeated doses of 
P(MAA-g-EG) microparticles showed no negative signs of kidney and liver health. No 
significant differences between the experimental and control groups for each study were 
found.  
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Figure 8-8. Blood urea nitrogen (BUN) concentrations for mice that received P(MAA-g-
EG) microparticles or water (control) via oral gavage for both the acute and 
long-term studies. (n ≥ 7, mean ± SE). 
 
8.3.4 Creatinine Analysis 
To further evaluate the effect of dosing P(MAA-g-EG) microparticles on renal 
function, we also quantified creatinine levels in urine samples. Creatinine is generated from 
creatine by nonenzymatic dehydration in muscles. Creatinine is produced at a fairly 
constant rate, depending on muscle mass, and is excreted from the body through kidney 
glomerular filtration.10 Decreased kidney function can affect the filtration rate of creatinine, 
which can be used a measure of kidney health. In the case of decreased renal function, the 
inability of the kidneys to eliminate creatinine through urine excretion results in increased 
serum creatinine levels and decreased urine creatinine levels.11  
 Results from the creatinine analysis (Figure 8-9) indicate that kidney function is 
not affected by administration of P(MAA-g-EG) microparticles, which agrees with the 
findings from the BUN analysis. Urine creatinine levels of mice that received 
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microparticles showed no significant difference compared to that of mice in the control 
group. Both a single dose of microparticles and repeated doses over 14 days had no 
negative effects on renal function.  
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Figure 8-9. Urine creatinine concentrations for mice that received P(MAA-g-EG) 
microparticles or water (control) via oral gavage for both the acute and long-
term studies. (n ≥ 7, mean ± SE). 
 
8.3.5 Histological Analysis 
Although the administration of P(MAA-g-EG) microparticles show no signs of 
inflammation and immune response (cytokine analysis) and cause no negative effects on 
kidney and liver function (BUN and creatinine analysis), we evaluated the spleen, liver, 
kidney, and GI tract for any changes in tissue pathology due to long-term, repeated 
microparticle administration. In a blind study, a pathologist examined the tissue sections 
stained with H&E. Overall, the general appearance and morphology of the tissues from the 
experimental group were similar to that of the control group. Histological analysis 
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indicated that the repeated administration of P(MAA-g-EG) did not result in any tissue 
damage/inflammation, which agrees with the biochemical analysis. (Further analysis of the 
histology images can be found in Appendix B.) 
8.3.5.1 Spleen 
The two main functions of the spleen are filtration and immunological processing 
and destruction. Structurally, the spleen consists of the white pulp (contains lymphocytes) 
and red pulp (composed of sinusoids lined by macrophages).12 A morphometric analysis 
of a rodent spleen is typically included in toxicity studies to determine changes in the 
cellular immune system.13 According to the pathologist’s examination, the findings for the 
spleen were normal. There was no evidence of morphological changes due to an immune 
response. 
 
 
Figure 8-10. Representative images of spleen sections (H&E staining, magnification 4x) 
of mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
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8.3.5.2 Liver 
The liver, which is the largest gland in the body, produces and secretes bile along 
with serving numerous metabolic functions for normal homeostasis.14 Hepatocytes 
compose about 60% of the liver, and such cells have a polyhedral morphology with the six 
facets covered with microvilli.13 For both the experimental and control groups, histological 
analysis showed normal liver architecture, as well as component of basic liver lobules with 
portal area (includes portal vein, hepatic artery, and small bile duct) and central venule 
(Figure 8-12).15 Additionally, the pathologist noted the presence of focal small collections 
of chronic inflammatory cells, which is often seen in murine liver. Results indicated that 
repeated doses of P(MAA-g-EG) microparticles do not cause any liver damage.  
 
 
Figure 8-11. Representative images of liver sections (H&E staining, magnification 4x) of 
mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
 
 179 
8.3.5.3 Kidney 
As part of the urinary system, kidneys are responsible for filtration and waste 
excretion. Additional homeostatic functions of the kidneys include regulation of water-
soluble molecules and electrolytes, maintenance of acid-base balance, and regulation of 
blood pressure.  The kidneys are a frequent site of toxic injury in rodent toxicity studies. 
Renal toxicity in preclinical studies is a good predictor of adverse renal effects in patients.13  
In general, examination of the kidneys showed normal findings for both the experimental 
and control groups (Figure 8-12). 
In addition to the normal findings, the pathologist noted a few cases of mild 
hydronephrosis. Hydronephrosis is the swelling of a kidney due to the build-up of urine 
caused by a blockage or obstruction.  The histopathology of hydronephrosis show marked 
loss of renal parenchyma, which is more evident in severe cases. Additionally, 
characteristic morphology of hydronephrosis can be detected in the medullar area 
(innermost part of the kidney) showing dilation of tubules ad widened interstitial space 
with interstitial fluid.16   
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Figure 8-12. Representative images of kidney sections (H&E staining, magnification 4x) 
of mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
 
8.3.5.4 Stomach 
In the oral route of administration, the administered drug delivery system remains 
in contact with the stomach mucosa at relatively high concentrations for up to several 
hours. The mouse stomach contains two regions, a forestomach and a glandular stomach, 
which are separated by a limiting ridge (an elevated mucosal fold at the junction of the two 
regions). The forestomach, which receives the esophagus at the cardiac antrum, is lined by 
stratified squamous epithelium. Humans lack a forestomach, and therefore, the relevance 
of changes by drugs and their carrier systems in the rodent forestomach is disputed. The 
glandular stomach, which opens into the pylorus and duodenum, is covered by a columnar 
epithelium containing gastric glands. Gastric glands are tubular structures that are lined by 
columnar epithelium and form deep gastric pits.  Additionally, the columnar epithelium of 
the mucosal surface contains mucus-secreting cells for protection against self-digestion.13  
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Safety studies in rodents can generally be used to predict adverse effects in 
patients.13  Normal findings were reported for the forestomach (Figure 8-13) and glandular 
stomach (Figure 8-14) sections of mice from both the experimental and control groups, 
indicating that repeated exposure to P(MAA-g-EG) microparticles does not negatively 
affect the stomach.  
 
 
Figure 8-13. Representative images of forestomach sections (H&E staining, 
magnification 4x) of mice that received water (control) and mice that were 
orally administered P(MAA-g-EG) microparticles (experimental).  
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Figure 8-14. Representative images of glandular stomach sections (H&E staining, 
magnification 4x) of mice that received water (control) and mice that were 
orally administered P(MAA-g-EG) microparticles (experimental).  
 
8.3.5.5 Small Intestine 
The small intestine is particularly important in the safety evaluation of oral drug 
delivery systems. In the case the P(MAA-g-EG) system, the residence time in the small 
intestine is increased due to PEG tethers. Generally, gastrointestinal findings in preclinical 
studies in rodents are reasonable predictors of gastrointestinal adverse effects in patients.13 
The main cell population of the epithelium is absorptive enterocytes with microvilli on the 
apical surface, allowing the small intestine to function as an absorptive surface. However 
other epithelial cell types, mucous (goblet) cells, Paneth cells, and endocrine cells are also 
present and serve important functions. Additionally, the small intestinal mucosa functions 
as a barrier to potentially pathogenic substances and micro-organisms. The gut associated 
lymphoid tissue (GALT) plays an important role of the protective system in the intestine. 
Peyer’s patches are prominent aggregates of lymphoid tissue. In humans, Peyer’s patches 
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are more common in the ileum, but in mice, they are more uniformly distributed.17 In 
Peyer’s patches, lymphoid follicles are surrounded by a corona of small lymphocytes, 
principally B cells, and the overlaying epithelium (dome area) contains specialized 
epithelial cells called microfold (also membranous or M) cells.13 
Histologically, the mucosa of the small intestine forms villi (finger-like projections) 
ad crypts (deep cavities between the villi).18 For the histological analysis, small intestine 
was divided into three sections—duodenum, jejunum, and ileum. The duodenum is 
characterized by tall, left-shaped villi and the submucosal Brunner’s glands. The mucosa 
of the duodenum is thick and forms permanent circular fold (plicae circulares). About 
halfway along the length of the duodenum, there are openings of common bile and 
pancreatic ducts in the medial wall. The jejunum and ileum are more histologically similar 
with minor differences in villi structure. In the jejunum, the villi are tall and cylindrical, 
while the villi are short and cylindrical in the ileum. Generally, the jejunum tends to be 
thicker-walled with more prominent plicae circulares and more numerous Peyer’s patches 
than the ileum.14  In mice, Paneth cells with very prominent granules are especially found 
in the jejunum.  
Examination of H&E stained sections of the duodenum (Figure 8-15), jejunum 
(Figure 8-16), and ileum (Figure 8-17) showed normal findings for both experimental and 
control groups. The absence of villae and crypts would be indicative of toxicity or damage 
to the small intestine,19 which is not the case for results presented here. However, lymphoid 
nodules along the small intestine were noted. As previously mentioned, Peyer’s patches 
(aggregates of lymphoid tissue) are commonly distributed along the small intestine. 
Histologically findings indicated that repeated dosing of P(MAA-g-EG) microparticles 
does not cause inflammation of the small intestine, which is critical for its application as 
an oral drug delivery vehicle.  
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Figure 8-15. Representative images of duodenum sections (H&E staining, magnification 
4x) of mice that received water (control) and mice that were orally 
administered P(MAA-g-EG) microparticles (experimental).  
 
 
Figure 8-16. Representative images of jejunum sections (H&E staining, magnification 
4x) of mice that received water (control) and mice that were orally 
administered P(MAA-g-EG) microparticles (experimental).  
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Figure 8-17. Representative images of ileum sections (H&E staining, magnification 4x) 
of mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
 
8.3.5.6 Cecum and Colon 
The large intestine of mice consists of the cecum, colon (ascending colon), and 
rectum (descending colon), where there is a lack of clearly defined transverse colon and an 
appendix as found in humans. The cecum of humans is a small diverticulum, but the 
enlarged cecum in mice is necessary for the breakdown of cellulose due to their 
omnivorous diets. The cecum, which is a kidney-shaped pouch, functions as a fermentation 
organ.13 Histologically, the cecum and colon are lined by a relatively uniform mucosa 
distinctly without villi. The mucosa of the cecum is thin with short crypts and transverse 
folds, while the mucosa of the colon has long crypts and forms longitudinal folds.13, 14  
 Safety evaluation in rodents does not always indicate safety in humans. While some 
substances do not show inflammation in mice, they may still result in an inflammatory 
response in humans. However, inflammation is mice is typically predictive of a similar 
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response in humans.13  Histologically, the cecum (Figure 8-18) and the colon (Figure 8-19) 
of mice from the experimental group were not different from the normal tissues from the 
control group. Similar to previously discussed results, the repeated dosing of P(MAA-g-
EG) microparticles does not cause inflammation in the large intestine. 
 
 
Figure 8-18. Representative images of cecum sections (H&E staining, magnification 4x) 
of mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
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Figure 8-19. Representative images of colon sections (H&E staining, magnification 4x) 
of mice that received water (control) and mice that were orally administered 
P(MAA-g-EG) microparticles (experimental).  
 
8.4 CONCLUSIONS 
Developing an orally administered hFIX therapy for the treatment of hemophilia B 
requires the use of a drug delivery system. As previously discussed, P(MAA-g-EG) 
hydrogel microcarriers have been designed for protection of hFIX in the stomach and site-
specific release of hFIX in the small intestine. While such systems have been evaluated in 
in vitro cytocompatibility studies, an evaluation of the in vivo biocompatibility is critical 
for establishing the clinical safety of P(MAA-g-EG) microparticles. Based on cytokine 
levels, the short-term and long-term administration of P(MAA-g-EG) microparticles did 
not cause any inflammatory reactions or immune response. Biochemical analysis (BUN 
and creatinine concentrations) indicated that the microparticles had no effects on kidney 
and liver health. Further histological examination of the spleen, liver, kidneys, and GI tract 
supported the findings of the cytokine and biochemical analyses. Based on the results 
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reported here, P(MAA-g-EG) microparticles are biocompatible in vivo and are safe for 
long-term, repeated use necessary for prophylactic regimens in protein replacement therapy 
applications.  
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Chapter 9: In Vivo Biodistribution of P(MAA-g-EG) Microcarriers5 
9.1 INTRODUCTION 
The oral delivery of factor IX is a highly desirable alternative to needle-based 
options for prophylactic therapy for hemophilia B patients. We have developed pH-
responsive P(MAA-g-EG) microcarriers to enable the oral route of factor IX.1, 2 For 
eventual clinical applications, understanding the biodistribution and clearance of 
microcarriers is important. Visualizing the passage of the microparticles through the GI 
tract provides critical details about the residence time in the small intestine as well as the 
time scale for clearance. The residence time in the small intestine affects the local 
concentration of the protein released, which will in turn affect the amount of protein in 
circulation. Increased residence time in the small intestine due to the mucoadhesive 
properties of the microparticles can improve the bioavailability of the therapeutic protein.  
Knowledge of the kinetic distribution of the microparticles in the GI tract can also provide 
insight into the pharmacokinetics of an orally administered drug using such microcarriers. 
An in vivo model is required to validate the performance of an oral delivery system. 
The IVIS® in vivo imaging system (PerkinElmer, Inc., Hopkinton, MA) allows for in vivo 
real-time imaging without radiation. This non-invasive method allows for visualization and 
quantification of microparticles moving through the GI tract after oral delivery.3 
Alternative ex vivo techniques, such as an everted rat intestinal sac, can be used to 
determine mucoadhesive properties of orally delivered microparticles. However, 
differences in the ex vivo and in vivo extracellular environments, as well as differences due 
                                                 
5 The in vivo biodistribution studies presented here were conducted as part of a study testing the safety of 
three hydrogel formulations. The biodistribution studies were performed by the author and Stephanie 
Steichen. 
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to the segmentation of the intestine, result in inaccuracies and may fail to predict what 
occurs in vivo.3  
In this Chapter, we determined the in vivo biodistribution of P(MAA-g-EG) 
microparticles post oral administration using a mouse model. Fluorescently-tagged 
P(MAA-g-EG) microparticles were tracked over time using the IVIS® in vivo imaging 
system. Furthermore, the specific location of the microparticles along the GI tract were 
evaluated by removing and imaging the GI tract.  
 
9.2 MATERIALS AND METHODS 
9.2.1 Polymer Synthesis 
P(MAA-g-EG) hydrogels were synthesized by bulk UV-polymerization as 
previously described in Chapter 4. Briefly, the feed composition of the pre-polymer was 
MAA and PEGMMA1000 at a 2:1 molar ratio of hydrogen bonding groups, 
PEGDMA1000 at 1.0 mol% of total monomers, and Irgacure 184® at 1.0 wt. % of total 
monomers in a 1:1 (w/w) mixture of deionized water and ethanol. After sonicating for 20 
minutes, the pre-polymer mixture was needle purged with nitrogen for 5 minutes in the 
nitrogen-rich environment of a glove box. The mixture was then dispensed between two 
quartz glass plates, separated with a 0.7 mm Teflon® spacer, and then polymerized for 30 
minutes under 35 mW cm-2 UV light using a UV flood source. After synthesis, the resulting 
polymer was removed from the plates, and then washed in deionized water for a total of 10 
water exchanges. The polymer was dried for 3 days in air and then for 3 additional days 
under vacuum at 37°C. Dried films were crushed and sieved into microparticles, sized 30-
45 µm. 
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9.2.2 Quantum Dot-Microparticle Conjugation 
After synthesis, microparticles were fluorescently labeled with near-infrared (NIR) 
quantum dots (QD) for biomedical imaging. Using NIR (700-1000 nm) light for in vivo 
imaging eliminates the auto-fluorescence of tissue. Furthermore, QDs are preferential to 
organic fluorophores due to their resistance to photobleaching.4 Microparticles were 
surface decorated with carboxyl QDs (Qdot® 705 ITK Carboxyl Quantum Dots, Life 
Technologies, Carlsbad, CA) via EDC-NHS chemistry using an ethylene diamine linkage 
(Figure 9-1).   
Figure 9-1. Simplified schematic of the QD-microparticle conjugation.  
The carboxyl QDs were first conjugated with ethylene diamine via EDC chemistry 
to add a prime amine to the QDs. Ethylene diamine and EDC where added at a 1:80:3000 
molar ratio of QD:ethylene diamine:EDC to a QD solution in 10 mM borate buffer (pH 
7.4), and the mixture was allowed to react for 1 h at room temperature while constantly 
stirring. After 1 h, the conjugate solution was filtered through a 0.2 µm PES syringe filter 
to remove any aggregates. Then the solution was transferred to a centrifugal ultrafiltration 
unit (10 kDa cutoff) and centrifuged for 10 minutes at 4696 x g. To remove any unbound 
ethylene diamine, the solution was purified by six buffer exchanges of 50 mM borate buffer 
(pH 8.3), added at 10-fold volume concentration, and centrifugation cycles. Immediately 
after the final ultracentrifugation, the solution was filtered through a 0.8/0.2 µm 
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combination PF syringe filter to remove any aggregates. The primary amine functionalized 
QD solution was stored at 4°C until further use. 
Separately, the carboxylic acids groups on the P(MAA-g-EG) microparticles were 
activated by EDC-NHS chemistry. Based on titration results previously reported, the 
amount of carboxylic acid (COOH) groups is approximately 1 x 10-5 mol COOH/mg 
microparticle. EDC and NHS were added at a molar ratio of 1.5:1:1 NHS:EDC:COOH in 
deionized water (pH 5.0), and the mixture was allowed to react for 30 minutes at room 
temperature under constant rotation. After the 30 minute incubation, the activated particles 
were collected by centrifugation at 8000 x g for 5 minutes, and the supernatant was 
removed. To further remove any excess EDC and NHS, the microparticles were 
resuspended in 50 mM MES buffer (pH 5.0) and centrifuged for three cycles.  
Immediately after carboxylic acid activation, the microparticles were conjugated 
with QDs. The primary amine functionalized QDs were added at 0.025 nmol QD/mg 
microparticle (1.33 x 10-6 mol QD/mol COOH) to the activated microparticles in a 50 mM 
MES buffer (pH 5.0). The coupling reaction was allowed to proceed for 10-12 h at room 
temperature under constant rotation. After the incubation, the QD-conjugated particles 
were collected by centrifugation at 8000 x g for 5 minutes, and the supernatant was 
removed. To remove any unbound QDs, 1x PBS with 0.05 (v/v) % Tween-20 was added 
to the microparticles, then vortexed for 30 seconds, and centrifuged. This wash step was 
repeated a total of three times. A second wash step with distilled water was completed at 
least three times. The QD-conjugated microparticles were stored in distilled water at 4°C 
until further use. 
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9.2.3 Animals and Treatment 
Female C57BL/6J mice (4-6 weeks old) were purchased from The Jackson 
Laboratory. We selected C57BL/6J mice since the hemophilia B mice are derived from 
this background. Adult mice entered the UT animal facility in the ARC building and were 
given at least three days to acclimate themselves to their new environment. Upon arrival 
mice were housed five per cage, and mice received ear punches as an identification marker. 
Mice were feed an alfalfa-free diet (2019 Teklad Global 19% Protein Extruded Rodent 
Diet) for at least 4 days prior to the imaging study to reduce intestinal auto-fluorescence.5, 
6 
Prior to administration, mice were fasted by the removal of solid food in the 
morning for two hours. The microparticle suspension (6.67 mg particle/mL distilled water) 
(n=3) for each time point were administered via oral gavage using a 22 gauge metal feeding 
tube (gavage needle) about 1.5 inches in length with a rounded tip. The dosing volume was 
0.15 mL for a 15 g mouse (based on the recommended 10 mL/kg). Based on the dosing for 
the safety studies, mice were administered 30-45 µm microparticle suspensions at a dose 
of 66.7 mg particle/kg body, which was 1 mg for a 15 g mouse. Additionally, a control 
group (n=3) was included in the study, where mice received 0.15 mL of distilled water via 
oral gavage. The mouse was manually restrained and the proper length of the gavage tube 
was determined. A dose of either microparticle suspension or water was administered by a 
syringe attached to the end of the tube.  After dosing, the tube was removed gently 
following the same angle as insertion. Each mouse was monitored for signs of labored 
breathing or distress for 5-10 minutes after oral gavage. Animals were monitored for the 
duration of the study.  
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9.2.4 IVIS Live Imaging 
Mice were imaged over the course of 24 h post administration. In mice, the gastric 
emptying time is 1-2 hours and the clearance time of the small intestine is 1-4 hours after 
gastric emptying.7 Mice were imaged at 1.5 h post administration to confirm that 
microparticles were localized in the stomach. To determine the residence time of the 
microparticles in the small intestine, mice were imaged at 4 h and 7 h post administration. 
Mice were also imaged at 24 h to ensure clearance. For each time point, three individual 
mice were imaged, and then sacrificed for further image analysis. The control mice were 
imaged 4 h post administration of water.  
  Mice were anesthetized 20 minutes prior to the pre-designated imaging time 
points. Mice were first placed in an induction chamber using 2% isoflurane-mixed oxygen, 
and then moved to nose cones, placed on their backs, in the IVIS imaging system. While 
under anesthesia, hair from the abdominal region was removed with depilatory cream 
(Nair) to reduce the light scattering/block effect.8  Fluorescent images were captured using 
the spectral unmixing protocol for QD705 (excitation at 640 nm and emission at 700, 720, 
740, 760, 780, and 800 nm) and a 5 second exposure. Additionally, photographs were 
captured.  After imaging, mice were euthanized with an overdose of CO2, and the 
secondary measure was a bilateral thoracotomy. 
9.2.5 IVIS Imaging of Organs 
Immediately after sacrifice, the GI tract (starting at the stomach and ending at the 
colon), liver, and kidneys were removed and subsequently imaged using the IVIS. The GI 
tract was imaged to determine the location and distribution of microparticles along the 
length of the GI tract. The liver and kidneys were also imaged to confirm that the 
microparticles were confined to the GI tract and were not accumulating in these organs. 
Fluorescent images were captured using the spectral unmixing protocol for QD705 
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(excitation at 640 nm and emission at 700, 720, 740, 760, 780, and 800 nm) and a 5 second 
exposure. Additionally, photographs were captured.   
9.2.6 Image Processing 
The fluorescent signal was converted to radiant efficiency with units of 
(p/sec/cm3/sr)/(µW/cm2). A common scale (minimum radiant efficiency = 1.00e7 and 
maximum = 1.50e8) was used to compare all images of the organs.   
 
9.3 RESULTS AND DISCUSSION 
9.3.1 QD-Microparticle Conjugation  
After conjugation of the QDs to the surface of the P(MAA-g-EG), the series of 
washes were completed until the supernatant was visible clear. The fluorescence 
(excitation at 640 nm and emission at 740) of a sample of QD-microparticles was 
confirmed using a BioTek Cytation 3 multi-mode reader (Winooski, VT). 
9.3.2 IVIS Live Imaging  
 Visualizing the transit of the microparticles through the GI tract after administration 
is critical for determine the residence time of the microcarriers in the small intestine (target 
site of drug delivery) and their clearance time. Images of the abdominal region of live mice 
were collected at 1.5, 4, 7, and 24 h post administration of QD-conjugated microparticles. 
A representative image shows the microparticles are localized in the abdominal region 4 h 
post administration (Figure 9-2). However, the exact location of the microparticles cannot 
be discerned from the live mice images.  Similar images were collected for all time points, 
and the location of the microparticles along the GI was further determined by removal of 
the relevant organs. 
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Figure 9-2. Images of an overlap of the fluorescent image and photograph of live mice 
taken 4 h post administration of QD-conjugated microparticles at an 
excitation of 640 nm. The different images are shown with different 
emission filters at 700, 720, 740, 760, 780, and 800 nm. 
 
Additionally, some mice had skin pigmentation (darkened areas, dark gray/black 
color) which interfered with the live imaging. For example, the right mouse in Figure 9-2 
had pigmented skin. The growth phase of the hair affects the skin pigmentation. In the 
anagen phase (active hair growth), the darkened skin color is from the melanin in the hair 
follicles in that area.9  
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9.3.3 Imaging of Organs 
In order to locate the microparticles along the GI tract, the GI tract from the stomach 
to the colon was removed and imaged. Additionally, the liver and kidneys were removed 
and imaged. Figure 9-3 shows the labeled organs. 
 
 
Figure 9-3. Image of organs labelled for the liver, kidneys, stomach, small intestine, 
cecum, and colon.  
As shown in Figure 9-4, the mice administered distilled water (blank) have a low 
fluorescent signal in the stomach, indicating that the stomach has auto-fluorescence. 
Additionally, the low fluorescent signal (indicated by dark red) in the lower GI tract is 
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likely due to auto-fluorescence. The kidneys show no fluorescent signal, while the liver 
sections have a low fluorescent signal, likely due to auto-fluorescence. 
 
 
Figure 9-4. Fluorescent images of the liver, kidneys, and GI tract. Organs were removed 
from mice 3 h post administration of distilled water (blank).  
 
Over the course of 24 h post administration, the transit of the QD-conjugated 
microparticles was visualized through the GI tract. Images were taken at 1.5, 4, 7, and 24 
h post administration of the QD-conjugated microparticles via oral gavage. As shown in 
Figure 9-5, the microparticles are mostly confined in the stomach 1.5 h post administration. 
Similar to the blank organs, there is a low fluorescent signal (indicated by dark red) in the 
lower GI tract and liver, while there is no fluorescence in the kidneys. It is important to 
note that the 1.5 h time point was administered a different batch of QD-conjugated 
microparticles than the later time points, and this batch for the 1.5 h time point had reduced 
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fluorescence. Mice used for the time points at 4, 7, and 24 h post administration received 
the same batch of QD-conjugated microparticles.  
 
 
Figure 9-5. Fluorescent images of the liver, kidneys, and GI tract. Organs were removed 
from mice 1.5 h post administration of QD-microparticles. Microparticles 
remain in the stomach 1.5 h post administration.  
 
At 4 h post administration, the microparticles have traveled through the small 
intestine, reaching the jejunum (middle section) and the ileum (final section), and passed 
through to the cecum and colon (Figure 9-6). However, the microparticles still remained in 
the stomach as indicated by the high fluorescent signal, which can be attributed to the 
feeding patterns in mice. Due to short delays between successive food intakes, the contents 
of the stomach are successively diluted. The gastric emptying in mice is nonlinear, unlike 
in humans where gastric empty is linear. Humans achieve nearly complete gastric emptying 
before each meal due to habits of eating three meals per day.10  
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Figure 9-6. Fluorescent images of the liver, kidneys, and GI tract, imaged at 4 h post 
administration. Microparticles have traveled to lower small intestine, cecum, 
and colon, while some still remain in the stomach.  
 
At 7 h post administration, the microparticles can be seen mostly in the jejunum, 
ileum, cecum, and colon (Figure 9-7). Additionally, the fluorescent signal in the stomach 
is reduced, indicating that the microparticles have exited the stomach. At 24 h post 
administration, the microparticles have mostly cleared the small intestine, with some 
fluorescent signal in the jejunum and ileum (9-8). The some microparticles are still retained 
in the cecum and colon. As expected, the majority of the microparticles have passed 
through the GI tract and cleared through excretion by 24 h post administration.  
 
 
 
 202 
 
 
 
Figure 9-7. Fluorescent images of the liver, kidneys, and GI tract, imaged at 7 h post 
administration. Microparticles have exited from the stomach and traveled to 
lower small intestine, cecum, and colon. 
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Figure 9-8. Fluorescent images of the liver, kidneys, and GI tract, imaged at 24 h post 
administration. Microparticles have mostly cleared the small intestine and 
some remain in the cecum and colon. 
 
Despite an extensive wash procedure to remove any unbound QDs, some unbound 
QDs appear to have been administered to the mice with the QD-conjugated microparticles. 
The fluorescence in the kidneys and liver slightly increased over the course of the 24 h 
study likely due to unbound QDs. While the size of the microparticles (30-45 µm, dried) 
excludes them from paracellular and transcellular transport and entering circulation, the 
unbound QDs (~10 nm) could possibly enter circulation.  
 
9.4 CONCLUSIONS 
Biodistribution studies can be used to determine the residence time of the 
microparticles in the small intestine, as well as the clearance time. The P(MAA-g-EG) 
microcarrier system is designed for targeted release of the drug (hFIX) in the small 
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intestine. The microparticles were observed in the small intestine at both 4 and 7 h post 
administration, while some microparticles still remained in the lower small intestine after 
24 h. At 24 h post administration, the majority of the microparticles had cleared the GI 
tract through excretion. Prolonged residence time of the microcarrier in the small intestine 
can increase the amount of drug released, which can also increase the amount of drug 
absorbed and therefore improve the overall bioavailability.  
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Appendix B: Histology 
Supporting Information for Chapter 8 
 
 
Figure B-1. Spleen. RePu- red pulp (contains macrophages); WhPu- white pulp (contains 
lymphocytes); GeCe- germinal center. 
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Figure B-2. Liver. CV- central vein; PV- portal vein (portal triad contains the portal vein, 
hepatic artery, and bile); LiPa- liver parenchyma (consists of hepatocytes 
arranged in cords).  
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Figure B-3. Kidney. BV- blood vessel; Co- renal cortex containing renal corpuscles 
(glomerulus surrounded by Bowman’s capsule) and proximal convoluted 
tubules; Gl- glomerulus; Me- renal medulla containing the loop of Henle 
(leads from proximal convoluted tubule to distal convoluted tubule), 
collecting tubules, and blood vessels; Pa- renal papilla formed by collecting 
ducts and blood vessels. 
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Figure B-4. Forestomach. FoSt- forestomach; LR- limiting ridge (margo plicatus) which 
separates the forestomach from the glandular stomach; GlSt- glandular 
stomach; Lu- lumen (with debris). The debris may include plant fragments 
with cell walls and cellular material, as well as hair fragments. 
 212 
 
Figure B-5. Glandular stomach. Mu- mucosa with gastric pits; Su- submucosa; Ml- 
muscularis; Lu- lumen (with debris).  
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Figure B-6. Duodenum. Vi- villus; Mu- mucosa; Ml- muscularis; Lu- lumen.  
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Figure B-7. Ileum. PePa- Peyer’s patch; Vi- villus; Mu- mucosa; Ml- muscularis; Lu- 
lumen (with debris). 
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Figure B-8. Cecum. MuFo- mucosal fold; Mu- mucosa; Ml- muscularis; Lu- lumen (with 
debris). 
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Figure B-9. Colon. BM- bowel movement; Mu- mucosa; Ml- muscularis; Lu- lumen. 
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Appendix C: Animal Studies 
C.1 PHARMACOKINETIC STUDIES 
C.1.1 Rationale  
In vivo studies will be conducted with male C57BL/6 mice prior to testing in the 
hemophilia B mouse model (B6.129P2-F9tm1Dws/J, The Jackson Laboratory) to determine 
the pharmacokinetics of orally administered factor IX. A pilot study will be used to 
determine a detectable oral dosage. Then a full scale pharmacokinetic study will be 
conducted using three different oral formulations to determine the best performing one. 
Using the best performing formulation, a multi-dose study will be conducted to mimic a 
prophylactic regimen. Prior to all studies, the drug delivery systems will be loaded with 
factor IX. The amount loaded will be quantified by ELISA.  
C.1.2 Pilot Study 
Male C57BL/6 mice (The Jackson Laboratory) of 4-6 weeks will be used for a pilot 
study with varying dosages for one oral formulation. The recommended formulation is 
P(MAA-g-EG) with 1 mol% PEGDMA1000. Three dosages will be tested: 5 µg, 10 µg, 
and 20 µg of hFIX, where 5 µg of hFIX has been shown to be sufficient in a previous study. 
Table 1 provides the conditions and size of experimental and control groups. Prior to the 
initial treatment, animals will be placed on a liquid diet for 72 hours with the first 24 hours 
as transition period, and then fasted for 24 hours. Blood will be sampled 1 day prior to 
treatment by saphenous vein blood collection. Immediately prior to administration, 
lyophilized hFIX-loaded particles will be suspended in sterile distilled water. Mice will 
receive hFIX based on group classification as positive control (IV injection) and 
experimental (oral gavage, particle suspension) (Table C-1).  
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To maximize the amount of blood per sample, each animal will only have two time 
points (the first sample taken by tail bleeding and the second by cardiac puncture 
immediately post euthanasia), see Table C-2. Since the average gastric emptying time for 
mice is 1-2 hours, the first time point using going be hFIX in plasma samples will be 
quantified by an ELISA and its activity will be assessed by a chromogenic assay. 
Additionally, gastrointestinal (GI) tract will be harvested. Each organ—stomach, small 
intestine, cecum, and colon—will be homogenized and analyzed for factor IX using an 
ELISA. An optimal dosage and timescale of blood collection will be selected for the 
pharmacokinetic study. 
The total number of animals required for the pilot study is:  
 Positive control: 1 group X 4 mice = 4 mice 
 Experimental: 1 formulation X 3 dosages X 6 mice = 18 mice 
 Total for pilot study: 22 mice 
 
Table C-1. Groups for in vivo pharmacokinetic studies. 
Group Positive Control Negative Control Experimental 
Administration Tail vein injection 
of hFIX concentrate 
Oral gavage of 
sterile distilled water 
Oral gavage of  
hFIX-loaded 
particles + sterile 
distilled water 
# Groups- Pilot 1 (n=4) 0 1 formulation x 3 
dosages  (n=4) 
# Groups- 
Pharmacokinetic 
1 (n=16) 1 (n=4) 3 formulations 
(n=16) 
# Groups- Multi-
dose 
1 x 5 doses (n=4) 0 1 formulation x 5 
doses (n=8) 
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Table C-2. Schedule for staggered blood draws. 
Animal # 1st Sample 2nd Sample 
Mouse 1 2 h 6 h 
Mouse 2 3 h 7 h 
Mouse 3 4 h 8 h 
Mouse 4 5 h 24 h 
 
C.1.3 Pharmacokinetic Study- Single Dose 
The pharmacokinetics of three oral formulations (at the dosage determined in the 
pilot study) will be determined using the protocol described above. Table C-1 provides the 
conditions and size of experimental and control groups. Similarly, each animal will only 
have two time points based on the results of the pilot study. For each time point, there will 
be four blood samples from independent animals. Therefore, there will be eight total time 
points collected for each formulation (i.e., for one formulation: 16 mice x 2 time points/4 
mice = 8 time points). Analysis will be carried out as previously described above. The total 
number of animals required for the single dose study is:  
 Positive control: 1 group X 16 mice = 16 mice 
 Negative control: 1 group X 4 mice = 4 mice 
 Experimental: 1 formulation X 3 dosages X 16 mice = 48 mice 
 Total for single dose study: 68 mice 
 
C.1.4 Pharmacokinetic Study- Multiple Doses 
Using the best performing oral formulation, a multi-dose study will be conducted 
where the treatment is administered every other day for ten days (i.e., five doses over 10 
days). The multi-dose study is designed to mimic the prophylactic regimen and to 
determine if a therapeutic concentration can be maintained overtime.  Table 1 provides the 
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conditions and size of experimental and control groups. Similarly, each animal will only 
have two time points based on previous results. For each time point for each dose, there 
will be four blood samples from independent animals and a total of four time points after 
each dose. Analysis will be carried out as previously described above. The total number of 
animals required for the multiple dose study is:  
 Positive control: 1 group X 5 doses X 4 mice = 20 mice 
 Experimental: 1 formulation X 5 doses X 8 mice = 60 mice 
 Total for pilot study: 60 mice. 
 
C.1.5 Expected Results 
The oral delivery hFIX using P(MAA-g-EG) microcarriers is expected to increase 
the amount of hFIX in circulation. Based on the pilot study, a detectable dose level will be 
selected. The pharmacokinetic curve for the orally administered hFIX is expected to look 
similar to a controlled release formulation, unlike the curve for the IV injection which is 
expected to show an immediate spike. The multiple dose study will be used to determine 
dosing intervals necessary to sustain therapeutically relevant levels of hFIX.   
 
C.2 THERAPEUTIC EFFICACY STUDY 
 C.2.1 Rationale 
In order to determine the clinical relevance of P(MAA-g-EG) microcarrier systems, 
using a hemophilia B model is necessary to access in vivo therapeutic efficacy. Testing the 
oral administration of hFIX-loaded microparticles in a humanized hemophilia B mouse can 
be used to determine in vivo bioactivity of hFIX. This experimental treatment is expected 
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to restore hemostasis in humanized hemophilia B, providing evidence of a novel clinically 
relevant treatment. 
C.2.2 Efficacy Studies 
Hemophilia B male mice (Strain B6.129P2-F9tmDws/J, The Jackson Library) with 
targeted deletion of endogenous F9 (“null” mutation for hFIX) will be used. Animals will 
be housed under pathogen-free conditions and will be 8-10 weeks old at the onset of 
experiments. The conditions and size of experimental and control groups will the same as 
in Table C-2. The procedure is the same as the pharmacokinetic studies. Blood samples 
will be collected based on the timescale determined in the pharmacokinetic studies. Using 
plasma samples, hFIX will be quantified by an ELISA and its activity will be assessed by 
a chromogenic assay. Clotting time will be assessed by an activated partial thromboplastin 
time (aPTT) assay, used for clinical detection of hemophilia. The normal time to form a 
thrombus is 25 -35 seconds using the aPTT assay, while deficiency of FIX results in a 
prolonged time with up to a 2.5 times increase.  
C.2.3 Expected Results 
It is expected that the mice orally administered hFIX-loaded microparticles will 
have increased levels of active hFIX in the circulation, which will restore hemostasis. 
Prophylactic treatment regimens increase circulating FIX by 10%; however, a one percent 
increase in FIX for severe hemophilia can reduce spontaneous bleeding episodes. Ideally, 
mice given the experimental treatment will have at least a 10% increase in active hFIX in 
the circulation as compared to the negative control groups and baseline measurements. 
Experimental treatment will also reduce the partial thromboplastin time to a normal level, 
which will also be seen with the positive control group. 
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